

Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data

*Alastair H Leyland, Samiratou Ouédraogo, Julian Nam, Lyndal Bond,
Andrew H Briggs, Ron Gray, Rachael Wood and Ruth Dundas*



***National Institute for
Health Research***

Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data

Alastair H Leyland,^{1*} Samiratou Ouédraogo,¹
Julian Nam,² Lyndal Bond,³ Andrew H Briggs,²
Ron Gray,⁴ Rachael Wood⁵ and Ruth Dundas¹

¹University of Montréal Hospital Research Centre, University of Montréal, Montréal, QC, Canada

²The NAM Group, Kitchener, ON, Canada

³College of Health and Biomedicine, Victoria Hospital, Melbourne, VIC, Australia

⁴National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK

⁵Information Service Division, NHS National Services Scotland, Edinburgh, UK

*Corresponding author

Declared competing interests of authors: The Social and Public Health Sciences Unit is core funded by the Medical Research Council (MRC) and the Scottish Government Chief Scientist Office (CSO). Neither funder had any input into the design, analysis, interpretation of results or conclusions drawn. Ruth Dundas declares grants from the MRC, CSO and National Institute for Health Research (NIHR) during the conduct of the study. Alastair Leyland declares grants from MRC, CSO and NIHR during the conduct of the study.

Published October 2017

DOI: 10.3310/phr05060

This report should be referenced as follows:

Leyland AH, Ouédraogo S, Nam J, Bond L, Briggs AH, Gray R, et al. Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data. *Public Health Res* 2017;**5**(6).

Public Health Research

ISSN 2050-4381 (Print)

ISSN 2050-439X (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full PHR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/phr. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Public Health Research* journal

Reports are published in *Public Health Research* (PHR) if (1) they have resulted from work for the PHR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Public Health Research* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

PHR programme

The Public Health Research (PHR) programme, part of the National Institute for Health Research (NIHR), evaluates public health interventions, providing new knowledge on the benefits, costs, acceptability and wider impacts of non-NHS interventions intended to improve the health of the public and reduce inequalities in health. The scope of the programme is multi-disciplinary and broad, covering a range of interventions that improve public health. The Public Health Research programme also complements the NIHR Health Technology Assessment programme which has a growing portfolio evaluating NHS public health interventions.

For more information about the PHR programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/phr>

This report

The research reported in this issue of the journal was funded by the PHR programme as project number 12/3070/02. The contractual start date was in March 2014. The final report began editorial review in October 2015 and was accepted for publication in April 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PHR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the PHR programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PHR programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2017. This work was produced by Leyland *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Public Health Research Editor-in-Chief

Professor Martin White Director of Research and Programme Leader, UKCRC Centre for Diet and Activity Research (CEDAR), MRC Epidemiology Unit, Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge; Visiting Professor, Newcastle University; and Director, NIHR Public Health Research Programme

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk

Abstract

Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data

Alastair H Leyland,^{1*} Samiratou Ouédraogo,¹ Julian Nam,² Lyndal Bond,³ Andrew H Briggs,² Ron Gray,⁴ Rachael Wood⁵ and Ruth Dundas¹

¹University of Montréal Hospital Research Centre, University of Montréal, Montréal, QC, Canada

²The NAM Group, Kitchener, ON, Canada

³College of Health and Biomedicine, Victoria Hospital, Melbourne, VIC, Australia

⁴National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK

⁵Information Service Division, NHS National Services Scotland, Edinburgh, UK

*Corresponding author alastair.leyland@glasgow.ac.uk

Background: Pregnancy and the period around birth are critical for the development and improvement of population health as well as the health of mothers and babies, with outcomes such as birthweight influencing adult health.

Objectives: We evaluated the clinical effectiveness and cost-effectiveness of the Health in Pregnancy (HiP) grants in Scotland, looking for differential outcomes when the scheme was in place, as well as before its implementation and after its withdrawal.

Design: The HiP grants were evaluated as a natural experiment using interrupted time series analysis. We had comparison groups of women who delivered before the grants were introduced and after the grants were withdrawn.

Setting: Scotland, UK.

Participants: A total of 525,400 singleton births delivered between 24 and 44 weeks in hospitals across Scotland between 1 January 2004 and 31 December 2014.

Intervention: The HiP grant was a universal, unconditional cash transfer of £190 for women in Great Britain and Northern Ireland reaching 25 weeks of pregnancy if they had sought health advice from a doctor or midwife. The grant was introduced for women with a due date on or after 6 April 2009 and subsequently withdrawn for women reaching the 25th week of pregnancy on or after 1 January 2011. The programme was paid for by Her Majesty's Treasury.

Main outcome measures: Our primary outcome measure was birthweight. Secondary outcome measures included maternal behaviour, measures of size, measures of stage and birth outcomes.

Data sources: The data came from the Scottish maternity and neonatal database held by the Information and Services Division at the NHS National Services Scotland.

Results: There was no statistically significant effect on birthweight, with births during the intervention period being, on average, 2.3 g [95% confidence interval (CI) -1.9 to 6.6 g] lighter than would have been expected had the pre-intervention trend continued. Mean gestational age at booking (i.e. the first antenatal appointment with a health-care professional) decreased by 0.35 weeks (95% CI 0.29 to 0.41 weeks) and the odds of booking before 25 weeks increased by 10% [odds ratio (OR) 1.10, 95% CI

1.02 to 1.18] during the intervention but decreased again post intervention (OR 0.91, 95% CI 0.83 to 1.00). The odds of neonatal death increased by 84% (OR 1.84, 95% CI 1.22 to 2.78) and the odds of having an emergency caesarean section increased by 7% (OR 1.07, 95% CI 1.03 to 1.10) during the intervention period.

Conclusions: The decrease in the odds of booking before 25 weeks following withdrawal of the intervention makes it likely that the HiP grants influenced maternal health-care-seeking behaviour. It is unclear why neonatal mortality and emergency caesarean section rates increased, but plausible explanations include the effects of the swine flu outbreak in 2009 and the global financial crisis. The study is limited by its non-randomised design. Future research could assess an eligibility threshold for payment earlier than the 25th week of pregnancy.

Funding: The National Institute for Health Research Public Health Research programme. The Social and Public Health Sciences Unit is core funded by the Medical Research Council (MC_UU_12017/13) and the Scottish Government Chief Scientist Office (SPHSU13).

Contents

List of tables	xv
List of figures	xxi
List of abbreviations	xxiii
Plain English summary	xxv
Scientific summary	xxvii
Chapter 1 Introduction	1
Background	1
The intervention	2
Rationale for the study	2
Socioeconomic position and inequalities	3
Research objectives	4
Chapter 2 Methods	5
Outcomes and causal pathway	5
Research design	6
<i>Natural experiment using interrupted time series analysis</i>	6
Study population including definitions of subgroups	8
Data	10
<i>Ethics and information governance</i>	10
<i>Structure of the data</i>	10
<i>Power calculation</i>	10
<i>Outcome measures</i>	10
<i>Covariates</i>	10
<i>Removing outliers</i>	11
<i>Imputation methods</i>	11
Numbers of observations used in analyses	12
Statistical analysis	12
<i>Fitting interaction models</i>	20
<i>Subgroup analyses</i>	21
<i>Ethnicity</i>	21
Economic analysis	21
<i>Model overview</i>	21
<i>Parameter sources</i>	22
<i>Health outcomes</i>	22
<i>Cost parameters</i>	23
<i>Analysis</i>	24
Strengthening the inference	24
Models fitted and interpretation	26
<i>Models fitted</i>	26
<i>Interpretation</i>	26
Changes from the protocol	26
<i>Not adjusting for maternal smoking or gestational age at booking</i>	26
<i>Not using health board and data zone clustering in the imputation model</i>	26

<i>Spontaneous delivery</i>	27
<i>Ethnicity breakdown into further ethnic groups</i>	27
<i>Fitting interactions between subgroup and intervention</i>	27
<i>Combinations of subgroups</i>	27
<i>Not adjusting for gestational age at delivery in models with caesarean section as outcomes</i>	27
Chapter 3 Results	29
Description of outcomes and covariates	29
Results for the main analysis	29
<i>Results for the primary outcome</i>	29
<i>Results for the secondary outcomes</i>	29
Results of the subgroup analysis	43
<i>The primary outcome</i>	43
<i>The secondary outcomes</i>	43
Results of sensitivity analysis	50
<i>Subgroup of nulliparous mothers</i>	50
<i>Impact of restricting the pre-intervention period to the period following the introduction of the smoking ban in public places</i>	50
<i>Impact of moving the Health in Pregnancy grant period</i>	50
<i>Impact of moving the intervention period to 1 year before the real Health in Pregnancy grant period</i>	50
<i>Impact of moving the intervention period to 6 months before the real Health in Pregnancy grant period</i>	51
<i>Impact of moving the intervention period to 6 months after the real Health in Pregnancy grant period</i>	51
<i>Impact of moving the intervention period to 1 year after the real Health in Pregnancy grant period</i>	51
Summary of results for the main analysis and moving windows	51
Economic analysis results	51
Chapter 4 Discussion	59
Principal findings	59
Impact on inequalities	60
<i>Robustness and generalisability</i>	61
Interpretation	63
Strengths and weaknesses	64
Patient and public involvement	65
Chapter 5 Conclusions	67
Implications for health care	67
Recommendations for research	68
Acknowledgements	71
References	73
Appendix 1 Models specification (adjusted on gestational age at booking and maternal smoking)	79
Appendix 2 Results of the analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: maternal behaviour	87

Appendix 3 The results of analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: measures of size	89
Appendix 4 The results of analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: measures of stage	91
Appendix 5 The results of analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: birth outcomes	93
Appendix 6 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: maternal behaviour	95
Appendix 7 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of size	97
Appendix 8 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of stage	99
Appendix 9 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: birth outcomes	101
Appendix 10 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: maternal behaviour	103
Appendix 11 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of size	105
Appendix 12 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of stage	111
Appendix 13 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: birth outcomes	117
Appendix 14 Variances and standard errors for the final models for each outcome	123
Appendix 15 Results of the analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – maternal behaviour	125
Appendix 16 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – measures of size	127

Appendix 17 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – measures of stage	129
Appendix 18 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – birth outcomes	131
Appendix 19 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – maternal behaviour	133
Appendix 20 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – measures of size	135
Appendix 21 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – measures of stage	137
Appendix 22 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – birth outcomes	139
Appendix 23 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – maternal behaviour	141
Appendix 24 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – measures of size	143
Appendix 25 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – measures of stage	145
Appendix 26 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – birth outcomes	147
Appendix 27 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – maternal behaviour	149
Appendix 28 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – measures of size	151
Appendix 29 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – measures of stage	153
Appendix 30 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – birth outcomes	155
Appendix 31 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – maternal behaviour	157
Appendix 32 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – measures of size	159
Appendix 33 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – measures of stage	161

Appendix 34 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – birth outcomes	163
Appendix 35 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – maternal behaviour	165
Appendix 36 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – measures of size	167
Appendix 37 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – measures of stage	169
Appendix 38 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – birth outcomes	171
Appendix 39 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m ²) – maternal behaviour	173
Appendix 40 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m ²) – measures of size	175
Appendix 41 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m ²) – measures of stage	177
Appendix 42 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m ²) – birth outcomes	179
Appendix 43 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – maternal behaviour	181
Appendix 44 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – measures of size	183
Appendix 45 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – measures of stage	185
Appendix 46 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – birth outcomes	187
Appendix 47 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – maternal behaviour	189
Appendix 48 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – measures of size	191

Appendix 49 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – measures of stage	193
Appendix 50 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – birth outcomes	195
Appendix 51 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – maternal behaviour	197
Appendix 52 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – measures of size	199
Appendix 53 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – measures of stage	201
Appendix 54 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – birth outcomes	203
Appendix 55 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – maternal behaviour	205
Appendix 56 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – measures of size	207
Appendix 57 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – measures of stage	209
Appendix 58 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – birth outcomes	211
Appendix 59 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – maternal behaviour	213
Appendix 60 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – measures of size	215
Appendix 61 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – measures of stage	217
Appendix 62 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – birth outcomes	219
Appendix 63 Results of the main analysis for the secondary outcomes adjusted for ethnicity and using the complete cases: maternal behaviour	221
Appendix 64 Results of the main analysis for the primary and secondary outcomes adjusted for ethnicity and using the complete cases: measures of size	223

Appendix 65 Results of the main analysis for the secondary outcomes adjusted for ethnicity and using the complete cases: measures of stage	225
Appendix 66 Results of the main analysis for the secondary outcomes adjusted for ethnicity and using the complete cases: birth outcomes	227
Appendix 67 Results of analysis for the secondary outcomes using the imputed data: subgroup of nulliparous mothers – maternal behaviour	229
Appendix 68 Results of analysis for the primary and secondary outcomes using the imputed data: subgroup of nulliparous mothers – measures of size	231
Appendix 69 Results of analysis for the secondary outcomes using the imputed data: subgroup of nulliparous mothers – measures of stage	233
Appendix 70 Results of analysis for the secondary outcomes using the imputed data: subgroup of nulliparous mothers – birth outcomes	235
Appendix 71 Impact of restricting the pre-intervention period to the period after the smoking ban: maternal behaviour	237
Appendix 72 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of size	239
Appendix 73 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of stage	241
Appendix 74 Impact of restricting the pre-intervention period to the period after the smoking ban: birth outcomes	243
Appendix 75 Impact of moving the real Health in Pregnancy grant period: restriction to 18 months	245
Appendix 76 Impact of moving the real Health in Pregnancy grant period: extension to 30 months	247
Appendix 77 Impact of moving the real Health in Pregnancy grant period: exclusion of births that occurred during the 2009 swine flu outbreak	249
Appendix 78 Impact of moving the start of the intervention period to one year before the real Health in Pregnancy grant period: 24-month intervention period	251
Appendix 79 Impact of moving the start of the intervention period to 1 year before the real Health in Pregnancy grant period: 18-month intervention period	253
Appendix 80 Impact of moving the start of the intervention period to 1 year before the real Health in Pregnancy grant period: 30-month intervention period	255
Appendix 81 Impact of moving the start of the intervention period to 6 months before the real Health in Pregnancy grant period: 24-month intervention period	257
Appendix 82 Impact of moving the start of the intervention period to 6 months before the real Health in Pregnancy grant period: 18-month intervention period	259

Appendix 83 Impact of moving the start of the intervention period to 6 months before the real Health in Pregnancy grant period: 30-month intervention period	261
Appendix 84 Impact of moving the start of the intervention period to 6 months after the real Health in Pregnancy grant period: 24-month intervention period	263
Appendix 85 Impact of moving the start of the intervention period to 6 months after the real Health in Pregnancy grant period: 18-month intervention period	265
Appendix 86 Impact of moving the start of the intervention period to 6 months after the real Health in Pregnancy grant period: 30-month intervention period	267
Appendix 87 Impact of moving the start of the intervention period to 1 year after the real Health in Pregnancy grant period: 24-month intervention period	269
Appendix 88 Impact of moving the start of the intervention period to 1 year after the real Health in Pregnancy grant period: 18-month intervention period	271
Appendix 89 Impact of moving the start of the intervention period to 1 year after the real Health in Pregnancy grant period: 30-month intervention period	273
Appendix 90 STrengthening the Reporting of OBservational studies in Epidemiology statement for reporting of observational studies	275

List of tables

TABLE 1 Dates for the study periods and washout periods	8
TABLE 2 Sample sizes for subgroup analyses	12
TABLE 3 Sample sizes for subgroup analyses	13
TABLE 4 Main models specification (unadjusted for gestational age at booking and maternal smoking)	15
TABLE 5 Parameters used in the model	22
TABLE 6 Cost of index hospitalisation by gestational age	23
TABLE 7 Cost of index hospitalisation by birthweight	23
TABLE 8 Start and end dates for moving window periods	25
TABLE 9 Proportion of preterm (< 37 weeks' gestation) births by mode of delivery	27
TABLE 10 Description of the outcomes over time: measures of size	30
TABLE 11 Description of the outcomes over time: measures of stage	31
TABLE 12 Description of the outcomes over time: birth outcomes	32
TABLE 13 Description of the outcomes over time: maternal behaviour	33
TABLE 14 Description of the covariates over time	34
TABLE 15 Results of analysis for the primary outcome using the complete cases and the imputed data both unadjusted and adjusted for gestational age at booking and maternal smoking	40
TABLE 16 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: maternal behaviour	40
TABLE 17 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: measures of size	41
TABLE 18 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: measures of stage	42
TABLE 19 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: birth outcomes	42
TABLE 20 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: maternal behaviour	44

TABLE 21 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: measures of size	44
TABLE 22 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: measures of stage	45
TABLE 23 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: birth outcomes	46
TABLE 24 Results of subgroup analysis for the primary outcome using the imputed data unadjusted for gestational age at booking and maternal smoking: subgroups related to the socioeconomic position of the area of residence (SIMD2009 version 2)	47
TABLE 25 Results of subgroup analysis for the primary outcome using the imputed data unadjusted for gestational age at booking and maternal smoking: other subgroups	49
TABLE 26 Incremental outcomes and costs attributable to HiP grant intervention	58
TABLE 27 Models specification (adjusted on gestational age at booking and maternal smoking)	80
TABLE 28 Complete cases unadjusted for gestational age at booking and maternal smoking: maternal behaviour	87
TABLE 29 Complete cases unadjusted for gestational age at booking and maternal smoking: measures of size	89
TABLE 30 Complete cases unadjusted for gestational age at booking and maternal smoking: measures of stage	91
TABLE 31 Complete cases unadjusted for gestational age at booking and maternal smoking: birth outcomes	93
TABLE 32 Complete cases and adjusting the model for gestational age at booking and maternal smoking: maternal behaviour	95
TABLE 33 Complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of size	97
TABLE 34 Complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of stage	99
TABLE 35 Complete cases and adjusting the model for gestational age at booking and maternal smoking: birth outcomes	101
TABLE 36 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: maternal behaviour	103

TABLE 37 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of size	106
TABLE 38 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of stage	112
TABLE 39 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: birth outcomes	118
TABLE 40 Variances and standard errors for the final models for each outcome	123
TABLE 41 Subgroup of mothers living in the most deprived areas (SIMD1): maternal behaviour	125
TABLE 42 Subgroup of mothers living in the most deprived areas (SIMD1): measures of size	127
TABLE 43 Subgroup of mothers living in the most deprived areas (SIMD1): measures of stage	129
TABLE 44 Subgroup of mothers living in the most deprived areas (SIMD1): birth outcomes	131
TABLE 45 Subgroup of mothers living in SIMD2 areas: maternal behaviour	133
TABLE 46 Subgroup of mothers living in SIMD2 areas: measures of size	135
TABLE 47 Subgroup of mothers living in SIMD2 areas: measures of stage	137
TABLE 48 Subgroup of mothers living in SIMD2 areas: birth outcomes	139
TABLE 49 Subgroup of mothers living in SIMD3 areas: maternal behaviour	141
TABLE 50 Subgroup of mothers living in SIMD3 areas: measures of size	143
TABLE 51 Subgroup of mothers living in SIMD3 areas: measures of stage	145
TABLE 52 Subgroup of mothers living in SIMD3 areas: birth outcomes	147
TABLE 53 Subgroup of mothers living in SIMD4 areas: maternal behaviour	149
TABLE 54 Subgroup of mothers living in SIMD4 areas: measures of size	151
TABLE 55 Subgroup of mothers living in SIMD4 areas: measures of stage	153
TABLE 56 Subgroup of mothers living in SIMD4 areas: birth outcomes	155
TABLE 57 Subgroup of mothers living in the least deprived areas: maternal behaviour	157

TABLE 58 Subgroup of mothers living in the least deprived areas: measures of size	159
TABLE 59 Subgroup of mothers living in the least deprived areas: measures of stage	161
TABLE 60 Subgroup of mothers living in the least deprived areas: birth outcomes	163
TABLE 61 Subgroup of mothers with diabetes mellitus (before or during pregnancy): maternal behaviour	165
TABLE 62 Subgroup of mothers with diabetes mellitus (before or during pregnancy): measures of size	167
TABLE 63 Subgroup of mothers with diabetes mellitus (before or during pregnancy): measures of stage	169
TABLE 64 Subgroup of mothers with diabetes mellitus (before or during pregnancy): birth outcomes	171
TABLE 65 Subgroup of obese mothers (BMI ≥ 35 kg/m ²): maternal behaviour	173
TABLE 66 Subgroup of obese mothers (BMI ≥ 35 kg/m ²): measures of size	175
TABLE 67 Subgroup of obese mothers (BMI ≥ 35 kg/m ²): measures of stage	177
TABLE 68 Subgroup of obese mothers (BMI ≥ 35 kg/m ²): birth outcomes	179
TABLE 69 Subgroup of lone mothers: maternal behaviour	181
TABLE 70 Subgroup of lone mothers: measures of size	183
TABLE 71 Subgroup of lone mothers: measures of stage	185
TABLE 72 Subgroup of lone mothers: birth outcomes	187
TABLE 73 Subgroup of mothers living in households where the head is in the group of working-class people: maternal behaviour	189
TABLE 74 Subgroup of mothers living in households where the head is in the group of working-class people: measures of size	191
TABLE 75 Subgroup of mothers living in households where the head is in the group of working-class people: measures of stage	193
TABLE 76 Subgroup of mothers living in households where the head is in the group of working-class people: birth outcomes	195
TABLE 77 Subgroup of mothers living in households where the head is in the group of people who have never worked: maternal behaviour	197
TABLE 78 Subgroup of mothers living in households where the head is in the group of people who have never worked: measures of size	199

TABLE 79 Subgroup of mothers living in households where the head is in the group of people who have never worked: measures of stage	201
TABLE 80 Subgroup of mothers living in households where the head is in the group of people who have never worked: birth outcomes	203
TABLE 81 Subgroup of teen mothers (< 20 years old): maternal behaviour	205
TABLE 82 Subgroup of teen mothers (< 20 years old): measures of size	207
TABLE 83 Subgroup of teen mothers (< 20 years old): measures of stage	209
TABLE 84 Subgroup of teen mothers (< 20 years old): birth outcomes	211
TABLE 85 Subgroup of non-white mothers: maternal behaviour	213
TABLE 86 Subgroup of non-white mothers: measures of size	215
TABLE 87 Subgroup of non-white mothers: measures of stage	217
TABLE 88 Subgroup of non-white mothers: birth outcomes	219
TABLE 89 Secondary outcomes adjusted for ethnicity and using the complete cases: maternal behaviour	221
TABLE 90 Primary and secondary outcomes adjusted for ethnicity and using the complete cases: measures of size	223
TABLE 91 Secondary outcomes adjusted for ethnicity and using the complete cases: measures of stage	225
TABLE 92 Secondary outcomes adjusted for ethnicity and using the complete cases: birth outcomes	227
TABLE 93 Subgroup of nulliparous mothers: maternal behaviour	229
TABLE 94 Subgroup of nulliparous mothers: measures of size	231
TABLE 95 Subgroup of nulliparous mothers: measures of stage	233
TABLE 96 Subgroup of nulliparous mothers: birth outcomes	235
TABLE 97 Impact of restricting the pre-intervention period to the period after the smoking ban: maternal behaviour	237
TABLE 98 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of size	239
TABLE 99 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of stage	241
TABLE 100 Impact of restricting the pre-intervention period to the period after the smoking ban: birth outcomes	243

TABLE 101 Impact of moving the real HiP grant period: restriction to 18 months	245
TABLE 102 Impact of moving the real HiP grant period: extension to 30 months	247
TABLE 103 Impact of moving the real HiP grant period: exclusion of births that occurred during the 2009 swine flu outbreak	249
TABLE 104 Impact of moving the start of the intervention period to 1 year before the real HiP grant period: 24-month intervention period	251
TABLE 105 Impact of moving the start of the intervention period to 1 year before the real HiP grant period: 18-month intervention period	253
TABLE 106 Impact of moving the start of the intervention period to 1 year before the real HiP grant period: 30-month intervention period	255
TABLE 107 Impact of moving the start of the intervention period to 6 months before the real HiP grant period: 24-month intervention period	257
TABLE 108 Impact of moving the start of the intervention period to 6 months before the real HiP grant period: 18-month intervention period	259
TABLE 109 Impact of moving the start of the intervention period to 6 months before the real HiP grant period: 30-month intervention period	261
TABLE 110 Impact of moving the start of the intervention period to 6 months after the real HiP grant period: 24-month intervention period	263
TABLE 111 Impact of moving the start of the intervention period to 6 months after the real HiP grant period: 18-month intervention period	265
TABLE 112 Impact of moving the start of the intervention period to 6 months after the real HiP grant period: 30-month intervention period	267
TABLE 113 Impact of moving the start of the intervention period to 1 year after the real HiP grant period: 24-month intervention period	269
TABLE 114 Impact of moving the start of the intervention period to 1 year after the real HiP grant period: 18-month intervention period	271
TABLE 115 Impact of moving the start of the intervention period to 1 year after the real HiP grant period: 30-month intervention period	273
TABLE 116 STrengthening the Reporting of OBservational studies in Epidemiology statement for reporting of observational studies	275

List of figures

FIGURE 1 Flow chart showing observations received from the Information and Services Division, removal of outliers and final sample size for analyses	7
FIGURE 2 Conceptual analysis approach	22
FIGURE 3 Coefficient and 95% CI for birthweight during the HiP grant period and moving windows	52
FIGURE 4 Coefficient and 95% CI for gestational age at booking during the HiP grant period and moving windows	53
FIGURE 5 Odds ratio and 95% CI for booking before 25 weeks during the HiP grant period and moving windows	54
FIGURE 6 Odds ratio and 95% CI for preterm delivery during the HiP grant period and moving windows	55
FIGURE 7 Odds ratio and 95% CI for very preterm delivery during the HiP grant period and moving windows	56
FIGURE 8 Odds ratio and 95% CI for neonatal death during the HiP grant period and moving windows	57

List of abbreviations

BMI	body mass index	MRC	Medical Research Council
CHD	coronary heart disease	NRS	National Records of Scotland
CI	confidence interval	NS-SEC	National Statistics Socioeconomic Classification
CSO	Chief Scientist Office	OR	odds ratio
HEAT	Health improvement, Efficiency and governance improvements, Access to services, Treatment appropriate to individuals	PPROM	preterm premature rupture of membranes
HiP	Health in Pregnancy	SBR	Scottish Birth Records
HMRC	Her Majesty's Revenue and Customs	SES	socioeconomic status
IQR	interquartile range	SGA	small for gestational age
ISD	Information and Services Division	SIMD	Scottish Index of Multiple Deprivation
LGA	large for gestational age	SMR	Scottish Morbidity Records
MICE	multiple imputation by chained equations		

Plain English summary

Several studies have reported that improving the health and nutrition of women during pregnancy could improve the health of their babies. From April 2009, for a 2-year period, a programme called Health in Pregnancy grants was implemented by the government across the UK. A cash sum of £190 was given to women reaching the 25th week of their pregnancy if they had been in contact with a doctor or midwife. The intention was to encourage pregnant women to visit a health professional earlier in their pregnancy, and to get advice related to a healthy lifestyle and diet. We investigated whether or not there was a difference in birthweight between babies born to mothers who were eligible for the grant and babies born either before the grant was introduced or after the programme had ended.

We used data relating to all single births in Scotland from 2004 to 2013. For our main analysis, this was 525,400 births. We found no evidence that the programme improved birthweight or babies' health. However, we found that, on average, women visited a doctor or midwife half a week earlier when the grant was in place than before the grant was introduced. Results were similar for all women, including those who might potentially have benefited most from the grant, such as single mothers or those living in disadvantaged areas. In terms of the overall cost of the programme, we found negligible financial savings compared with the existing costs of health care for babies and mothers.

Scientific summary

Background

Pregnancy and the perinatal period are critical stages for the development and improvement of population health. Lower birthweight babies have a higher risk of adverse perinatal outcomes and, although mean birthweight has increased in the UK, the social patterning of birthweight has become more pronounced. Low birthweight also has an impact on adult health; it is associated with a higher risk of coronary heart disease death and diabetes mellitus. An improvement in fetal nutrition may, therefore, have far-reaching consequences in terms of the prevention of disease. Antenatal care is widely considered to be an effective method of improving pregnancy and birth outcomes, through its ability to offer advice and help regarding the modification of health behaviours. For such care to be effective, it should be offered in a timely manner, that is, early in the pregnancy.

This study evaluates the clinical effectiveness and cost-effectiveness of the Health in Pregnancy (HiP) grant. This was a universal, unconditional cash transfer of £190 for women in Great Britain and Northern Ireland reaching 25 weeks of pregnancy if they had sought health advice from a doctor or midwife. The grant was introduced for women with a due date on or after 6 April 2009 and was subsequently withdrawn for women reaching the 25th week of pregnancy on or after 1 January 2011. It was intended to provide additional financial support in the last months of pregnancy to contribute towards a healthy lifestyle (e.g. in terms of diet), and it was suggested that the link to the requirement for pregnant women to seek health advice from a health professional may provide an incentive for expectant mothers to seek the recommended health advice at the appropriate time. The grant was paid by Her Majesty's Revenue and Customs to pregnant women on receipt of a claim form partly completed by a doctor or midwife, and the programme was paid for by Her Majesty's Treasury.

Our evaluation was restricted to Scotland and used the high-quality and complete maternal hospital discharge forms linked to the birth registration system (Scottish Birth Records).

Objectives

Our objective was to evaluate the clinical effectiveness and cost-effectiveness of the HiP grants in Scotland. We did this by assessing the difference in birthweight between babies born to those mothers who were eligible for the HiP grant, and babies born either before the HiP grants were introduced or after they were withdrawn. Specific questions that we address include the following:

- Did the HiP grant result in a change in birthweight (our primary outcome measure) or any of a number of secondary outcomes grouped as measures of maternal behaviour [gestation at booking (i.e. the first antenatal appointment with a health-care professional), booking before 25 weeks and maternal smoking during this pregnancy], measures of size [very low birthweight (< 1500 g), low birthweight (< 2500 g), high birthweight (> 4000 g), crown-to-heel length and head circumference], measures of stage [gestational age at delivery, preterm (< 37 weeks), very preterm (< 32 weeks), weight for dates (standardised, small and large for gestational age)] and birth outcomes (elective caesarean section, emergency caesarean section, stillbirths, neonatal deaths and 5-minute Apgar score)?
- Were there differential impacts of the intervention for particular subgroups defined by socioeconomic (both area deprivation and individual occupational social class), demographic (marital status, age, ethnicity) or obstetric (parity, maternal obesity, maternal diabetes mellitus) factors?
- Were the HiP grants cost-effective? What were their total aggregate health and cost consequences? How did cost-effectiveness vary across important subgroups identified as having differential outcomes?

Methods

The HiP intervention was evaluated as a natural experiment using interrupted time series analysis. The interrupted time series approach allowed us to compare an intervention group that received the HiP grant both with a comparison group of pregnant women who delivered before the HiP grant was introduced and with a post-intervention group of women who delivered after the HiP grant was withdrawn.

The data came from the Scottish maternity and neonatal database held by the Information and Services Division at the NHS National Services Scotland. These data are routinely collected information from maternal and birth records from all hospitals in Scotland. Individual birth records were available for analysis in this study. The data covered 10 years from 1 January 2004 to 31 December 2013. During this time, some mothers gave birth more than once. Therefore, the structure of the data was multilevel; births were nested within mothers and mothers were nested within small geographic areas (data zones).

Our primary outcome measure, birthweight, had a completion rate of 99.9%. There was a high completion rate for all outcome variables (< 1.5% missing), with the exception of crown-to-heel length (46.4% missing), head circumference (26.3% missing), gestational age at booking (15.4% missing) and maternal smoking (8.9% missing). Birthweight can be affected by many factors; we were able to adjust for a range of routinely collected obstetric and maternal characteristics such as sociodemographic classifications and medical risks of the current and previous pregnancies, as well as environmental and behavioural characteristics of the mother. In addition, we adjusted for time trends and seasonality in the data.

Extreme data values (implausible observations and outliers) were excluded. A total of 18,276 (3.4%) singleton births delivered between 24 and 44 weeks were excluded, leaving 525,400 births for the main analysis. Item non-response values were imputed using multiple imputation by chained equations. A total of 30 imputed data sets were created and analysed identically, and the results were combined to obtain estimates and standard errors for the multiply imputed data. Multilevel models were used to determine whether or not the outcomes changed during the intervention period in which the HiP grants were in effect. Multilevel linear regression was used for continuous outcomes, and multilevel logistic regression was used when the outcome was dichotomous. Results from imputed data were compared with those from complete cases, but the results from the imputed data were favoured because these take into account the non-random pattern in data missingness.

Subgroup analyses were conducted for those groups seen as having the greatest potential to benefit from the payments, namely those living in the most deprived areas, those in the 'never worked' social class group, those in the 'manual worker' social class group, lone mothers and teen mothers, and for mothers for whom an increase in mean birthweight was not desirable, namely obese mothers and mothers with diabetes mellitus. For each group the main analysis was replicated and the results from the combined analysis of the 30 imputed data sets are reported.

Ethnicity was poorly recorded in the routine data set, with 56.5% of data missing over the 10-year period. Missingness varied across the years: 83.3% of data were missing in 2004 and 23.6% of data were missing in 2013. Ethnicity was not imputed and was not included in the main analyses. In order to gauge the effect of ethnicity on the HiP grant intervention, analyses were carried out on the subgroup of non-white mothers identified in the data set. In addition, the models for the complete cases were fitted to include ethnicity along with other covariates.

Different forms of sensitivity analysis were conducted in an attempt to ascertain whether or not any effects were attributable to the HiP grant. The exact window in which the intervention was in place was defined by two parameters, namely the start date (a due date of delivery on or after 6 April 2009) and the duration of the intervention (2 years). We allowed both the start date and duration to vary; five different start dates and three different durations were chosen, giving 15 different windows tested. In all cases in which this window differed from the real intervention period, a dilution of any effects of the HiP grant was expected.

The introduction of the smoking ban in public places in Scotland in March 2006 may have had an effect on the level of smoking in pregnant women and, therefore, may have affected the rate of change of birthweight of babies born after this time, as well as other outcomes examined. We carried out a further analysis, restricting the pre-intervention period to 1 January 2007 to 1 April 2009, to ensure that pregnancies included in the pre-intervention period were all after the smoking ban had come into effect.

The effect of the HiP grant on birthweight and other secondary outcomes might have had a carryover effect after the withdrawal of the programme. In other words, the trend in birthweight post intervention might not return to the same rate as pre intervention. This contamination could be attributable to women who gave birth during the intervention subsequently having a birth post intervention but still heeding the health advice given during their first pregnancy. An additional analysis using only the subgroup of primiparous women was carried out to avoid such contamination.

In 2009 there was an outbreak of swine flu (influenza virus A/H1N1pdm09) in Scotland (and the rest of the UK). Pregnant women were adversely affected by this virus, resulting in poorer perinatal outcomes. There were two outbreak periods, in July 2009 and October–November 2009. To try to take this into account, a further analysis removing births from 1 July 2009 to 30 November 2009 in the intervention period was carried out.

Health and cost consequences were mediated through either a birthweight or gestational age at birth perspective, in addition to smoking during pregnancy. All costs were presented in 2015 Great British pounds using the Hospital and Community Health Services index to adjust. Health and cost changes during the intervention period were presented relative to the pre-intervention period. The model used was based on the incremental numbers of cases (of preterm, low birthweight or poor maternal outcomes) attributable to the HiP grant. Unit costs by outcomes were based on published results.

Results

The mean birthweight for live singleton births during the study period was 3418 g. There was no statistically significant effect of the intervention on birthweight, with birthweight during the intervention period being, on average, 2.3 g [95% confidence interval (CI) –1.9 to 6.6 g] lighter than would have been expected had the pre-intervention trend continued. [The general trend was one of birthweight increasing by 3.3 g per year (95% CI 2.4 to 4.2 g).]

There was no statistically significant effect of the HiP grants on most of the measures of stage and size. However, compared with the pre-intervention period, maternal booking behaviour changed during the intervention period. The mean gestational age at booking decreased by 0.35 weeks (95% CI 0.29 to 0.41 weeks) during the period when the grant was in place, and the odds of booking before 25 weeks increased by 10% [odds ratio (OR) 1.10, 95% CI 1.02 to 1.18]. However, the odds of neonatal death increased by 84% (OR 1.84, 95% CI 1.22 to 2.78), and the odds of having an emergency caesarean section also increased by 7% (OR 1.07, 95% CI 1.03 to 1.10) during the intervention period.

The decrease in mean gestational age at booking seen during the intervention period was extended post intervention; relative to the pre-intervention period, mean gestational age at booking was 1.10 weeks (95% CI 1.02 to 1.20 weeks) lower post intervention. However, following the withdrawal of the HiP grants there was a small decrease in the odds of booking before 25 weeks (OR 0.91, 95% CI 0.83 to 1.00).

These findings were largely replicated across subgroups. For example, looking at fifths of the population defined by area deprivation, there was a small decrease in mean birthweight during the intervention period in the most deprived areas [12.2 g (95% CI 3.6 to 20.8 g)] but no significant difference in the other groups. Mean gestational age at booking decreased in all deprivation groups, but slightly more so in the more deprived area groups; there was a reduction of 0.5 weeks (95% CI 0.4 to 0.6 weeks) in the most deprived 20% of areas and a reduction of 0.2 weeks (95% CI 0.1 to 0.4 weeks) in the least deprived 20% of areas.

The HiP grants were not associated with any significant changes in birthweight, gestational age or maternal outcomes. As a result, their impact on costs was negligible. The total estimated grant cost was £20.4M.

Conclusions

There was no impact of the HiP grants on birthweight, our primary outcome measure. In fact, most measures of stage or size appeared to be little changed by the intervention. There was, however, some influence on health-care-seeking behaviour, namely gestational age at booking and the likelihood of booking before 25 weeks. Other studies have similarly shown that behaviour can be changed through relatively modest financial incentives.

It is likely that the decrease in mean gestational age reflects the introduction and pursuit of a Health improvement, Efficiency and governance improvements, Access to services, Treatment appropriate to individuals (HEAT) target related to earlier booking for antenatal care. The same is not true, however, for the increase in the odds of booking before 25 weeks. The target of 25 weeks was related to the eligibility for the HiP grants and not to the HEAT targets, and the decrease in the odds of booking before 25 weeks following withdrawal of the intervention appears to be a response to the withdrawal of the incentive. Those failing to book before 25 weeks were notably disadvantaged compared with those booking earlier, particularly in terms of lone parenthood, worklessness and the mother being under 20 years of age.

It is unclear why increases were seen for the probability of neonatal mortality and caesarean sections. Both remained high following withdrawal of the intervention. It is possible that both were affected by wider environmental factors that coincided with the intervention period, such as the global financial crisis and the swine flu pandemic of 2009.

Our study was limited by the implementation of the HiP grants in a way that neither was randomised nor facilitated their evaluation.

Our recommended priorities for future research are as follows:

1. Test whether an eligibility threshold earlier than 25 weeks would lead to increased exposure to antenatal care and advice (increased frequency of antenatal visits) and whether any accompanying change in health behaviour (such as smoking or diet) occurring earlier in the pregnancy would lead to improvements in maternal and infant health outcomes. Evaluate the economic benefit that can be achieved through such a modified threshold and any consequent improvement in results.
2. Evaluate whether or not this intervention has greater impact, and higher cost-effectiveness, when delivered as a targeted intervention or as a universal intervention.
3. Test if outcomes differ depending on whether or not the payment is conditional or unconditional.
4. Investigate the relationship between the size of the payment and subsequent outcomes.

Funding

Funding for this study was provided by the Public Health Research programme of the National Institute for Health Research. The Social and Public Health Sciences Unit is core funded by the Medical Research Council (MC_UU_12017/13) and the Scottish Government Chief Scientist Office (SPHSU13).

Chapter 1 Introduction

Background

Pregnancy and the perinatal period are critical stages for the development and improvement of population health. Deaths in infancy have considerable impact on population life expectancy, and the long-term consequences of problems arising during pregnancy, including very preterm birth, track through childhood and into adult life.

Babies of lower birthweight, whether as a result of preterm birth or of an intra-uterine growth restriction, which can lead to a neonate being small for gestational age (SGA), have a higher risk of adverse perinatal outcomes. Low birthweight is an important factor in neonatal deaths¹ and poorer development.² Although mean birthweight has been increasing in the UK, inequalities in birthweight have increased. The UK has an incidence of low birthweight (< 2500 g) and very low birthweight (< 1500 g) in the top third compared with other western European countries.³ The proportion of preterm births (< 37 weeks) is also high in the UK compared with other western European countries.

Low birthweight also has an impact on adult disease, being associated with a higher risk of coronary heart disease (CHD) death and diabetes mellitus. The developmental model of the origins of chronic disease proposes the causal influence of undernutrition in utero on CHD and stroke in adult life,⁴ and longer-term consequences have been demonstrated for many diseases.^{5–14} The association between maternal nutrition and birth outcome is complex and is influenced by many biological, socioeconomic and demographic factors, which vary widely in different populations.^{15,16} However, it has been reported that favourable prenatal nutrition associated with adequate prenatal care can have a positive impact on birth outcomes and morbidity in adult life.^{17,18} In addition to poor maternal nutrition being associated with adverse birth outcomes, a review of maternal nutrition and birth outcomes identified improving maternal nutrition as contributing to the prevention of adverse birth outcomes in lower social class groups.¹⁵ An improvement in fetal nutrition may, therefore, have far-reaching consequences in terms of the prevention of disease.

Low birthweight is not the only adverse perinatal outcome associated with poor infant outcomes and poorer long-term health. Across Europe, approximately 75% of neonatal deaths and 60% of all infant deaths occur among those births classified as preterm (births before 37 weeks of gestation), despite preterm births constituting only a small proportion of all births; the preterm birth rate ranges between 5.2% and 10.4% across countries, and is 7.0% in the UK.¹⁹ A low Apgar score²⁰ – a commonly used indicator of health in the immediate neonatal period – has been shown to be associated with increased neonatal and infant mortality²¹ and additional educational support needs in later life.²²

Considerable attention has been focused on the causal determinants of low birthweight in order to identify potentially modifiable factors. A substantial proportion of low birthweight is attributable to the mother's cultural and socioeconomic circumstances, such as socioeconomic status (SES), harmful behaviours (smoking and excessive alcohol consumption) and poor nutrition during pregnancy.^{14,23–25} Any social impact may vary with maternal factors such as age and smoking status. Smoking during pregnancy reduces birthweight by 162–377 g, depending on daily consumption (there is a greater reduction for heavy smokers) and the trimester in which exposure occurs (a greater reduction is seen during the third trimester).^{24,26,27}

A number of interventions have been developed to improve pregnancy outcomes,²⁸ but evidence of the success of any interventions is, in most cases, still limited. An analysis of the potential to reduce preterm birth rates in high-income countries focused solely on five interventions for which there were high levels of evidence: (1) smoking cessation; (2) progesterone; (3) cervical cerclage; (4) decrease in non-medically indicated caesarean delivery and induction; and (5) a limit on multiple embryo transfer in assisted reproductive technology.²⁹

Although there is uncertainty over how to intervene to improve birth outcomes, many outcomes show strong patterning by measures of socioeconomic position. For example, in Scotland between 1995 and 2000, the odds of preterm birth were 56% higher in social class V (unskilled manual workers) than in social class I (professional workers; prevalence 5.7% vs. 3.7%).³⁰ Comparing these two groups, the odds were 107% higher for low birthweight (5.8% vs. 3.8%) and 128% higher for SGA (i.e. babies falling on or below the fifth centile of the appropriate age and sex distribution in Scotland; 5.1% vs. 3.1%). A systematic review and meta-analysis of social inequality and infant health in the UK found an odds ratio (OR) for low birthweight of 1.79 in the lowest compared with the highest social class.³¹ It is, therefore, no surprise that many attempts to improve outcomes have concentrated on the most disadvantaged populations. For example, the Healthy Baby programme in Manitoba, Canada, which was designed to promote prenatal and perinatal health, comprised a targeted income supplement for low-income women and educational and supportive groups for all mothers up to the infant's first birthday. Evaluation of this complex programme found that receipt of the prenatal benefit was associated with a reduction in incidence of both low birthweight babies and preterm births.³²

A recent systematic review of the effectiveness of antenatal care programmes for socially disadvantaged and vulnerable women noted that antenatal care was generally thought to be an effective method of improving pregnancy and birth outcomes, although the authors noted that many antenatal care practices had not been subjected to rigorous evaluation.³³ If receiving antenatal care is beneficial, then it is reasonable to think that earlier uptake of antenatal care should be better than later uptake, as this will allow more time for the beneficial effects of behaviour change to be realised.

The intervention

The intervention being evaluated is the Health in Pregnancy (HiP) grant. This was a universal, unconditional, cash transfer of £190 for women in Great Britain and Northern Ireland reaching 25 weeks of pregnancy if they had sought health advice from a doctor or midwife. The grant was introduced for women with a due date on or after 6 April 2009 and subsequently withdrawn for women reaching the 25th week of pregnancy on or after 1 January 2011.³⁴ The payment was not taxable and was disregarded for the purpose of means-tested benefits. Claim forms were available from the doctor or midwife; the health professional completed their section of the form, leaving the claimant to complete her part and return the form.

The HiP grant was designed to provide additional financial support in the last months of pregnancy towards a healthy lifestyle (e.g. in terms of diet), and it was suggested that the link to the requirement for pregnant women to seek health advice from a health professional may have provided an incentive for expectant mothers to seek the recommended health advice at the appropriate time.

The grant was paid by Her Majesty's Revenue and Customs (HMRC) on receipt of a claim form partly completed by the midwife or doctor. Payment was made directly into a bank account, with a telephone helpline available to provide support through the claims process, including options for payment in the event of difficulties opening a bank account. Take-up of the grant was said to be at about the same level as for child benefit (92%; HMRC, 2011, personal communication). Advice was offered as normal by doctors and midwives. Payment was made and administration undertaken by HMRC. The cost of the grant was met by the Treasury.

Rationale for the study

The HiP grant represented an attempt to influence behaviour – appropriate and timely receipt of antenatal care and advice – by means of a relatively modest, universally applied cash transfer. The evaluation of the effect of such a payment may inform other policy aiming to change behaviour. A study evaluating payments to influence health behaviour found that financial incentives were effective in increasing infrequent

behaviours such as attending clinic appointments, particularly in low-income groups, and recommended payments as being more effective than information and less restrictive than legislation.³⁵ In general, financial incentives have been shown to be a successful means of promoting behaviour change in general populations.³⁶ More recently, financial incentives have been shown to be effective in smoking cessation among pregnant women.³⁷ Among the general population, however, there is a suggestion of some mistrust of financial incentives as a means of promoting healthy behaviour.³⁸

The evaluation was restricted to Scotland based on the use of routinely collected data for the following reasons. First, data are available at a national level for the approximately 56,000 deliveries per year. Second, the coverage, completeness and quality of the data are considered to be very high. Third, the concentration of deprivation within parts of Scotland is unique within the UK. For example, 6 of the 10 most deprived electoral constituencies in the UK are in Scotland,³⁹ and using a UK-wide Cartstairs index Scotland's population is over-represented in the bottom five deciles compared with England.⁴⁰ If the programme was more beneficial to disadvantaged women, then the higher proportion of such women in Scotland than in the rest of the UK should make it easier to detect such a subgroup effect. Fourth, data on smoking at booking (i.e. the first antenatal appointment with a health-care professional) have been routinely recorded in Scotland for a number of years. This is not yet the case in England and Wales. Maternal discharge forms in Scotland can be linked to National Records of Scotland (NRS) civil registration data, which provide an estimate of completeness and also contribute further information such as social class.

In addition to the differences in terms of their deprivation profiles, England and Scotland differ markedly in terms of the ethnic composition of the two countries. In the 2011 census, 14% of the population of England and Wales described themselves as belonging to a non-white ethnic group⁴¹ compared with just 4% of the population of Scotland,⁴² and birthweight has been shown to vary markedly between the different ethnic groups within England and Wales.⁴³ Despite such differences, it is reasonable to believe that the results of this study will be generalisable both to the rest of the UK and internationally. If the HiP grant proved beneficial in Scotland, then there is every reason to believe that a similar impact on outcomes could be achieved elsewhere, and certainly in countries with similar health systems and comparable circumstances. Likewise, if the intervention was found to have been more effective for specific subgroups, then it might be expected that similar subgroups would show greater benefits in other settings.

The nature of the HiP grant meant that there were potential risks and harms to the population. The HiP grant was in the form of cash, which was given to the pregnant women with no constraint on what the money was used for or spent on. However, economic theory would suggest that cash transfers are more efficient than 'vouchers' or subsidies which try to target the expenditure in the direction of 'appropriate expenditure'. This is because vouchers, for example, free up disposable income if they displace planned expenditure.

Socioeconomic position and inequalities

This study focuses on socioeconomic position not only through examination of the causes of ill health – behavioural and biological factors, and the extent to which the socioeconomic patterning of these leads to health inequalities – but also through the causes of the causes.⁴⁴ Income is regarded as one marker of social position that may impact on, enhance or constrain health behaviours, and this in turn may be influenced by the wider policy context. A cash transfer such as this amounts to a change in material circumstances, and to the poorest this may be a substantial and enabling change.

The use of Scottish routine data sources means that socioeconomic position and inequalities can be assessed at both the individual and the area levels. The availability of both area-based deprivation and individual social class data enable the identification of the relative importance of context and composition and any interaction between individual- and area-level inequalities. This may, in turn, lead to the targeting of any cash transfers to particular groups of areas or individuals. With the large numbers of data available,

we have the power to examine the impact on different subgroups including the most deprived socioeconomic groups. Subgroup analyses are conducted for those groups seen as having the greatest potential to benefit from the payments, such as those living in the most deprived areas, those in the lowest social classes, lone mothers, primiparous women and teen mothers. These groups have been identified as having more adverse birth outcomes than the general population.³⁰

Marital status is an important subgroup, as single mothers have consistently been shown to have poorer birth outcomes.⁴⁵ We are particularly interested in single mothers and social class. The father's social class is used when he is included on the birth certificate, and the mother's social class is used if no father is present. Social class for lone mothers is therefore an amalgamation of socioeconomic position and lone parenthood.

Although the routinely collected data on ethnicity are incomplete and of dubious quality, ethnicity remains important for birthweight and other neonatal outcomes.⁴⁶ We shall, therefore, within the constraints of the data, undertake all analyses on the subgroup of women from a (non-white) minority ethnic background.

These subgroup analyses may lead to conclusions regarding whether or not the reintroduction of a cash transfer benefit universally or targeted at certain groups would help to reduce inequalities in birthweight and other adverse perinatal events.

Research objectives

The objective of this work is to evaluate the clinical effectiveness and cost-effectiveness of the HiP grants in Scotland. We do this by assessing the difference in birthweight between babies born to those mothers who were eligible for the HiP grant, and babies born either before the HiP grants were introduced (women delivering on or after 1 January 2004 and with a due date before 6 April 2009) or after it was withdrawn (women reaching the 25th week of pregnancy on or after 1 January 2011 and delivering on or before 31 December 2013). Specific questions that we address are outlined below.

- Did the HiP grant result in a change in birthweight (our primary outcome measure) or any of a number of secondary outcomes grouped as measures of maternal behaviour (gestation at booking, booking before 25 weeks and maternal smoking during this pregnancy), measures of size [very low birthweight (< 1500 g), low birthweight (< 2500 g), high birthweight (> 4000 g), crown-to-heel length and head circumference], measures of stage [gestational age at delivery, preterm (< 37 weeks), very preterm (< 32 weeks), weight for dates [standardised, SGA and large for gestational age (LGA)], and birth outcomes (elective caesarean section, emergency caesarean section, stillbirths, neonatal deaths and 5-minute Apgar score)?
- Were there differential impacts of the intervention for particular subgroups defined by socioeconomic (both area deprivation and individual occupational social class), demographic (marital status, age, ethnicity) or obstetric (parity, maternal obesity, maternal diabetes mellitus) factors?
- Were the HiP grants cost-effective? What were their total aggregate health and cost consequences? How did cost-effectiveness vary across important subgroups identified as having differential outcomes?

Chapter 2 Methods

Outcomes and causal pathway

The primary outcome measure was birthweight. This is influenced by maternal nutrition, and one of the intentions of the HiP grant was to improve this. There was also a range of secondary outcomes, which may influence and be influenced by birthweight. Having a wide range of secondary outcomes is included in the guidelines for evaluating natural experiments.⁴⁷ The secondary outcomes for this evaluation were maternal behaviour measures (gestation at booking, booking before 25 weeks and maternal smoking during this pregnancy), measures of size [very low birthweight (< 1500 g), low birthweight (< 2500 g), high birthweight (> 4000 g), crown-to-heel length and head circumference], measures of stage [gestational age at delivery, preterm (< 37 weeks), very preterm (< 32 weeks), weight for dates (standardised, SGA and LGA)], and birth outcomes (elective caesarean section, emergency caesarean section, stillbirths, neonatal deaths and 5-minute Apgar score).

If maternal nutrition is seen as a key behaviour that could be influenced both through the antenatal advice offered and through the money provided through the HiP grant, then we would expect to see changes only in the outcomes that we were studying if there was evidence of a link between maternal nutrition and birthweight and other outcomes. To be eligible for the HiP grant, women had to seek advice before the 25th week of their pregnancy. Although there was nothing to stop women booking earlier in their pregnancy, we might expect the group most impacted by the grant to be women who would normally have booked later but were incentivised to bring forward their booking to shortly before 25 weeks. For the intervention to work for such women, we would therefore need evidence that nutrition in the third trimester could affect birthweight (as our primary outcome).

A recent review of dietary intake during pregnancy based on epidemiological studies and randomised controlled trials suggested that there was evidence that maternal nutrition during the third trimester could have an impact on birth outcomes.⁴⁸ Adequate long-chain omega-3 polyunsaturated fatty acids are crucial during the third trimester for fetal growth and the development of the nervous system,⁴⁹ and a low leucocyte zinc concentration in the third trimester is associated with low birthweight.⁵⁰ Furthermore, a meta-analysis indicated that maternal haemoglobin levels in the third trimester were associated with birthweight, suggesting that iron is beneficial at this stage.⁵¹

An additional outcome of interest was maternal smoking. Maternal smoking is recorded at booking and during pregnancy, and is known to be a modifiable risk factor with a large impact on birthweight.^{52–54} We wanted to examine the effect of the health advice given when receiving the HiP grant. This may have had an impact on smoking during pregnancy rates, over and above that of the smoke-free legislation. The smoking ban in public places was introduced in Scotland in March 2006.⁵⁵

In the protocol we stated that models would be adjusted for maternal smoking. During the project, following discussion of the causal pathway with the project steering group, we refined the logic model. We decided that maternal smoking was something that could be affected by the antenatal care received as part of the HiP intervention and, therefore, that models should not be adjusted for maternal smoking. If the health advice given as part of the intervention reduced smoking, and models were then adjusted for smoking, any effect of the intervention would be undetectable.

Research design

Natural experiment using interrupted time series analysis

The HiP intervention was evaluated as a natural experiment using interrupted time series analysis.^{56,57} It was not possible to use a randomised or pseudo-randomised design for a number of reasons. The HiP grant was available to all pregnant women over 25 weeks' gestation so there was no control group. The grant was introduced in April 2009 and withdrawn in January 2011 and was universal, so there was no random allocation to the population. The interrupted time series approach allowed us to compare an intervention group that received the HiP grant both with a comparison group of pregnant women who delivered before the HiP grant was introduced and with a post-intervention group of women who delivered after the HiP grant was withdrawn.

Outcomes before the introduction of the HiP grant in Scotland and immediately after its withdrawal were compared with those during the period for which HiP existed. This interrupted time series approach allowed adjustment for seasonality and temporal trends as well as for the sociodemographic and obstetric characteristics of the mother. This adjustment for seasonality and temporal trends was important, as birthweight (our primary outcome) is known to vary by month of birth (babies born in March, April and May are heavier than those born in June, July and August) and, in addition, mean birthweight has been increasing in Scotland.⁵⁸

The Medical Research Council (MRC) has issued guidelines regarding the use of natural experiments to evaluate population health interventions when exposure to the intervention has not been manipulated by the researchers.⁴⁷ The guidance advocates a number of designs including regression discontinuity designs such as interrupted time series.

Interrupted time series can detect a discontinuity in the intercept and a discontinuity in the slope of estimates during the intervention period compared with before the intervention period.⁵⁹ The interrupted time series design can describe the effect of the intervention on three dimensions: (1) the intercept and slope; (2) the permanence of the effect; and (3) the immediacy of the effect. In terms of the HiP grant, permanence was assumed during the period in which the HiP grant was in place, such that the effect of HiP did not dilute over time, as everyone during that period was given the health advice and the £190 cash intervention. Once HiP was removed, the assumption was that any effect stopped. Sensitivity analyses were carried out on nulliparous women to determine any carryover effect on those who had never received advice or cash (see *Strengthening the inference*).

In order to conduct an analysis using interrupted time series, a well-defined interruption in the time series is required, and it is recommended that there are at least eight data points in the time series before the interruption and eight data points after the interruption. Other weaknesses include the inability to determine whether or not any effects on the intercept or slope were attributable to something other than the intervention which affected the outcome and which happened at the same time as the intervention; if using routinely collected data, robust evaluation may be hampered by any changes to the data collection method or coding of items, and a change in the composition of the group experiencing the intervention compared with those who do not experience the intervention may make comparison difficult.

The HiP grant was introduced for all pregnant women over 25 weeks' gestation from a fixed date, meaning that there is a well-defined interruption in the time series of births in Scotland. Individual births were used and the pre-intervention time period ran from 1 January 2004 to 30 March 2009. Our data included month of birth, meaning that there were 63 time points (months) before the interruption; the intervention period ran from 14 April 2009 to 7 April 2011 (25 time points) and the post-intervention period ran from 23 April 2011 to 31 December 2013 (33 time points). Each of these is markedly greater than the minimum recommendation of eight time points but these figures do not reflect the full power of the study, which is achieved by using 525,400 individual observations (births; *Figure 1*). The routine data used here have not been subject to any changes in the data collection method or coding, other than




FIGURE 1 Flow chart showing observations received from the Information and Services Division, removal of outliers and final sample size for analyses. BMI, body mass index; IQR, interquartile range.

better (more complete) recording of each item. There have been changes in the composition of mothers who gave birth during the intervention period compared with those who gave birth pre and post intervention, but maternal social and obstetric factors were adjusted for in the analyses. However, one of the potential weaknesses of the interrupted time series design, namely the inability to control for external events that happen at the same time, is much harder to overcome. Sensitivity analyses were carried out moving the HiP grant window to determine any changes in the effect of HiP on birthweight and other secondary outcomes (see *Strengthening the inference*).

Study population including definitions of subgroups

The population under study was all births in Scotland between 1 January 2004 and 31 December 2013. This was split into three distinct periods: the pre-intervention period, the intervention period during which the HiP grant was in place and the post-intervention period. The grant was introduced for women with a due date on or after 6 April 2009 and subsequently withdrawn for women reaching the 25th week of pregnancy on or after 1 January 2011.³⁴ Therefore, the HiP grant was effectively in place for all births with a due date of delivery during the period 6 April 2009 to 15 April 2011.

In order to assign births to the correct study period, the estimated due date of delivery was calculated from the gestational age at delivery and date of birth. Gestational age at delivery was recorded in weeks, so there was a small loss of precision around the estimated due date of delivery. A washout period of 2 weeks around the start was chosen to ensure that births were assigned to the correct group. Births 1 week before the date on which the intervention was introduced and 1 week after the intervention start date were excluded. A similar washout period of 1 week before the end date and 1 week after the end date was used. The births occurring in the pre- and post-washout periods were excluded from the analyses. Therefore, the dates for the three study periods were: pre-intervention period, 1 January 2004 to 30 March 2009; intervention period, 14 April 2009 to 7 April 2011; post-intervention period, 23 April 2011 to 31 December 2013 (*Table 1*).

This evaluation used pre-existing routinely collected health data. There was no recruitment, assessment or follow-up of individuals to the study, as the information is already available in routinely collected data. The Scottish maternity and neonatal database, a comprehensive record linkage system, was used.⁶⁰ Probabilistic linkage procedures are used to add a unique identifier to all data sets to ensure that all records relating to an individual can be linked as required. It facilitates the linkage of a number of records from the system of Scottish Morbidity Records (SMR), including the mother's obstetric records (SMR02) and the baby's birth and neonatal information from Scottish Birth Records (SBR).⁶¹ Further links to the Stillbirth and Infant Death Survey and the NRS birth, stillbirth and infant death records can be carried out.⁶⁰ All births in Scotland are required to be registered at NRS within 4 weeks, and 98% of these births are included in the Scottish maternity and neonatal database. This link to NRS civil registration data provides an estimate of completeness and contributes further information such as social class and marital status.

TABLE 1 Dates for the study periods and washout periods

Period	Start date	End date
Pre intervention	1 January 2004	30 March 2009
2-week washout	31 March 2009	13 April 2009
Intervention	14 April 2009	7 April 2011
2-week washout	8 April 2011	22 April 2011
Post intervention	23 April 2011	31 December 2013

Socioeconomic position and inequalities were measured at both the individual and area level. The availability of both area-based deprivation and individual social class allowed for the identification of the relative importance of context and composition. Area deprivation was measured using the Scottish Index of Multiple Deprivation (SIMD) 2009.⁶² The SIMD combines information across six domains: (1) income; (2) employment; (3) health; (4) education; (5) housing; and (6) geographical access. It provides a comprehensive picture of material deprivation in small areas within Scotland. The index ranks 6505 areas from the most deprived to the least deprived and measures the degree of deprivation of an area relative to that of other areas. The areas employed by the SIMD are data zones; each of the 6505 zones has a mean population of 780 people. The reason for employing small-area geography at this scale is to permit identification of relatively small pockets of deprivation. The health domain includes an indicator of the proportion of live singleton births of low birthweight. Outcomes for this project are birthweight and low birthweight; therefore, it was not appropriate to use the health domain or the composite index, which includes the health domain. The income domain was used to assess inequalities at the area level. The income domain contains six indicators relating to receipt of means-tested benefits and tax credits.

Individual socioeconomic position was measured using data from the birth registrations at NRS. NRS collects occupation information for both fathers and mothers for births registered to married couples and jointly registered by unmarried couples. For sole registered births only the mother's occupation is recorded. National Statistics Socioeconomic Classification (NS-SEC) was used to measure individual socioeconomic position. The father's social class is used when the father is included on the birth certificate and the mother's social class is used if no father is present.

The HiP grant was a universal benefit. We wanted to examine the impact of HiP on subgroups, as this may lead to the targeting of any cash transfers to particular groups of areas or individuals. With the large numbers of data available, there was power to examine the impact on different subgroups, including the most deprived socioeconomic groups. Subgroup analyses were conducted for those groups seen as having the greatest potential to benefit from the payments. The subgroups that we analysed were those groups previously identified as having more adverse birth outcomes, specifically those living in the most deprived areas (SIMD = 1), mothers who had never worked, working-class mothers (three-class collapsed version of NS-SEC⁶³), lone mothers, teen mothers (aged < 20 years), severely obese mothers [body mass index (BMI) of $\geq 35 \text{ kg/m}^2$], and mothers who had diabetes mellitus. We carried out further analyses on all SIMD quintiles to look for evidence of a threshold effect of the HiP grant.

Marital status was an important subgroup, as single mothers have consistently been shown to have poorer birth outcomes.⁴⁵ We were particularly interested in the relationship between single mothers and social class. Social class for lone mothers is an amalgamation of socioeconomic position and lone parenthood.

An increase in birthweight, although desirable at a population level, may not be a beneficial outcome if a baby is already at risk of being LGA. Separate subgroup analyses were conducted for women seen to be at high risk of delivering a LGA baby, namely women with a BMI of $\geq 35 \text{ kg/m}^2$ and women with diabetes mellitus.

A further key subgroup for birth outcomes was the ethnicity of the mother. In Scotland the routinely collected data on ethnicity are incomplete and of dubious quality (56.5% missing over the period 2004–13). We carried out analyses of the primary and secondary outcomes on the subgroup of women from a minority ethnic background. In practice, this was all non-white mothers who had their ethnicity recorded on the birth record data. It was not possible to examine further distinctions within this non-white ethnic group.

We hoped that these subgroup analyses would inform a discussion regarding the reintroduction of a cash transfer benefit universally or its potential to be targeted at certain groups, thus reducing inequalities in birthweight and other adverse perinatal events.

Data

Ethics and information governance

The data came from the Scottish maternity and neonatal database held by the Information and Services Division (ISD) at the NHS National Services Scotland. These data are routinely collected information from maternal and birth records from all hospitals in Scotland. The release of the data for research purposes was subject to agreement (6 May 2014; PAC38A/13) from the Privacy Advisory Committee at NHS National Services Scotland and the Registrar General.⁶⁴ This approval served as ethical approval to undertake the research. The data collection, storage and release for research purposes were subject to strict ISD protocols governing privacy, confidentiality and disclosure of data (www.isdscotland.org/Products-and-Services/Data-Protection-and-Confidentiality) and, as such, the data cannot be shared by the researchers. The MRC/Chief Scientist Office (CSO) Social and Public Health Science Unit, University of Glasgow was the nominated sponsor of the research. The data provided by the ISD were anonymised, and access to the individual data was restricted to three of the investigators (SO, RD and AL).

Structure of the data

Individual birth records were available for analysis in this study. Over the 10-year time period there were multiple births to some mothers. Therefore, the structure of the data was multilevel; births were nested within mothers and mothers were nested within small geographic areas known as data zones. It was necessary to take this structure into account when calculating the power and effect sizes detectable for the study and also during the analyses.

Power calculation

The data were clustered in small areas, that is, 6505 data zones. Each data zone has an average population of 780. The sample size calculation takes this clustering into account. Assuming an average of 56,000 singleton live births per year, and allowing for the clustering within the 6505 data zones in Scotland with an estimated intraclass correlation coefficient of 0.05, there was a power of 0.90 to detect an effect of a 7-g change in birthweight at a 95% significance level. It was acknowledged that 7 g was unlikely to be a clinically important threshold; rather, it was indicative of the power of the study. The large data set available allowed for subgroup analysis. In the 20% most deprived areas there was a power of 0.80 to detect an effect of 13 g; among the 26% of single mothers, there was a power of 0.80 to detect an effect of 11 g. To put these small effects into context, 50 g was the estimated mean birthweight reduction reported in the meta-analysis of the effect of interventions in pregnancy on maternal and obstetric outcomes.⁶⁵ In terms of gains in birthweight a recent study showed a 70-g increase for every 10-mg/day increase in dietary iron intake (reducing to 34 g on adjustment for maternal factors).⁶⁶

Outcome measures

The primary outcome measure, birthweight, had a completion rate of 99.9%. There was a high completion rate (< 1.5% missing) for all outcome variables, with the exception of crown-to-heel length (46.4% missing), head circumference (26.3% missing), gestational age at booking (15.4% missing) and maternal smoking (8.9%).

Covariates

Birthweight can be affected by many obstetric and maternal characteristics, such as the sociodemographic determinants of the baby and mother and medical risks of the current and previous pregnancies, as well as the environmental and behavioural characteristics of the mother. (For the covariates used in this study, see *Table 4*. Item non-response rates for each of the covariates by year are shown in *Table 14*.) The missingness ranged from no missing values for the baby's sex (although note that 44 cases with missing sex were excluded; see *Figure 1*) to 83.3% for ethnicity in the year 2004. As marital status was poorly recorded in the ISD maternity data, marital status from the linked NRS birth registration was used.

The linkage to the NRS birth records allowed for the measurement of individual social class. Occupational social class as measured by NS-SEC was used as a measure of individual socioeconomic position. SIMD 2009 was used as a measure of area-based deprivation.

Removing outliers

A strength of using routinely collected data is the size of the sample available to analyse. However, a drawback is that researchers are unable to return to the original data collector to check and edit implausible values. There were issues with extreme values for some of the continuous variables such as maternal height and weight. In order to ensure the quality of the data, two methods were used to identify implausible values and outliers. Previously published values were used to identify completely implausible values for head circumference, crown-to-heel length, maternal weight and maternal BMI,^{67,68} and Tukey's method for removing outliers was used.⁶⁹ Tukey's method identifies values above and below a certain fraction of the interquartile range (IQR). The formulae used to identify the outliers in the data set were:

$$\text{Values} < (\text{Quartile } 1) - (3 \times \text{IQR}). \quad (1)$$

$$\text{Values} > (\text{Quartile } 3) + (3 \times \text{IQR}). \quad (2)$$

These cases were identified as outliers and removed from the data set (see *Figure 1*).

Imputation methods

Item non-response values were imputed using multiple imputation by chained equations (MICE). MICE uses a series of univariate analyses to predict missing values. For each variable to be imputed, imputed values are drawn from a conditional distribution based on univariate regression models. This process is repeated multiple times using previously estimated values and converges to a stable multivariate solution. The multiple imputation commands within Stata (StataCorp LP, College Station, TX, USA) version 13 were used.⁷⁰

The variables used in the imputation model to predict the missing values were: health board of residence; health board of treatment; birthweight; head circumference; gestational age at booking; gestational age at delivery; maternal age; maternal weight at booking; maternal height; parity; SIMD; primary household SES; ethnicity; marital status; maternal smoking during pregnancy; maternal smoking at booking; diabetes mellitus; 5-minute Apgar score; mode of delivery; outcome of the pregnancy; sex; birth year; birth month; and study period (pre intervention, intervention, post intervention).

Before being used in the imputation model, continuous variables were transformed using the *Inskew0* command in Stata. The transformations were $\ln(-x - k)$ if x was negatively skewed and $\ln(x - k)$ if x was positively skewed.⁷¹

Owing to the large proportion of missing values, ethnicity was not used in the imputation model and missing values for ethnicity were not imputed. Given that a high proportion of values were missing for crown-to-heel length (46.4%), we also chose not to impute these data. The clustering of births within mothers, data zones and health board was ignored when creating the imputed data sets. Instead of using the hierarchical structure of the data – births nested within mothers nested within data zones nested within health board – health board of hospital of birth and health board of residence of mother were used in the imputation model as fixed effect parameters. The variable included in the imputation that had the most missing values over the study period (2004–13) was head circumference, with 26.3% missing. Therefore, 30 imputed data sets were created, in line with recommendations.⁷² Although there are no strict rules regarding the circumstances under which multiple imputation should be conducted, we felt that it was reasonable to impute just over one-quarter of the data for this one variable given the large number of covariates available on which to base our imputation. These data sets were analysed identically and the results were combined to get estimates and standard errors for the multiple imputed data. These results were compared with the complete-case analysis results.

Numbers of observations used in analyses

The data set from ISD contained all singleton births in Scotland with a date of birth between 1 January 2004 and 31 December 2013. For this analysis, only births between 24 and 44 weeks' gestation were included. *Figure 1* details how observations were removed. The initial population size was 543,676 births (24–44 weeks' gestation). There were exclusions attributable to impossible-to-resolve gestational age at booking and gestational age at delivery, implausible values and outliers. Births with an expected date of delivery before 1 January 2004 and after 31 December 2013, and births during the washout period around the intervention introduction and withdrawal dates were also removed. Overall, 18,276 (3.4%) cases were removed from the data set sent by ISD. The final sample available for analyses was 525,400.

For the subgroup analyses the size of the data sets are shown in *Tables 2* and *3*. The sample sizes are shown for the complete cases and also the sizes for the imputed data sets. There were a range of values for five subgroups and one strengthening the inference group. These were mothers with diabetes mellitus, severely obese mothers, lone mothers, mothers in working-class households, mothers in never-worked households and nulliparous mothers. This was due to missing values for these variables and, therefore, they were imputed, sometimes as being in the category concerned and sometimes not. The sample sizes range from just over 8000 in the diabetes mellitus subgroup to > 180,000 mothers in working-class households. There were over 240,000 births in the nulliparous group.

Statistical analysis

It is possible that harm may have occurred as a result of the cash transfer. The £190 was given as money to the pregnant women with no restriction on how it should be spent, and we do not know what the money was spent on. The aim was to examine how the intervention group differed from the comparison groups; birthweight could have reduced or increased. We carried out two-sided hypothesis tests to ensure that potentially harmful effects could be detected.

TABLE 2 Sample sizes for subgroup analyses

Imputed	Numbers ^a			
	Pre intervention	Intervention	Post intervention	Total
Main population	271,826	109,366	144,208	525,400
SIMD1	69,975	28,669	38,004	136,648
SIMD2	55,685	23,127	30,788	109,600
SIMD3	50,328	20,738	27,624	98,690
SIMD4	48,680	19,421	25,207	93,308
SIMD5	47,158	17,411	22,585	87,154
Mothers with diabetes mellitus	3170–3331	1713–1748	3448–3481	8361–8529
Severely obese mothers	19,216–19,612	9027–9175	12,879–13,039	41,249–41,739
Lone mothers	15,978–16,040	5881–5929	7255–7284	29,147–29,214
Working class	94,468–94,644	37,598–37,661	49,480–49,593	181,635–181,827
Never worked class	41,612–41,701	17,423–17,457	23,309–23,366	82,398–82,501
Teen mothers	20,764	7364	7821	35,949
Nulliparous	126,843–126,963	51,705–51,747	65,336–65,379	243,921–244,048
After smoking ban (main population)	122,012	109,775	144,663	375,093

TABLE 2 Sample sizes for subgroup analyses (*continued*)

	Numbers ^a			
Imputed	Pre intervention	Intervention	Post intervention	Total
Complete cases				
SIMD1	69,975	28,669	38,004	136,648
SIMD2	55,685	23,127	30,788	109,600
SIMD3	50,328	20,738	27,624	98,690
SIMD4	48,680	19,421	25,207	93,308
SIMD5	47,158	17,411	22,585	87,154
Mothers with diabetes mellitus	2422	1664	3390	7476
Severely obese mothers	11,539	7208	10,852	29,599
Lone mothers	15,546	5824	7200	28,570
Working class	92,067	37,181	48,694	177,942
Never worked class	40,471	17,216	22,932	80,619
Teen mothers	20,764	7364	7821	35,949
Nulliparous	126,005	51,392	65,198	242,595
Non-white mothers	4810	4631	7694	17,135
<p>a The numbers relate to the following outcomes: birthweight; low birthweight; high birthweight; gestational age at booking; booking before 25 weeks; gestational age at delivery; preterm; very preterm; weight-for-dates z-score; SGA; LGA; head circumference; crown-to-heel length; elective caesarean; emergency caesarean; 5-minute Apgar score; neonatal death.</p> <p>Note Stillbirths were not included when analysing the above outcomes.</p>				

TABLE 3 Sample sizes for subgroup analyses

Imputed	Numbers ^a			Total
	Pre intervention	Intervention	Post intervention	
Main population	272,935	109,775	144,663	527,373
SIMD1	70,344	28,793	38,139	137,276
SIMD2	55,929	23,220	30,882	110,031
SIMD3	50,525	20,829	27,710	99,064
SIMD4	48,845	19,478	25,280	93,603
SIMD5	47,292	17,455	22,652	87,399
Mothers with diabetes mellitus	3199–3366	1725–1760	3471–3504	8428–8597
Severely obese mothers	19,341–19,739	9091–9239	12,954–13,115	41,522–42,014
Lone mothers	15,978–17,144	5881–6,332	7255–7732	29,153–31,178
Working class	94,683–95,610	37,629–37,982	49,591–49,944	181,903–183,536
Never work class	41,638–42,623	17,454–17,792	23,331–23,704	82,445–84,119
Teen mothers	20,864	7393	7849	36,106
Nulliparous	126,556	51,604	65,447	243,607
After smoking ban (main population)	122,012	109,775	144,663	376,450
continued				

TABLE 3 Sample sizes for subgroup analyses (*continued*)

	Numbers ^a			
Imputed	Pre intervention	Intervention	Post intervention	Total
Complete cases				
SIMD1	70,344	28,793	38,139	137,276
SIMD2	55,929	23,220	30,882	110,031
SIMD3	50,525	20,829	27,710	99,064
SIMD4	48,845	19,478	25,280	93,603
SIMD5	47,292	17,455	22,652	87,399
Mothers with diabetes mellitus	2446	1675	3410	7531
Severely obese mothers	11,617	7260	10,914	29,791
Lone mothers	15,546	5824	7200	28,570
Working class	92,070	37,181	48,695	177,946
Never worked class	40,471	17,217	22,932	80,620
Teen mothers	20,864	7393	7849	36,106
Nulliparous	127,399–127,516	51,917–51,959	65,585–65,629	243,607
Non-white mothers	4838	4655	7726	17,219
^a The numbers relate to the following outcomes: stillbirth, maternal smoking.				
Note				
Stillbirths were included when analysing the above outcomes.				

The main statistical design used was interrupted time series.⁵⁹ Interrupted time series can detect whether or not the intervention has an effect over and above the underlying temporal trend; it detects whether or not the effect size (slope) changes after the intervention has been introduced. The use of interrupted time series overcomes other biases such as autocorrelation of repeated measurements (measurements taken close together are related), seasonal effects (birthweight varies according to month of birth), the duration of the intervention (pre-intervention, intervention and post-intervention comparisons) and random variation of the measurement (birthweight).

Outcomes were measured on individual births, which were nested within mothers, with mothers themselves clustered within data zones. Multilevel models were used to determine whether or not the outcomes changed during the intervention period in which the HiP grants were in effect. Multilevel linear regression was used for continuous outcomes (birthweight, gestation at booking, gestational age at delivery, weight-for-dates). Multilevel logistic regression was used when the outcome was dichotomous [booking before 25 weeks, maternal smoking during pregnancy, stillbirths, neonatal deaths, very low birthweight (< 1500 g), low birthweight (< 2500 g) and high birthweight (> 4000 g), preterm (< 36 weeks), very preterm (< 32 weeks), SGA and LGA, elective caesarean section, emergency caesarean section and 5-minute Apgar score of < 7]. Two-level models with births nested within data zones were fitted for the following outcomes: very low birthweight, very preterm, stillbirth and neonatal deaths (*Table 4*), as the three-level model, which included a level for mothers nested within data zones, did not converge owing to the sparseness of the data (few, and often just one, births per woman).

All analyses were adjusted for temporal trends and seasonal variations in outcomes as well as for maternal age, sex of baby, gestational age at delivery, parity, mode of delivery, marital status, maternal height, maternal BMI, maternal diabetes mellitus, social class and area deprivation. *Table 4* details the exact covariates included in the model for birthweight and all secondary outcomes. (Note that not all covariates were included in each model.) In the protocol, it was stated that adjustments would also be made for

TABLE 4 Main models specification (unadjusted for gestational age at booking and maternal smoking)

	Birthweight ^a				Booking status		Measures of stage						Measures of size		Other birth outcomes					Maternal smoking during pregnancy
Covariates	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD					
															ElC	EmC	SB	5 ApS	ND	
Periods	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Period 1: pre intervention	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Period 2: intervention (HiP grant)																				
Period 3: post intervention																				
Year	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<i>Interaction year period</i>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Period 1																				
Period 2																				
Period 3																				
Months	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
January	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
February																				
March																				
April																				
May																				
June																				
July																				
August																				
September																				
October																				
November																				
December																				

continued

continued

TABLE 4 Main models specification (unadjusted for gestational age at booking and maternal smoking) (*continued*)

Covariates	Birthweight ^a				Booking status		Measures of stage						Measures of size		Other birth outcomes					Maternal smoking during pregnancy	
	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD		EIC	EmC	SB		5 ApS
Sex	X	X	X	X			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Male	Ref	Ref	Ref	Ref			Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Female																					
Gestational age at delivery (weeks)	X	X	X	X						X			X	X	X	X	X	X	X	X	X
Quadratic term gestational age at delivery (weeks)	X			X						X			X	X	X	X	X	X	X		
Birthweight (g)													X	X					X	X	
Quadratic term birthweight (g)													X	X					X		
Modes of delivery																			X	X	
Vaginal																				Ref	Ref
Elective caesarean																					
Emergency caesarean																					
Age (years) group	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
< 20	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
20–24																					
25–29																					
30–34																					
35–39																					
≥ 40																					

Covariates	Birthweight ^a				Booking status		Measures of stage						Measures of size		Other birth outcomes					Maternal smoking during pregnancy
	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD		SB	5 ApS	ND	
BMI at booking (kg/m²)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X	X	
Quadratic term BMI at booking (kg/m²)	X	X		X	X	X	X	X	X	X	X	X			X	X				
Height (cm)	X	X	X	X			X	X	X	X	X	X	X	X	X	X		X	X	
Quadratic term height (cm)	X	X		X			X	X		X	X		X		X	X				
Ethnic groups^a	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Non-white	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
White																				
Parity	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
0	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
1																				
2																				
3+																				
Marital status	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X	X	X
Married to each other	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref		Ref	Ref	Ref
Joint registration: same address																				
Joint registration: different address																				
Sole registration																				

continued

TABLE 4 Main models specification (unadjusted for gestational age at booking and maternal smoking) (continued)

[illegible]

Covariates	Birthweight ^a				Booking status		Measures of stage						Measures of size		Other birth outcomes					Maternal smoking during pregnancy		
	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD	EIC	EmC	SB	5 ApS		ND	
Previous caesarean section																						
No				X																		X
Yes				Ref																		Ref
Statistical models																						
Three-level linear regression (area, maternal and baby level)	+				+		+			+			+	+								
Three-level binomial logistic regression (area, maternal and baby level)		+		+		+		+			+	+				+	+		+	+		
Two-level binomial logistic regression (area and baby level)			+						+									+		+		
X, variables considered for adjustment in the statistical analysis; +, statistical models; 5 ApS, 5-minutes Apgar score; Bb425W, booking before 25 weeks; BW, birthweight; CHL, crown-to-heel length; EIC, elective caesarean; EmC emergency caesarean; GB, gestational age at booking; GD, gestational age at delivery; HBW, high birthweight; HC, head circumference; LBW, low birthweight; MD, mode of delivery; ND, neonatal death; Ref, reference; SB, stillbirth.																						
a Complete cases adjusted for ethnicity.																						

maternal smoking. However, this was not done owing to the intention of the intervention to have a potential effect on maternal behaviour such as maternal smoking (see *Outcomes and causal pathway*). In order to comply with the protocol, results are presented for both adjusting and not adjusting for maternal smoking. Temporal trends were assessed by the inclusion of time (year and month) terms in the model, and seasonal variations were assessed by the inclusion of month as a fixed effect. Departures from a linear trend were assessed using quadratic terms in addition to linear terms for maternal height, maternal BMI, gestational age and birthweight when used as a covariate and categories for maternal age. Quadratic terms were assessed in the models for each outcome and tested for significance using the complete cases. The best fit for each outcome was chosen and that model was used for all other models for that outcome. *Table 4* details which models had quadratic terms included for maternal height, maternal BMI, gestational age at delivery and birthweight.

The simplest model for the intervention effect included a dummy variable 'intervention period' with three categories (pre intervention, intervention and post intervention), with adjustment for relevant factors (see *Table 4*). To assess whether or not the temporal trend was constant across the three different periods, an interaction between the intervention period and year was fitted for each outcome.

The modelling strategy was to fit a series of increasingly complex models for each outcome. The first model was a null model containing the outcome and a constant. Models with two or three levels were fitted according to whether or not the models converged (*Table 4*). Then, a model including the relevant covariates was fitted and, finally, a model including all relevant covariates and the interaction between period and year was fitted. If the interaction was significant, then that model was chosen; if the interaction was not significant, then the model without the interaction was chosen. This strategy was followed using the complete cases and once the final model (including interaction or not) was selected, that model was used to fit all subsequent models for that outcome, including the subgroups and moving window analyses.

In order to make the results for period interpretable when the interaction was significant, two separate models were fitted.

Fitting interaction models

To estimate the effect for the intervention period, the variable *year* was centred around 2010 (i.e. coded from -6 in 2004 to +3 in 2013). Using the variables *period_1* (pre intervention: 1, yes; 0, no), *period_2* (intervention: 1, yes; 0, no) and *period_3* (post intervention: 1, yes; 0, no), the interactions were created as follows (model M1):

$$\begin{aligned} \text{int_1} &= \text{period_1} \times \text{year} \\ \text{int_2} &= \text{period_2} \times \text{year} \\ \text{int_3} &= \text{period_3} \times \text{year}. \end{aligned}$$

To estimate the effect for the post-intervention period (*period_3*), *year* was centred around 2012 and the interactions were created as follows (model M2):

$$\begin{aligned} \text{int_1} &= \text{period_1} \times (\text{year} - 2) \\ \text{int_2} &= \text{period_2} \times (\text{year} - 2) \\ \text{int_3} &= \text{period_3} \times (\text{year} - 2). \end{aligned}$$

In each case the model contained an intercept, *period_2*, *period_3*, *int_1*, *int_2* and *int_3* in addition to the other variables. Identical estimates of *int_1*, *int_2* and *int_3* (and all other variables) were obtained under both models; only the estimates of the intercept, *period_2* and *period_3* differed.

The interpretation of *period_2* is then the effect of the intervention in the middle of the intervention period compared with the outcome that would have been expected had the pre-intervention trend continued. Similarly, the interpretation of *period_3* is the post-intervention effect, measured in the middle of the post-intervention period, compared with the effect that would have been expected had the pre-intervention trend continued.

Subgroup analyses

Subgroup analyses were conducted for those groups seen to have the greatest potential to benefit from the payments, namely those living in the most deprived areas, those in the 'never worked' social class group, those in the 'manual worker' social class group, lone mothers, teen mothers, and those mothers for whom an increase in mean birthweight was not desirable, namely severely obese mothers and mothers with diabetes mellitus. For each group the main analysis was replicated, and the results from the combined analysis of the 30 imputed data sets are reported.

Given that some subgroups contained small numbers, and bearing in mind the potential importance of the intervention, the results of all subgroup analyses are reported rather than just those that reached statistical significance. The above process involved conducting many tests which are not independent of each other. Rather than adjusting confidence intervals (CIs) or *p*-values to account for this, the results of all analyses are presented, and caution should be exercised when interpreting results that are close to conventional statistical significance. Readers should use the width of the CI, which shows the range of possible effect sizes, to aid their interpretation.

Ethnicity

Ethnicity was poorly recorded in the routine data set, with 56.5% of data missing over the 10-year period. Missingness varied across the years; 83.3% of data were missing in 2004 and 23.6% in 2013. Ethnicity was not imputed and was not included in the main analyses. In order to gauge the effect of ethnicity on the HiP grant intervention, analyses were carried out on the subgroup of non-white mothers identified in the data set. In addition, the models for the complete cases were fitted to include ethnicity along with other covariates.

Economic analysis

The objective of the economic analysis was to assess the total aggregate health and cost consequences attributable to the HiP grant during its years of implementation (April 2009 to April 2011) from the perspective of the NHS. The pre-intervention years (January 2004 to March 2009) served as the comparison.

Health and cost consequences were mediated through either a birthweight or a gestational age at birth perspective, in addition to smoking during pregnancy. Birthweight was categorised as very low (< 1500 g), low (1500–2499 g) or normal (> 2500 g). Gestational age at birth was categorised as very preterm (< 33 weeks), preterm (33–36 weeks) or normal (> 36 weeks).

All costs are presented in 2015 Great British pounds using the Hospital and Community Health Services index⁷³ to adjust, where necessary. No discounting was used.

Model overview

Figure 2 presents the conceptual analysis approach. We presented the health and cost change during the intervention period compared with during the pre-intervention period. The model is based on the incremental numbers of cases (of preterm, low birthweight or poor maternal outcomes) attributable to the HiP grant. This can be explained in five steps:

1. estimate the baseline cases per annum during the pre-intervention period, apply to an intervention duration
2. apply the adjusted effect of the intervention
3. estimate the intervention period cases
4. estimate the total incremental cases during the entire intervention period
5. estimate the cost impact.




FIGURE 2 Conceptual analysis approach.

Parameter sources

A summary of parameters used in the model is presented in *Table 5*.

Health outcomes

The incremental number of cases attributable to the HiP grant was derived from adjusted effect estimates from the HiP grant analysis. The outputs of the HiP grant analysis included a number of dependent variables, including each of the birthweight, gestational age and maternal smoking covariates that were adjusted for a number of covariates (see *Statistical analysis*). In the main analysis using imputed data, the HiP grant had no significant effect on very preterm (OR 1.11, 95% CI 0.98 to 1.25) and preterm (OR 1.02, 95% CI 0.97 to 1.08) births. The HiP grant also trended towards a reduction of very low birthweight (OR 0.87, 95% CI 0.68 to 1.10) but had a negligible effect on low birthweight (OR 1.02, 95% CI 0.96 to 1.09). The HiP also had no effect on maternal smoking (OR 1.02, 95% CI 0.99 to 1.06). The effect of maternal smoking on health was, in turn, mediated through a composite of ectopic pregnancy, placenta previa, abruptio placentae, preterm premature rupture of membranes (PPROM) and pre-eclampsia.

TABLE 5 Parameters used in the model

Adjusted intervention effect	Mean, OR	SE, ln OR	Source
Preterm	1.02	0.06	HiP
Very preterm	1.11	0.06	HiP
Smoking during pregnancy	1.02	0.02	HiP
Low birthweight	1.02	0.03	HiP
Very low birthweight	0.87	0.12	HiP
Baseline maternal smoking	23%		HiP
Cost of HiP grant (£1 × 6)	20.422		HiP
Costs by gestational age	Mean (£)	SE (£)	Source
Very preterm (< 33 weeks)	7591	363	74–76
Preterm (33–36 weeks)	2078	25	74–76
Normal (> 36 weeks)	893	3	74–76
Costs by birthweight	Mean (£)	SE (£)	Source
Very low (< 1500 g)	6428	380	74–76
Low (1500–2499 g)	2138	36	74–76
Normal (> 2500 g)	905	3	74–76
Costs by maternal outcome	Mean (£)	SE (£)	Source
Ectopic pregnancy	2083	417	74–76
Placenta previa	12,099	2420	74–76
Abruptio placentae	9139	1828	74–76
PPROM	4772	954	74–76
Pre-eclampsia	10,466	2093	74–76

In OR, natural logarithm of the OR; PPRM, preterm premature rupture of membranes; SE, standard error; £, 2015 Great British pounds.

Cost parameters

Unit costs by gestational age, birthweight and maternal outcomes were derived from a re-analysis of the Oxford Record Linkage Study⁷⁵ and NHS Reference Costs,⁷⁶ which were summarised in a report by Godfrey *et al.*⁷⁴ on smoking during pregnancy.

Because the cost of a preterm birth is a composite cost of different costs related to different gestational ages, a weighted cost must be derived. In Godfrey *et al.*'s⁷⁴ report, gestational age was categorised as 20–23 weeks; 24–27 weeks; 28–31 weeks; 32–36 weeks; or 37+ weeks (*Table 6*). Each cost by gestational age was then weighted by the estimates of prevalence in the HiP pre-intervention period to derive weighted estimates of very preterm (< 33 weeks), preterm (33–36 weeks) and normal (> 36 weeks). Note that very preterm consisted of the categories including 28–31 weeks and preterm consisted of 32–36 weeks.

The total weighted index hospitalisation cost of a preterm birth was £2801 (*Table 6*), whereas the cost of a birth at normal gestational age was estimated to be £893.

Similar methods were used to generate unit costs for birthweight (*Table 7*). The weighted costs of very low birthweight (< 1500 g), low birthweight (1500–2499 g) and normal birthweight (> 2500 g) were £6428, £2138 and £905, respectively.

Smoking during pregnancy costs were estimated by taking account of their attributable effects on negative pregnancy outcomes. Smoking during pregnancy increases the risks of poor maternal outcomes, such as ectopic pregnancy, placenta previa, abruptio placentae, PPRM and pre-eclampsia.⁷⁴ The unit costs of each are summarised in *Table 5*.

The cost of the HiP grant used in the model was £20.422 million. It should be noted that this is a slight underestimation of the true cost (£20.780 million); this reflects the fact that the annual number of births

TABLE 6 Cost of index hospitalisation by gestational age

Gestational age	Mean (£)	SE (£)	<i>n</i>	Weight	Weighted cost (£)
20–23 weeks	1367	3024	0	0.00	0
24–27 weeks	7980	535	385	0.02	196
28–31 weeks	7501	130	1675	0.11	799
32–36 weeks	2078	15	13,655	0.87	1806
Total	–	–	15,715	1.00	2801
37+ weeks	893	2	256,111	1.00	893

SE, standard error; £, 2015 Great British pounds.

TABLE 7 Cost of index hospitalisation by birthweight

Birthweight	Mean (£)	SE (£)	<i>n</i>	Weight	Weighted cost (£)
< 1000 g	6970	516	411	0.23	1618
1000–1499 g	6264	156	1360	0.77	4810
1500–1999 g	3506	63	2907	0.23	790
2000–2499 g	1741	14	9994	0.77	1349
Total weighted 'very low birthweight'	–	–	1771	1	6428
Total weighted 'low birthweight'	–	–	12,901	1	2138
> 2500 g	905	2	257,154		905

SE, standard error; £, 2015 Great British pounds.

was increasing over the period but we use the number of births in the pre-intervention period, as we need to be able to make a comparison to this time.

Analysis

Baseline cases were estimated assuming a constant rate throughout the pre-intervention period applied to a duration of the HiP intervention years. Baseline risks were converted to odds in order to apply the HiP effect estimate. The resultant effects were converted back to risks to estimate the absolute number of cases.

For maternal outcomes, the attributable risk and number of cases attributable to smoking were estimated before applying an effect estimate of HiP on maternal smoking. The population attributable risk as a result of smoking is estimated using the following equation:

$$\frac{E \cdot (RR - 1)}{E \cdot (RR - 1) + 1} \quad (3)$$

where E = prevalence of smoking during pregnancy [23% (HiP study)] and RR = relative risk of the outcome for smoking during pregnancy versus no smoking during pregnancy. The relative risks of ectopic pregnancy, placenta previa, abruptio placentae, PPRM and pre-eclampsia were 1.89, 2.84, 2.62, 2.30 and 0.59, respectively, derived from Godfrey *et al.*'s report.⁷⁴ The baseline prevalence for each pregnancy was not measured in the HiP study. Therefore, Godfrey *et al.*'s⁷⁴ estimates for England were scaled by the Scottish population.

Uncertainty was incorporated using probabilistic sensitivity analysis and bootstrapping. The model was built in Microsoft Excel® 2007 (Microsoft Corporation, Redmond, WA, USA).

Strengthening the inference

As the allocation of the intervention was not randomised and the intervention and control periods occurred at different time points, pregnant women in the intervention and control groups could have been subjected to different exposures. In particular, the timing of the introduction and withdrawal of the HiP grant overlapped with other policies and interventions that may have had an impact on birthweight. Here, we consider a number of factors that could have affected birth outcomes during the intervention period that may not be attributable to the HiP grant.

Healthy Start is a means-tested voucher scheme for pregnant women and women with children under 4 years of age.⁷⁷ If the women are in receipt of certain benefits then they are eligible for free vitamins and vouchers to be spent on liquid and formula milk and fruit and vegetables. This scheme replaced the means-tested parts of the Welfare Food Scheme in the UK (including Scotland) in 2006 and is still currently in place.

We conducted sensitivity analyses to try to ascertain whether or not any observed effects could be attributed to the HiP grant as opposed to Healthy Start or other such interventions. The basis for these sensitivity analyses was the timing of the HiP intervention. This timing – of both introduction and withdrawal – was well defined and fixed, and using the interrupted time series approach enabled us to estimate any effects associated with this intervention window and ascribe those to HiP grants. The HiP intervention window was defined by two parameters, namely the start date and the duration. We repeatedly varied these parameters – effectively changing the start and end dates of the HiP intervention window – to examine the extent to which the effects that we found were dependent on the dates. If the strongest 'intervention' effect coincided with the dates during which the HiP grant was in place, then we could be more confident that the effect was associated with the HiP grants rather than another intervention with a slightly different timeline. For the strengthening the inference sensitivity analysis, we therefore varied both the start date and duration; five different start dates and three different durations were chosen, giving 15 different potential 'intervention' windows (note that one of these windows was the actual HiP window). We expected to find a dilution of any effects of the HiP grant when the intervention window was moved.

Table 8 shows the start and end dates for each of the moving window or potential 'intervention' periods considered. In order to mimic the main analyses, there was a 2-week washout period applied to all dates so the actual date used to calculate the end of the pre-intervention period was 1 week before the start dates shown in Table 8; the start of the intervention period was 1 week after the start dates, the end of the intervention period is 1 week before the end dates, and the start of the post-intervention period was 1 week after the end dates.

A further piece of legislation that may have affected birthweight was the introduction of the smoking ban in public places in Scotland in March 2006. This may have had an effect on the level of smoking in pregnant women and, therefore, may have affected the rate of change of birthweight of babies born after this time. We carried out a further analysis using 1 January 2007 to 1 April 2009 as the pre-intervention HiP grant period. This time period was chosen to ensure that pregnancies in the pre-intervention period were all after the smoking ban had come into effect.

The effect of the HiP grant on birthweight and other secondary outcomes might have had a carryover effect after the withdrawal of the programme. In other words, post intervention, the trend in birthweight might not return to the same rate as pre intervention. This contamination could be attributable to women who gave birth during the intervention subsequently having a birth post intervention but still heeding the health advice given during their first pregnancy. An additional analysis using only the subgroup of primiparous women was carried out to avoid such contamination.

In 2009 there was an outbreak of swine flu (influenza virus A/H1N1pdm09) in Scotland (and the UK). Pregnant women were adversely affected by this virus, resulting in poorer perinatal outcomes.⁷⁸ There were two outbreak periods, July 2009 and October–November 2009. To try to take this into account, a further analyses removing births from 1 July 2009 to 30 November 2009 in the intervention period was carried out.

TABLE 8 Start and end dates for moving window periods

Time period	Duration		
	18 months	24 months ^a	30 months
Actual HiP			
Start date	6 April 2009	6 April 2009	6 April 2009
End date	6 October 2010	15 April 2011	6 October 2011
12 months before			
Start date	6 April 2008	6 April 2008	6 April 2008
End date	6 October 2009	15 April 2010	6 October 2010
6 months before			
Start date	6 October 2008	6 October 2008	6 October 2008
End date	6 April 2010	15 October 2010	6 April 2011
6 months after			
Start date	6 October 2009	6 October 2009	6 October 2009
End date	6 April 2011	15 October 2011	6 April 2012
12 months after			
Start date	6 April 2010	6 April 2010	6 April 2010
End date	6 October 2011	15 April 2012	6 October 2012

^a This is a 2-year + 1-week period in all cases. The actual HiP grant was in place for 2 years and 1 week, so the same length of time was chosen for all the moving window periods to mirror the main results.

Models fitted and interpretation

Models fitted

For birthweight, gestational age at booking, booking before 25 weeks, preterm delivery, very preterm delivery, and neonatal death there was a main analysis, 12 subgroup analyses and 17 analyses designed to strengthen inference. For other outcomes, there was a main analysis, 12 subgroup analyses and two analyses strengthening the inference. Within that framework multiple imputation was used to account for missing data. Models were fitted using the complete cases and using the combined results from the 30 imputation models. The results of complete-case analysis and multiple imputations were compared. There was also the change from the protocol of not adjusting for maternal smoking. Models were fitted both adjusting and not adjusting for maternal smoking and these results were compared. We detail below the models that are presented for each of the main analyses and subgroup analyses.

For the main analyses four different models are reported: (1) complete cases not adjusting for maternal smoking; (2) imputed not adjusting for maternal smoking; (3) complete cases adjusting for maternal smoking; and (4) imputed adjusting for maternal smoking.

For the subgroup analyses, only the models using imputed data and not adjusting for maternal smoking are reported.

For the strengthening the inference analyses, only the models using imputed data and not adjusting for maternal smoking are reported.

For the ethnicity analyses, only the models using complete cases and not adjusting for maternal smoking are reported.

Interpretation

The results are displayed in two different ways depending on whether or not the interaction between year and period (pre intervention, intervention and post intervention) was significant.

The models with no interaction showed the main effects of the intervention and post-intervention periods compared with the pre-intervention period, over and above the overall trend over time. The trend was fitted using the year of birth as a continuous variable.

The models with a significant interaction showed the main effects of the intervention and post-intervention periods compared with the pre-intervention period. This time the trend was not consistent over time, but different for each period. There were three trends shown, one for each period.

Changes from the protocol

Not adjusting for maternal smoking or gestational age at booking

In the protocol we stated that models would be adjusted for maternal smoking and gestational age at booking. During the project, following discussion of the causal pathway with the project steering group, we refined the logic model. We decided that both maternal smoking and gestational age at booking were behaviours that could be affected by the HiP intervention. Therefore, models should not be adjusted for maternal smoking or gestational age at booking. If the health advice given as part of the intervention reduced smoking and then models were adjusted for smoking, any effect of the intervention would be undetectable. The same is true for gestational age at booking.

Not using health board and data zone clustering in the imputation model

In the protocol, it was stated that a joint modelling approach to account for the clustering within data zones and health boards would be undertaken. It was not possible to use this approach, as the size (525,400 observations) and the structure (four levels of nesting) of the data set meant the models would take too long to run and thus threaten the completion of the project within the timescale. In practice,

the clustering of births within mothers, data zones and health board was ignored when creating the imputed data sets. Instead of using the hierarchical structure of the data, that is, births nested within mothers nested within data zones nested within health board, health board of hospital of birth and health board of residence of mother were used in the imputation model as fixed-effect parameters. It is unlikely that this approach would have had a major influence on the size and direction of the effect of the HiP grant on birthweight or other secondary outcomes.

Spontaneous delivery

In the protocol, it was stated that mode of delivery would be used to identify spontaneous preterm births and induced preterm births. Mode of delivery was of interest, because a potential reason for induced preterm births was evidence of poor fetal growth; a proportion of these babies would become more severely growth retarded (more extreme SGA) or stillborn. The protocol specified that an analysis of preterm births stratified by mode of delivery and according to whether the birth was induced or spontaneous would be carried out. This was not done, as the data available from ISD were not able to distinguish the categories of induced or spontaneous birth.

Ethnicity breakdown into further ethnic groups

In the protocol, we said that the possibility of further distinction between ethnic groups would be examined. This was not done, as the variable from ISD was categorised only as 'white' and 'non-white'. The ethnicity variable was incomplete, as only 43.5% of the observations included information on ethnicity.

Fitting interactions between subgroup and intervention

In the protocol, it was stated that before carrying out specific subgroup analysis, interaction terms would be used to identify differential effects (e.g. an assessment of whether or not there was a differential effect of the intervention for single women would involve a test of the significance of the interaction between marital status and the intervention effect). In practice, the models took a long time to run (each outcome required 31 models to be fitted and took 3–4 days). It was decided that all the subgroup analyses would be run as specified in the protocol, whether or not any differential effects existed. This means that all results are presented.

Combinations of subgroups

In the protocol, it was stated that subgroup analyses would be conducted for selected combinations of those groups seen as having the greatest potential to benefit from the HiP grant. As there was little difference in effect size and significance from the main results, and little difference between the subgroups, no combinations were selected to be analysed.

Not adjusting for gestational age at delivery in models with caesarean section as outcomes

In the protocol's statistical analysis plan it was stated that gestational age at delivery would be included in the models for outcomes emergency caesarean section and elective caesarean section. In practice, it was not possible to adjust for gestational age, as there was a strong association between births at early gestational age and emergency caesarean section (*Table 9*) and between births at late gestational age and elective caesarean section.

TABLE 9 Proportion of preterm (< 37 weeks' gestation) births by mode of delivery

Mode of delivery, <i>n</i> (%)	Preterm (< 37 weeks)	
	No	Yes
Vaginal	373,184 (95.6)	17,235 (4.4)
Elective caesarean	52,784 (95.3)	2575 (4.7)
Emergency caesarean	69,596 (87.6)	9886 (12.4)
Missing	133	7

Chapter 3 Results

Description of outcomes and covariates

Summary statistics for all outcomes by year are presented in *Tables 10–13*. In the main analysis, the mean birthweight for live singleton births was 3418 g. Of live singleton births, 0.63% were low birthweight, 5.65% were preterm and 4.89% were SGA babies (*Table 10*). Stillbirths and neonatal deaths represented 0.37% and 0.07%, respectively, of the study population (*Table 12*). Maternal- and family-level as well as area-level variables are described by year and over the study period in *Table 14* before and after multiple imputation.

Results for the main analysis

For the main analysis, we reported the results for the primary and secondary outcomes using the imputed data, both with and without adjusting the models for gestational age at booking and maternal smoking during pregnancy. The results for the complete cases are presented in *Appendices 2 and 3*. We have more confidence in the results obtained from the imputed data, as it is easy to find examples for which the complete cases are not a random sample of all births. For example, in 2004 3.64% of women had a BMI at booking recorded as being ≥ 35 kg/m². With BMI missing for 54.51% of births, this meant that the observed prevalence of severe obesity was 8.00%, somewhat larger than the average imputed prevalence across the 30 imputed data sets of 7.01%. We have included the results for the complete-case analyses for completeness. Similarly, we believe that we were mistaken to suggest in our protocol that we would adjust for gestational age at booking and maternal smoking during pregnancy for the reasons given in *Chapter 2, Changes from the protocol*. We favour the unadjusted results, but, again, present the adjusted results for completeness as a per-protocol analysis.

Results for the primary outcome

The analyses using the imputed data show no statistically significant effect of the intervention on birthweight. The results are similar whether adjusting the model for gestational age at booking and maternal smoking during pregnancy or not, with the estimated changes in birthweight and 95% CI being –2.6 g (95% CI –6.9 to 1.7 g) and –2.3 g (95% CI –6.6 to 1.9 g), respectively (*Table 15*). Over the 10-year period under study there was a general trend of increasing birthweight. Based on the analysis of the imputed data, without adjustment for gestational age at booking or maternal smoking during pregnancy, we estimate this increase to have been 3.3 g per year (95% CI 2.4 to 4.2 g). This trend did not differ significantly between the pre-intervention, intervention and post-intervention periods.

The analysis of complete cases suggested that, compared with the pre-intervention period, birthweight decreased by 9.0 g (95% CI 3.7 to 14.3 g) during the intervention period when not adjusting the model for gestational age at booking and maternal smoking during pregnancy. The result was similar when adjusting the model for gestational age at booking and maternal smoking during pregnancy (*Table 15*).

Results for the secondary outcomes

The analysis performed on imputed data not adjusting for gestational age at booking and maternal smoking during pregnancy showed no statistically significant effect of the programme on most of the measures of stage and size (*Tables 16–19*). However, compared with the pre-intervention period, maternal booking behaviour changed during the intervention period. The mean gestational age at booking decreased by 0.35 weeks (95% CI 0.29 to 0.41 weeks) during the period in which the HiP grant was in place and the odds of booking before 25 weeks increased by 10% (OR 1.10, 95% CI 1.02 to 1.18; *Table 16*). However, the odds of neonatal death increased by 84% (OR 1.84, 95% CI 1.22 to 2.78; *Table 19*) and the

TABLE 10 Description of the outcomes over time: measures of size

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Birthweight (g)											
CC, mean (SD)	3396.70 (574.10)	3399.60 (575.70)	3408.00 (569.90)	3411.30 (569.00)	3416.10 (570.60)	3424.50 (565.80)	3426.60 (561.20)	3427.50 (569.60)	3431.90 (560.70)	3438.10 (545.90)	3418.30 (566.40)
Very LBW (< 1500 g)											
CC, yes (%)	0.71	0.66	0.68	0.69	0.64	0.63	0.59	0.64	0.61	0.43	0.63
LBW (< 2500 g)											
CC, yes (%)	5.66	5.76	5.41	5.43	5.28	5.02	4.86	5.18	4.85	4.33	5.17
HBW (≥ 4000 g)											
CC, yes (%)	13.29	13.27	13.51	13.75	13.95	14.10	13.98	14.28	14.12	14.08	13.84
Head circumference (cm)											
CC											
Mean (SD)	34.67 (1.45)	34.69 (1.45)	34.72 (1.45)	34.75 (1.45)	34.71 (1.47)	34.74 (1.48)	34.71 (1.50)	34.70 (1.48)	34.67 (1.51)	34.59 (1.50)	34.70 (1.48)
Missing (%)	23.65	24.81	22.28	25.64	24.98	19.98	21.10	31.08	33.13	36.76	26.32
Imputed											
Mean (min., max.)	34.57 (34.57, 34.57)	34.59 (20.5, 42.00)	34.62 (34.58, 34.59)	34.65 (34.64, 34.65)	34.64 (34.63, 34.64)	34.66 (34.65, 34.66)	34.64 (34.63, 34.64)	34.62 (34.61, 34.63)	34.61 (34.60, 34.61)	34.58 (34.57, 34.58)	34.60
Crown-to-heel length (cm)											
CC											
Mean (SD)	51.05 (2.93)	51.13 (3.05)	51.11 (3.08)	51.17 (3.06)	50.96 (3.08)	51.20 (3.09)	51.25 (3.11)	51.38 (3.06)	51.51 (3.05)	51.50 (3.06)	51.2 (3.10)
Missing (%)	47.67	48.42	44.60	49.24	50.22	42.22	44.85	45.85	46.20	44.88	46.42
CC, complete case; (min., max.), minimum and maximum (of mean or % yes) across the 30 imputations; SD, standard deviation.											

TABLE 11 Description of the outcomes over time: measures of stage

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Gestational age at delivery (weeks)											
CC, mean (SD)	39.28 (1.86)	39.33 (1.84)	39.30 (1.84)	39.33 (1.82)	39.34 (1.83)	39.36 (1.81)	39.37 (1.79)	39.34 (1.80)	39.32 (1.78)	39.35 (1.68)	39.34 (1.80)
Preterm											
CC, yes (%)	6.08	6.04	5.84	5.65	5.90	5.67	5.39	5.53	5.53	4.92	5.65
Very preterm											
CC, yes (%)	1.19	1.05	1.10	1.06	1.08	1.02	1.02	1.09	1.00	0.74	1.04
Weight-for-dates (z-score)											
CC, mean (SD)	−0.023 (1.01)	−0.034 (1.01)	−0.016 (1.00)	−0.011 (1.00)	−0.0029 (1.00)	0.009 (1.00)	0.007 (0.99)	0.020 (1.00)	0.035 (0.99)	0.033 (0.98)	0.0019 (1.00)
SGA											
CC, yes (%)	5.46	5.59	5.17	5.06	5.01	4.83	4.62	4.65	4.38	4.23	4.89
LGA											
CC, yes (%)	9.81	9.50	9.45	9.76	9.73	9.99	9.61	10.02	10.15	9.97	9.80
CC, complete case; SD, standard deviation.											

TABLE 12 Description of the outcomes over time: birth outcomes

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Elective caesarean											
CC											
Yes (%)	8.76	9.02	9.70	10.02	9.97	10.30	11.19	11.57	11.96	12.73	10.54
Missing (%)	0.03	0.03	0.03	0.04	0.03	0.02	0.02	0.02	0.02	0.03	0.03
Imputed											
Yes, % (min., max.)	8.76 (8.76, 8.77)	9.02 (9.02, 9.03)	9.70 (9.70, 9.71)	10.02 (10.02, 10.03)	9.97 (9.97, 9.97)	10.30 (10.30, 10.31)	11.19 (11.19, 11.20)	11.58 (11.57, 11.58)	11.96 (11.96, 11.96)	12.73 (12.73, 12.74)	10.54
Emergency caesarean											
CC											
Yes (%)	14.87	15.23	14.92	14.85	14.77	14.71	15.15	15.67	15.32	15.83	15.13
Missing (%)	0.03	0.03	0.03	0.04	0.03	0.02	0.02	0.02	0.02	0.03	0.03
Imputed											
Yes, % (min., max.)	14.88 (14.87, 14.88)	15.23 (15.23, 15.24)	14.93 (14.92, 14.93)	14.86 (14.85, 14.87)	14.77 (14.77, 14.77)	14.71 (14.71, 14.71)	15.16 (15.16, 15.15)	15.67 (15.67, 15.67)	15.32 (15.32, 15.33)	15.83 (15.83, 15.84)	15.13
Stillbirth											
CC, yes (%)	0.44	0.42	0.40	0.41	0.41	0.37	0.36	0.37	0.33	0.24	0.37
5-minute Apgar score of < 7											
CC											
Yes (%)	1.43	1.41	1.40	1.48	1.38	1.33	1.35	1.29	1.30	1.26	1.36
Missing (%)	2.14	2.24	2.79	1.31	0.87	0.78	0.65	0.69	0.80	0.89	1.29
Imputed											
Yes, % (min., max.)	1.43 (1.43, 1.44)	1.42 (1.42, 1.43)	1.42 (1.42, 1.42)	1.49 (1.49, 1.50)	1.39 (1.38, 1.39)	1.34 (1.34, 1.35)	1.36 (1.35, 1.36)	1.30 (1.30, 1.30)	1.31 (1.31, 1.31)	1.26 (1.26, 1.27)	1.37
Neonatal death											
CC											
Yes (%)	0.09	0.08	0.06	0.06	0.08	0.09	0.08	0.09	0.06	0.03	0.07

CC, complete case; (min., max.), minimum and maximum (of mean or % yes) across the 30 imputations.

TABLE 13 Description of the outcomes over time: maternal behaviour

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Gestation at booking, weeks											
CC											
Mean (SD)	13.42 (5.43)	13.32 (5.32)	13.12 (5.29)	12.97 (5.16)	12.69 (4.97)	12.97 (4.73)	12.32 (4.58)	11.56 (4.62)	11.03 (4.69)	10.98 (4.85)	12.37 (5.05)
Missing (%)	9.99	13.60	18.57	23.11	21.38	29.23	18.84	12.38	4.40	0.93	15.35
Imputed											
Mean (min., max.)	13.38 (13.37, 13.39)	13.23 (13.22, 13.24)	13.10 (13.08, 13.11)	13.02 (13.00, 13.04)	12.76 (12.75, 12.77)	12.72 (12.70, 12.75)	12.20 (12.19, 12.22)	11.47 (11.46, 11.47)	11.06 (11.05, 11.07)	10.97 (10.97, 10.97)	12.38
Booking before 25 weeks											
CC											
Yes (%)	85.22	82.11	77.54	73.53	75.57	68.10	78.62	85.17	93.02	95.93	81.39
Missing (%)	9.99	13.60	18.57	23.11	21.38	29.23	18.84	12.38	4.40	0.93	15.35
Imputed											
Yes, % (min., max.)	95.00 (94.96, 95.04)	95.48 (95.43, 95.54)	95.68 (95.63, 95.75)	96.06 (96.01, 96.14)	96.44 (96.39, 96.51)	96.93 (96.88, 96.98)	97.27 (97.24, 97.30)	97.47 (97.46, 97.49)	97.38 (97.36, 97.40)	96.86 (96.85, 96.86)	96.48
Maternal smoking during pregnancy											
CC											
Yes (%)	23.60	21.85	20.10	18.17	18.26	18.90	17.91	18.09	17.95	18.06	19.24
Missing (%)	9.06	9.36	13.17	15.55	13.66	6.85	6.11	6.36	5.36	4.13	8.93
Imputed											
Yes, % (min., max.)	25.84 (25.75, 25.92)	24.71 (24.64, 24.81)	23.21 (23.05, 23.34)	22.31 (22.17, 22.48)	21.37 (21.27, 21.50)	20.42 (20.30, 20.52)	19.16 (19.10, 19.22)	19.32 (19.25, 19.40)	19.02 (18.97, 19.07)	18.78 (18.73, 18.83)	21.36
CC, complete cases; (min., max.), minimum and maximum (of mean or % yes) across the 30 imputations; SD, standard deviation.											

TABLE 14 Description of the covariates over time

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Baby's sex											
CC											
Male	51.23	51.70	51.12	51.30	51.06	51.29	50.81	51.45	51.43	51.49	51.28
Female	48.77	48.30	48.88	48.70	48.94	48.71	49.19	48.55	48.57	48.51	48.72
Maternal age (years)											
CC											
< 20	7.90	7.89	7.59	7.64	7.32	6.95	6.66	5.99	5.51	5.06	6.84
20–24	18.66	18.93	18.89	19.29	19.24	19.34	18.58	18.40	18.09	17.66	18.71
25–29	24.51	24.56	25.26	25.93	27.20	27.52	27.64	27.32	27.74	27.39	26.54
30–34	29.62	29.12	28.30	26.90	26.40	26.73	27.65	28.64	29.46	30.37	28.29
35–39	16.22	16.34	16.80	16.99	16.38	16.00	15.96	15.9	15.5	15.64	16.17
≥ 40	3.09	3.16	3.16	3.26	3.46	3.46	3.50	3.74	3.70	3.88	3.44
Maternal height (cm)											
CC											
Mean (SD)	163.48 (6.48)	163.59 (6.48)	163.67 (6.48)	163.84 (6.47)	163.84 (6.50)	163.99 (6.43)	164.06 (6.45)	164.13 (6.43)	164.27 (6.42)	164.29 (6.41)	163.9 (6.50)
Missing (%)	19.82	18.99	18.12	18.69	17.10	15.28	8.84	8.04	9.56	3.94	13.79
Imputed											
Mean (min., max.)	163.51 (163.49, 163.53)	163.61 (163.58, 163.63)	163.65 (163.63, 163.67)	163.79 (163.76, 163.81)	163.81 (163.78, 163.83)	163.99 (163.97, 164.02)	164.06 (164.04, 164.07)	164.12 (164.11, 164.13)	164.26 (164.24, 164.27)	164.27 (164.26, 164.28)	163.90
Maternal BMI (kg/m²)											
CC											
Mean (SD)	25.93 (5.44)	25.87 (5.41)	25.92 (5.39)	25.95 (5.46)	26.05 (5.53)	26.00 (5.46)	26.09 (5.57)	26.13 (5.61)	26.18 (5.63)	26.09 (5.60)	26.05 (5.53)
Missing (%)	54.50	50.43	46.70	47.90	29.20	25.10	13.64	12.03	13.13	5.23	29.44
Imputed											
Mean (min., max.)	25.88 (25.83, 25.92)	25.87 (25.84, 25.89)	25.98 (25.86, 25.93)	25.94 (25.91, 25.97)	26.08 (26.06, 26.11)	26.06 (26.04, 26.08)	26.25 (26.24, 26.27)	26.31 (26.29, 26.33)	26.43 (26.42, 26.44)	26.15 (26.13, 26.16)	26.09

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Gestational age at booking											
CC											
0–12 weeks	46.78	44.34	44.08	42.00	45.06	37.99	49.19	61.44	71.74	77.22	51.97
13–24 weeks	38.44	37.77	33.47	31.52	30.51	30.11	29.42	23.74	21.28	18.71	29.42
≥ 25 weeks	4.79	4.29	3.88	3.36	3.05	2.67	2.55	2.45	2.58	3.14	3.25
Missing (%)	9.99	13.60	18.57	23.11	21.38	29.23	18.84	12.38	4.40	0.93	15.35
Imputed, mean (min., max.)											
0–12 weeks	52.47 (52.35, 52.57)	52.48 (52.32, 52.62)	54.63 (54.47, 54.96)	54.79 (54.67, 55.01)	57.20 (57.05, 57.35)	56.84 (56.54, 57.07)	62.12 (61.87, 62.22)	70.75 (70.64, 70.89)	74.72 (74.63, 74.82)	77.97 (77.94, 78.00)	61.46
13–24 weeks	42.47 (42.36, 42.59)	42.93 (42.80, 43.08)	40.93 (40.60, 41.14)	41.10 (40.97, 41.27)	39.10 (38.94, 39.26)	39.96 (39.73, 42.55)	35.09 (34.93, 35.34)	21.70 (26.57, 26.85)	22.64 (22.26, 22.74)	18.89 (18.86, 18.91)	34.94
≥ 25 weeks	5.06 (5.03, 5.11)	4.60 (4.51, 4.65)	4.44 (4.39, 4.50)	4.11 (4.03, 4.18)	3.70 (3.63, 3.75)	3.20 (3.14, 3.77)	2.80 (2.76, 2.84)	2.55 (2.53, 2.58)	2.64 (2.62, 2.66)	3.14 (3.14, 3.17)	3.60
Parity											
CC											
0	43.91	45.47	46.96	47.34	47.11	49.57	45.56	45.64	44.88	45.13	46.17
1	33.76	32.27	32.8	33.26	33.82	31.93	34.33	33.16	34.74	34.46	33.47
2	13.67	13.76	12.8	12.83	12.73	12.28	13.22	13.05	13.42	13.26	13.09
3+	7.01	6.98	6.39	6.16	6.22	6.03	6.50	6.72	6.79	6.84	6.56
Missing (%)	1.65	1.52	1.04	0.41	0.12	0.18	0.38	1.44	0.18	0.31	0.71
Imputed, mean (min., max.)											
0	44.53 (44.47, 44.61)	46.04 (45.99, 46.17)	47.36 (47.33, 47.41)	47.49 (47.46, 47.53)	47.15 (47.14, 47.17)	49.63 (49.62, 49.64)	45.70 (45.68, 45.74)	46.22 (46.18, 46.28)	44.94 (44.92, 44.95)	45.24 (45.22, 45.26)	46.44
1	34.43 (34.33, 34.49)	32.90 (32.77, 32.95)	33.23 (33.20, 33.29)	33.42 (33.39, 33.46)	33.87 (33.85, 33.89)	32.01 (31.99, 32.02)	34.49 (34.46, 34.51)	33.75 (33.70, 33.79)	34.81 (34.79, 34.84)	34.57 (34.56, 34.60)	33.76
2	13.97 (13.89, 14.01)	14.04 (14.00, 14.09)	12.98 (12.95, 13.03)	12.91 (12.88, 12.94)	12.76 (12.74, 12.77)	12.32 (12.30, 12.33)	13.30 (13.28, 13.31)	13.29 (13.26, 13.33)	13.46 (13.44, 13.47)	13.33 (13.31, 13.34)	13.22
3+	7.06 (7.04, 7.13)	7.03 (7.01, 7.05)	6.42 (6.41, 6.44)	6.18 (6.17, 6.19)	6.23 (6.22, 6.23)	6.04 (6.03, 6.05)	6.52 (6.51, 6.52)	6.75 (6.74, 6.77)	6.80 (6.79, 6.81)	6.85 (6.84, 6.86)	6.58
											continued

TABLE 14 Description of the covariates over time (*continued*)

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Previous caesarean section											
CC											
Yes (%)	11.27	10.75	10.75	10.85	10.61	10.38	11.25	10.7	10.72	10.94	10.82
Missing (%)	0.00	0.00	0.03	0.13	0.00	0.00	0.17	1.28	0.05	0.22	0.19
Imputed											
Yes, % (min., max.)	11.27 (11.27, 11.27)	10.75 (10.75, 10.75)	10.75 (10.75, 10.75)	10.87 (10.86, 10.88)	10.61 (10.61, 10.61)	10.38 (10.38, 10.38)	11.26 (11.25, 11.27)	10.81 (10.79, 10.82)	10.73 (10.72, 10.73)	10.97 (10.96, 10.98)	10.84
Diabetes mellitus											
CC											
Yes (%)	0.74	0.83	0.78	0.87	1.15	1.44	1.52	1.74	2.39	2.71	1.42
Missing (%)	34.63	30.66	29.25	30.36	16.28	8.42	2.31	2.14	2.49	2.41	15.61
Imputed											
Yes, % (min., max.)	1.06 (1.00, 1.12)	1.15 (1.11, 1.19)	1.12 (1.06, 1.20)	1.25 (1.19, 1.32)	1.35 (1.31, 1.38)	1.55 (1.53, 1.58)	1.57 (1.55, 1.59)	1.79 (1.77, 1.80)	2.44 (2.43, 2.46)	2.77 (2.74, 2.79)	1.61
Obese (BMI ≥ 35 kg/m²)											
CC											
Yes (%)	3.64	3.55	3.90	3.97	5.74	5.77	7.05	7.28	7.43	7.70	5.63
Missing (%)	54.51	50.43	46.69	47.86	29.22	25.09	13.64	12.03	13.13	5.23	29.44
Imputed											
Yes, % (min., max.)	7.01 (6.82, 7.17)	6.76 (6.59, 6.88)	6.80 (6.57, 6.94)	7.06 (6.87, 7.15)	7.97 (7.76, 8.06)	7.69 (7.56, 7.79)	8.73 (8.64, 8.81)	8.93 (8.83, 9.01)	9.54 (9.43, 9.65)	8.27 (8.22, 8.33)	7.90

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Marital status											
CC											
Married to each other	52.05	51.21	50.56	48.45	47.59	48.56	48.26	47.48	48.00	48.14	48.99
Joint same address	29.98	30.00	30.76	31.51	32.74	33.50	33.49	33.8	34.10	34.43	32.47
Joint different address	9.85	10.43	10.40	10.72	10.83	11.33	11.56	11.92	12.26	11.96	11.14
Sole	6.07	5.69	5.78	5.71	5.43	5.35	5.30	5.25	5.03	4.86	5.44
Missing (%)	2.05	2.66	2.50	3.62	3.41	1.61	1.39	1.91	0.60	0.63	1.97
Imputed, mean (min., max.)											
Married to each other	53.05 (52.99, 53.09)	52.48 (52.44, 52.54)	51.79 (51.73, 51.84)	50.41 (50.33, 50.48)	49.46 (49.37, 49.54)	49.12 (49.09, 49.16)	49.02 (48.98, 49.06)	48.31 (48.26, 48.34)	48.27 (48.25, 48.29)	48.42 (48.40, 48.45)	49.99
Joint same address	30.63 (30.57, 30.69)	30.86 (30.80, 30.90)	31.57 (31.51, 31.63)	32.60 (32.53, 32.69)	33.77 (33.70, 33.84)	33.92 (33.87, 33.98)	33.91 (33.87, 33.95)	34.28 (34.22, 34.32)	34.32 (34.28, 34.34)	34.62 (34.63, 34.70)	33.09
Joint different address	10.10 (10.09, 10.16)	10.77 (10.73, 10.81)	10.70 (10.66, 10.74)	11.08 (11.01, 11.12)	11.17 (11.10, 11.21)	11.51 (11.49, 11.57)	11.71 (11.68, 11.73)	12.09 (12.06, 12.13)	12.35 (12.34, 12.36)	12.05 (12.03, 12.08)	11.37
Sole	6.22 (6.18, 6.25)	5.88 (5.86, 5.91)	5.95 (5.92, 5.99)	5.91 (5.86, 5.96)	5.60 (5.57, 5.63)	5.44 (5.41, 5.47)	5.36 (5.34, 5.38)	5.32 (5.30, 5.35)	5.07 (5.05, 5.08)	4.87 (4.85, 4.88)	5.56
continued											

TABLE 14 Description of the covariates over time (*continued*)

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Social class											
CC											
Managerial and professional	28.10	28.08	29.04	28.68	28.50	29.68	29.14	29.66	29.84	29.29	29.01
Intermediate	20.69	20.35	19.81	19.35	19.45	19.78	19.42	18.77	19.34	18.82	19.57
Working	34.13	34.18	33.52	33.71	33.79	34.03	34.02	34.04	33.97	33.29	33.87
Never worked/long-term unemployed	15.04	14.73	15.13	14.64	14.85	15.26	16.04	15.98	16.25	15.45	15.34
Missing (%)	2.05	2.66	2.50	3.62	3.41	1.25	1.39	1.55	0.60	3.15	2.21
Imputed, mean (min., max.)											
Managerial and professional	28.62 (28.58, 28.66)	28.79 (28.76, 28.83)	29.76 (29.70, 29.83)	29.90 (29.83, 29.96)	29.68 (29.62, 29.77)	30.01 (29.98, 30.04)	29.64 (29.60, 29.66)	30.20 (30.15, 30.24)	30.01 (29.98, 30.05)	30.26 (30.21, 30.34)	29.70
Intermediate	21.11 (21.06, 21.19)	20.89 (20.81, 20.94)	20.32 (20.26, 20.38)	20.11 (20.00, 20.17)	20.17 (20.10, 20.23)	20.03 (20.00, 20.07)	19.70 (19.66, 19.73)	19.08 (19.05, 19.13)	19.46 (19.43, 19.48)	19.42 (19.34, 19.50)	20.02
Working	34.85 (34.78, 34.89)	35.10 (35.05, 35.16)	34.37 (34.28, 34.43)	34.85 (34.77, 34.95)	34.87 (34.78, 34.93)	34.44 (34.41, 34.49)	34.45 (34.40, 34.48)	34.53 (34.47, 34.58)	34.17 (34.14, 34.23)	34.35 (34.24, 34.41)	34.60
Never worked/long-term unemployed	15.41 (15.38, 15.47)	15.22 (15.18, 15.26)	15.55 (15.51, 15.62)	15.14 (15.10, 15.19)	15.28 (15.24, 15.33)	15.51 (15.49, 15.55)	16.22 (16.19, 16.25)	16.19 (16.17, 16.24)	16.35 (16.33, 16.38)	15.97 (15.95, 16.00)	15.69
Ethnic group											
CC											
White	13.02	15.38	20.20	24.00	30.19	41.66	54.82	63.60	65.63	70.55	40.21
Non-white	1.20	1.28	1.54	1.86	2.49	3.71	4.40	5.02	4.99	5.88	3.26
Missing (%)	85.77	83.34	78.26	74.14	67.22	54.63	40.77	31.38	29.38	23.57	56.53

Outcomes	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2004–13
Smoking at booking											
CC											
Never smoked	60.78	61.98	57.97	57.90	59.88	58.67	63.60	62.80	63.65	65.88	61.31
Current smoker	9.17	8.67	9.23	8.75	8.86	9.34	12.35	12.48	13.17	12.77	10.50
Former smoker	23.04	21.84	21.07	19.51	18.51	18.43	19.30	19.76	18.55	17.71	19.73
Missing (%)	7.02	7.51	11.72	13.83	12.75	13.56	4.76	4.95	4.63	3.64	8.45
Imputed, mean (min., max.)											
Never smoked	65.47 (65.38, 65.60)	66.98 (66.89, 67.06)	66.02 (65.84, 66.15)	67.55 (67.41, 67.69)	68.95 (68.86, 69.09)	68.13 (68.00, 68.22)	66.99 (66.93, 67.06)	66.33 (66.21, 66.42)	66.90 (66.81, 66.99)	68.46 (68.41, 68.51)	67.20
Current smoker	9.90 (9.84, 9.99)	9.53 (9.47, 9.60)	10.50 (10.41, 10.59)	10.15 (10.07, 10.23)	10.12 (10.05, 10.23)	10.90 (10.79, 11.00)	12.91 (12.84, 12.97)	13.06 (12.97, 13.12)	13.74 (13.67, 13.82)	13.23 (13.18, 13.27)	11.42
Former smoker	24.62 (24.53, 24.74)	23.49 (23.41, 23.57)	23.48 (23.39, 23.63)	22.30 (22.15, 22.44)	20.93 (20.82, 21.08)	20.97 (20.88, 21.09)	20.10 (20.04, 20.15)	20.60 (20.53, 20.65)	19.37 (19.28, 19.42)	18.30 (18.25, 18.36)	21.38
SIMD 2009 income quintiles											
CC											
1: most deprived	25.16	25.66	25.60	26.14	26.08	25.93	26.31	26.47	26.34	26.29	26.01
2	20.28	20.08	20.43	20.79	20.79	21.00	21.05	21.56	21.33	21.23	20.86
3	18.36	18.38	18.51	18.22	18.84	19.20	18.93	18.87	19.36	19.07	18.78
4	18.07	18.18	17.83	17.89	17.69	17.70	17.84	17.59	17.34	17.51	17.76
5: least deprived	18.13	17.70	17.63	16.96	16.60	16.14	15.88	15.52	15.64	15.90	16.59
Missing (%)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CC, complete cases; (min., max.), minimum and maximum (of mean or % yes) across the 30 imputations; SD, standard deviation.											

RESULTS

TABLE 15 Results of analysis for the primary outcome using the complete cases and the imputed data both unadjusted and adjusted for gestational age at booking and maternal smoking

Parameter	Birthweight (g), coefficient (95% CI)			
	Analysis unadjusted on gestational age at booking and maternal smoking		Analysis adjusted on gestational age at booking and maternal smoking as suggested in the protocol paper	
	Complete cases	Imputed data	Complete cases	Imputed data
Period				
Period 1 ^a	0.00	0.00	0.00	0.00
Period 2 ^b	-9.00 (-14.30 to 3.70)	-2.60 (-6.90 to 1.70)	-9.20 (-15.00 to -3.40)	-2.30 (-6.60 to 1.90)
Period 3 ^c	-13.40 (-21.00 to 5.80)	-5.00 (-11.10 to 1.00)	-17.60 (-25.90 to 9.40)	-5.20 (-11.20 to 0.80)
Global test 1 ^d	0.002	0.30	0.0001	0.20
Trend				
All years ^e	4.80 (3.60 to 6.00)	3.30 (2.40 to 4.20)	1.80 (0.50 to 3.10)	0.80 (-0.10 to 1.70)
Interactions				
Interaction 1 ^f				
Interaction 2 ^g				
Interaction 3 ^h				
Global test 2 ⁱ	0.06	0.20	0.03	0.06
a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.				

TABLE 16 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	-0.35 (-0.41 to 0.29)	1.10 (1.02 to 1.18)	1.02 (0.99 to 1.06)
Period 3 ^c	-1.10 (-1.20 to 1.02)	0.91 (0.83 to 1.00)	1.17 (1.11 to 1.22)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	-0.14 (-0.15 to 0.13)	1.09 (1.08 to 1.11)	0.92 (0.91 to 0.93)
Interaction 2 ^g	-0.57 (-0.62 to 0.53)	1.11 (1.04 to 1.18)	0.92 (0.90 to 0.95)

TABLE 16 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: maternal behaviour (*continued*)

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Interaction 3 ^h	−0.21 (−0.24 to 0.17)	0.88 (0.84 to 0.91)	0.99 (0.97 to 1.01)
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

TABLE 17 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.87 (0.68 to 1.10)	1.02 (0.96 to 1.09)	0.98 (0.94 to 1.01)	−0.04 (−0.05 to 0.03)	0.07 (0.04 to 0.10)
Period 3 ^c	0.92 (0.66 to 1.28)	1.06 (0.97 to 1.17)	0.96 (0.92 to 1.01)	−0.11 (−0.13 to 0.09)	0.23 (0.18 to 0.27)
Global test 1 ^d	0.40	0.40	0.30		
Trend					
All years ^e	1.00 (0.95 to 1.05)	0.98 (0.96 to 0.99)	1.01 (1.00 to 1.02)		
Interactions					
Interaction 1 ^f				0.007 (0.004 to 0.01)	0.023 (0.016 to 0.031)
Interaction 2 ^g				−0.02 (−0.03 to −0.01)	0.08 (0.05 to 0.10)
Interaction 3 ^h				−0.033 (−0.04 to 0.025)	0.04 (0.02 to 0.06)
Global test 2 ⁱ	0.90	0.05	0.20	< 0.0001	0.0004

HBW, high birthweight; LBW, low birthweight.

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

TABLE 18 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	-0.04 (-0.06 to 0.02)	1.02 (0.97 to 1.08)	1.11 (0.98 to 1.25)	-0.007 (-0.02 to 0.002)	1.01 (0.96 to 1.06)	0.99 (0.95 to 1.03)
Period 3 ^c	-0.17 (-0.19 to 0.14)	1.22 (1.14 to 1.31)	1.46 (1.25 to 1.71)	-0.01 (-0.03 to 0.0008)	1.02 (0.95 to 1.10)	0.98 (0.93 to 1.04)
Global test 1 ^d				0.10	0.80	0.80
Trend						
All years ^e				0.007 (0.005 to 0.009)	0.97 (0.96 to 0.98)	0.997 (0.989 to 1.01)
Interactions						
Interaction 1 ^f	0.025 (0.020 to 0.029)	0.96 (0.95 to 0.97)	0.93 (0.91 to 0.95)			
Interaction 2 ^g	0.15 (0.13 to 0.17)	0.73 (0.70 to 0.76)	0.61 (0.56 to 0.68)			
Interaction 3 ^h	0.06 (0.04 to 0.07)	0.86 (0.83 to 0.88)	0.71 (0.66 to 0.76)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.06	0.40	0.20
a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.						

TABLE 19 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: birth outcomes

Parameter	Other birth outcomes				
	Mode of delivery				
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	1.00
Period 2 ^b	1.01 (0.97 to 1.05)	1.07 (1.03 to 1.10)	1.01 (0.85 to 1.21)	0.92 (0.84 to 1.01)	1.84 (1.22 to 2.78)
Period 3 ^c	1.07 (1.00 to 1.13)	1.17 (1.12 to 1.23)	0.91 (0.71 to 1.17)	0.88 (0.78 to 1.01)	1.52 (0.84 to 2.74)
Global test 1 ^d	0.01		0.40	0.20	0.004

TABLE 19 Results of analysis for the secondary outcomes using the imputed data unadjusted for gestational age at booking and maternal smoking: birth outcomes (*continued*)

Parameter	Other birth outcomes				
	Mode of delivery				
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Trend					
All years ^e	1.05 (1.04 to 1.06)		0.98 (0.94 to 1.01)	1.01 (0.99 to 1.03)	0.91 (0.83 to 0.995)
Interactions					
Interaction 1 ^f		0.983 (0.976 to 0.990)			
Interaction 2 ^g		1.02 (0.99 to 1.05)			
Interaction 3 ^h		1.00 (0.98 to 1.02)			
Global test 2 ⁱ	0.08	0.02	0.10	0.90	0.10
a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

odds of having an emergency caesarean section also increased by 7% during the intervention period (OR 1.07, 95% CI 1.03 to 1.10; *Table 19*).

The results were similar when using the imputed data and adjusting the models for gestational age at booking and maternal smoking during pregnancy (*Tables 20–23*).

Results of the subgroup analysis

For the subgroup analysis, we report the results for the primary and secondary outcomes using the imputed data, unadjusted for gestational age at booking and maternal smoking during pregnancy.

The primary outcome

Using the imputed data, the results showed that birthweight decreased by 12.2 g (95% CI 3.6 to 20.8 g) in the most deprived areas during the intervention period (*Table 24*), and that there was no statistically significant effect of the intervention on birthweight in any of the subgroups of mothers who we might have expected to benefit the most from the grant (*Table 25*).

The secondary outcomes

During the intervention period, gestational age at booking decreased in all the SIMD subgroups: –0.5 weeks (95% CI –0.6 to –0.4 weeks) in SIMD1 (the most deprived areas; see *Appendix 15*); –0.32 weeks (95% CI –0.45 to –0.19 weeks) in SIMD2 (see *Appendix 19*); –0.34 weeks (95% CI –0.48 to –0.20 weeks) in SIMD3

RESULTS

TABLE 20 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: maternal behaviour

Imputed	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	-0.35 (-0.41 to 0.28)	1.09 (1.02 to 1.17)	1.02 (0.98 to 1.06)
Period 3 ^c	-1.10 (-1.19 to 1.02)	0.91 (0.83 to 0.99)	1.03 (0.95 to 1.11)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	-0.14 (-0.15 to 0.13)	1.09 (1.08 to 1.11)	0.918 (0.912 to 0.925)
Interaction 2 ^g	-0.57 (-0.62 to 0.52)	1.11 (1.04 to 1.17)	0.92 (0.90 to 0.95)
Interaction 3 ^h	-0.21 (-0.24 to 0.18)	0.88 (0.84 to 0.92)	0.99 (0.90 to 0.95)
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001
a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.			

TABLE 21 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: measures of size

Imputed	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.86 (0.68 to 1.10)	1.01 (0.95 to 1.09)	0.98 (0.94 to 1.01)	-0.04 (-0.05 to 0.03)	0.07 (0.03 to 0.10)
Period 3 ^c	0.93 (0.66 to 1.30)	1.05 (0.96 to 1.15)	0.96 (0.92 to 1.01)	-0.10 (-0.12 to 0.09)	0.22 (0.17 to 0.27)
Global test 1 ^d	0.40	0.50	0.30		
Trend					
All years ^e	1.01 (0.96 to 1.06)	0.99 (0.98 to 1.01)	1.00 (0.99 to 1.01)		

TABLE 21 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: measures of size (*continued*)

Imputed	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Interactions					
Interaction 1 ^f				0.007 (0.004 to 0.01)	0.02 (0.01 to 0.03)
Interaction 2 ^g				−0.02 (−0.03 to 0.01)	0.07 (0.05 to 0.10)
Interaction 3 ^h				−0.033 (−0.040 to 0.025)	0.04 (0.02 to 0.06)
Global test 2 ⁱ	0.90	0.05	0.10	< 0.0001	0.0009
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

TABLE 22 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: measures of stage

Imputed	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.03 (−0.05 to 0.01)	1.01 (0.96 to 1.07)	1.09 (0.97 to 1.24)	−0.007 (−0.02 to 0.003)	1.01 (0.95 to 1.06)	0.99 (0.95 to 1.03)
Period 3 ^c	−0.15 (−0.17 to 0.12)	1.19 (1.11 to 1.28)	1.41 (1.20 to 1.65)	−0.01 (−0.03 to 0.001)	1.01 (0.94 to 1.09)	0.98 (0.93 to 1.04)
Global test 1 ^d				0.10	0.90	0.80
Trend						
All years ^e				0.002 (−0.0002 to 0.004)	0.99 (0.98 to 0.998)	0.99 (0.98 to 0.99)
continued						

TABLE 22 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: measures of stage (*continued*)

Imputed	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Interactions						
Interaction 1 ^f	0.023 (0.020 to 0.028)	0.96 (0.95 to 0.97)	0.93 (0.91 to 0.96)			
Interaction 2 ^g	0.16 (0.14 to 0.17)	0.73 (0.70 to 0.76)	0.61 (0.55 to 0.67)			
Interaction 3 ^h	0.06 (0.05 to 0.07)	0.85 (0.83 to 0.88)	0.70 (0.66 to 0.75)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.02	0.30	0.10
a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.						

TABLE 23 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: birth outcomes

Imputed	Birth outcomes				
	Mode of delivery				
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	1.00
Period 2 ^b	1.01 (0.97 to 1.05)	1.06 (1.03 to 1.10)	1.01 (0.84 to 1.21)	0.92 (0.84 to 1.01)	1.84 (1.22 to 2.78)
Period 3 ^c	1.08 (1.01 to 1.14)	1.17 (1.11 to 1.22)	0.90 (0.70 to 1.16)	0.88 (0.77 to 1.00)	1.54 (0.85 to 2.78)
Global test 1 ^d	0.004		0.40	0.10	0.004
Trend					
All years ^e	1.05 (1.04 to 1.06)		0.98 (0.94 to 1.02)	1.01 (0.99 to 1.03)	0.91 (0.84 to 0.997)

TABLE 23 Results of analysis for the secondary outcomes using the imputed data and adjusting for gestational age at booking and maternal smoking: birth outcomes (*continued*)

Imputed	Birth outcomes				
	Mode of delivery				
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Interactions					
Interaction 1 ^f		0.983 (0.975 to 0.99)			
Interaction 2 ^g		1.02 (0.99 to 1.04)			
Interaction 3 ^h		1.00 (0.98 to 1.02)			
Global test 2 ⁱ	0.10	0.02	0.10	0.90	0.10
<div>a Pre-intervention period.</div> <div>b Intervention HiP grant.</div> <div>c Post-intervention period.</div> <div>d Global test for the periods in which the interactions were not significant.</div> <div>e Trend over the study period 2004–13.</div> <div>f Trend pre intervention.</div> <div>g Trend during the HiP grant period.</div> <div>h Trend post intervention.</div> <div>i Global test for the interactions.</div>					

TABLE 24 Results of subgroup analysis for the primary outcome using the imputed data unadjusted for gestational age at booking and maternal smoking: subgroups related to the socioeconomic position of the area of residence (SIMD2009 version 2)

Parameter	Birthweight (g), coefficient (95% CI)				
	SIMD1: most deprived areas	SIMD2	SIMD3	SIMD4	SIMD5: least deprived areas
Periods					
Period 1 ^a	0.00	0.00	0.00	0.00	0.00
Period 2 ^b	−12.20 (−20.80 to 3.60)	−1.30 (−10.80 to 8.20)	−1.80 (−11.50 to 8.00)	3.80 (−6.00 to 13.70)	1.10 (−9.00 to 11.20)
Period 3 ^c	−22.10 (−34.20 to 10.00)	−8.00 (−21.40 to 5.30)	1.30 (−12.50 to 15.00)	6.80 (−7.10 to 20.80)	1.00 (−13.30 to 15.30)
Global test 1 ^d	0.002	0.30	0.70	0.60	0.90
Trend					
All years ^e	7.00 (5.20 to 8.90)	4.30 (2.20 to 6.40)	2.30 (0.20 to 4.40)	0.70 (−1.50 to 2.80)	0.10 (−2.10 to 2.30)

continued

TABLE 24 Results of subgroup analysis for the primary outcome using the imputed data unadjusted for gestational age at booking and maternal smoking: subgroups related to the socioeconomic position of the area of residence (SIMD2009 version 2) (*continued*)

Parameter	Birthweight (g), coefficient (95% CI)				
	SIMD1: most deprived areas	SIMD2	SIMD3	SIMD4	SIMD5: least deprived areas
Interactions					
Interaction 1 ^f					
Interaction 2 ^g					
Interaction 3 ^h					
Global test 2 ⁱ	0.02	0.40	0.90	0.30	0.40

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Note

When using the complete cases and adjusting the analysis for ethnicity, the mean gestational age at booking decreased by 1.1 weeks (95% CI 1.0 weeks to 1.2 weeks) and the odds of booking before 25 weeks increased by 36% (OR 1.36, 95% CI 1.17 to 1.58; see *Appendix 63*). However, birthweight decreased by 12.8 g (95% CI 4.6 to 20.9 g; see *Appendix 64*) and the odds of neonatal death increased by > 180% (OR 2.84; 95% CI 1.26% to 6.38%; see *Appendix 66*) during the intervention.

(see *Appendix 23*); –0.24 weeks (95% CI –0.39 to –0.10 weeks) in SIMD4 (see *Appendix 27*); and –0.2 weeks (95% CI –0.4 to –0.1 weeks) in SIMD5 (the least deprived areas; see *Appendix 31*).

In the most deprived areas (SIMD1), the odds of having an emergency caesarean section increased by 10% (OR 1.10, 95% CI 1.03 to 1.18; see *Appendix 18*).

In the 20% of areas in the middle of the deprivation range (SIMD3), the odds of the mothers booking before 25 weeks increased by 24% during the intervention period (OR 1.24, 95% CI 1.06 to 1.45) but the odds of the mothers smoking during pregnancy increased by 10% (OR 1.10, 95% CI 1.01 to 1.20; see *Appendix 23*).

During the intervention, babies' standardised weight-for-dates (z-score) decreased by 0.4 for mothers with diabetes mellitus (95% CI 0.1 to 0.6; see *Appendix 37*).

For severely obese mothers, the odds of booking before 25 weeks increased by 35% during the intervention period (OR 1.35, 95% CI 1.05 to 1.72; see *Appendix 39*).

Sole registered mothers were more likely to book earlier during the intervention period; the mean gestational age at booking decreased by 0.4 weeks (95% CI 0.1 to 0.7 weeks; *Appendix 43*).

In the working-class group, mothers were likely to book 0.5 weeks earlier (95% CI 0.4 to 0.6 weeks), and the odds of booking before 25 weeks in this group increased by 19% (OR 1.19, 95% CI 1.04% to 1.35%; see *Appendix 47*).

TABLE 25 Results of subgroup analysis for the primary outcome using the imputed data unadjusted for gestational age at booking and maternal smoking: other subgroups

Parameter	Birthweight (g), coefficient (95% CI)						
	Severely obese mothers	Mothers with diabetes mellitus	Lone mothers	Mothers from working-class group	Mothers from never worked group	Teen mothers	Non-white mothers
Periods							
Period 1 ^a	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Period 2 ^b	-13.20 (-33.00 to 6.70)	-14.08 (-62.90 to 34.80)	-4.00 (-23.50 to 15.50)	-5.90 (-13.40 to 1.60)	-1.60 (-13.00 to 9.80)	-1.50 (-17.90 to 15.00)	-6.00 (-30.50 to 18.40)
Period 3 ^c	-41.00 (-69.30 to 12.70)	-68.60 (-138.30 to 1.10)	-22.30 (-49.30 to 4.70)	-13.50 (-24.00 to 2.90)	-10.60 (-26.50 to 5.40)	-11.60 (-34.70 to 11.50)	-20.70 (-56.70 to 15.30)
Global test 1 ^d	0.003	0.03	0.10	0.04	0.20	0.40	0.40
Trend							
All years ^e	1.20 (-3.20 to 5.70)	-8.90 (-19.90 to 2.00)	5.50 (1.40 to 9.60)	5.30 (3.70 to 6.90)	3.40 (1.00 to 5.90)	5.10 (1.60 to 8.50)	7.50 (1.50 to 13.60)
Interactions							
Interaction 1 ^f							
Interaction 2 ^g							
Interaction 3 ^h							
Global test 2 ⁱ	0.007	0.0002	0.60	0.60	0.40	0.30	0.40

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Note

When using the complete cases and adjusting the analysis for ethnicity, the mean gestational age at booking decreased by 1.1 weeks (95% CI 1.0 weeks to 1.2 weeks) and the odds of booking before 25 weeks increased by 36% (OR 1.36, 95% CI 1.17 to 1.58; see *Appendix 63*). However, birthweight decreased by 12.8 g (95% CI 4.6 to 20.9 g; see *Appendix 64*) and the odds of neonatal death increased by > 180% (OR 2.84; 95% CI 1.26 to 6.38; see *Appendix 66*) during the intervention.

For mothers who lived in households in which the head of the household had never worked, there was no statistically significant effect of the intervention on the primary outcome or most of the secondary outcomes (see *Appendices 51–54*), but there was a reduction of 0.3 weeks in the mean gestation at booking (95% CI 0.1 weeks to 0.5 weeks; see *Appendix 51*).

Gestational age at booking decreased by 0.5 weeks among teen mothers during the intervention period (95% CI 0.2 to 0.8 weeks; see *Appendix 55*).

Gestational age at booking decreased by 0.7 weeks among non-white mothers during the intervention period (95% CI 0.2 to 1.1 weeks; see *Appendix 59*). However, the odds of being SGA increased by 30% for this group (OR 1.30, 95% CI 1.01 to 1.67; see *Appendix 61*).

Results of sensitivity analysis

Subgroup of nulliparous mothers

In the subgroup of nulliparous mothers (see *Appendix 70*), the odds of having a 5-minute Apgar score of < 7 decreased by 13% during the intervention period (OR 0.87, 95% CI 0.77 to 0.99), but the odds of having an elective caesarean section increased by 16% during the same period (OR 1.16, 95% CI 1.08 to 1.26; see *Appendix 70*).

Impact of restricting the pre-intervention period to the period following the introduction of the smoking ban in public places

When restricting the pre-intervention period to the post-smoking-ban period, the odds of preterm birth increased by 81% and the odds of very preterm birth increased by 280% during the intervention period (see *Appendix 73*). The odds of neonatal deaths increased by 108% during the intervention period (see *Appendix 74*).

Impact of moving the Health in Pregnancy grant period

When restricting the pre-intervention period to 18 months, the odds of booking before 25 weeks increased by 12% (OR 1.12, 95% CI 1.03 to 1.22) and the odds of preterm birth decreased by 10% (OR 0.90, 95% CI 0.84 to 0.96) during the intervention period. However, the odds of neonatal deaths also increased by 98% (OR 1.98, 95% CI 1.31 to 2.98; see *Appendix 75*).

When the pre-intervention period was extended to 30 months, the odds of booking before 25 weeks increased by 10% (OR 1.10, 95% CI 1.03 to 1.17) during the supposed intervention period. However, the odds of preterm birth increased by 10% (OR 1.10, 95% CI 1.04 to 1.16), the odds of very preterm birth increased by 28% (OR 1.28, 95% CI 1.14 to 1.44) and the odds of neonatal death increased by 76% (OR 1.76, 95% CI 1.16 to 2.66; see *Appendix 76*).

When births that occurred during the peak months of the 2009 swine flu outbreak were excluded, the odds of booking before 25 weeks increased by 9% (OR 1.09, 95% CI 1.02 to 1.17) during the intervention period. However, the odds of preterm birth increased by 7% (OR 1.07, 95% CI 1.01 to 1.13), the odds of very preterm birth by 19% (OR 1.19, 95% CI 1.04 to 1.34) and the odds of neonatal death by 97% (OR 1.97, 95% CI 1.27 to 3.06; see *Appendix 77*).

Impact of moving the intervention period to 1 year before the real Health in Pregnancy grant period

When moving the HiP grant period to 1 year before the real intervention period but maintaining its length at 24 months, the odds of neonatal death increased by 85% during the supposed intervention period (OR 1.85, 95% CI 1.22 to 2.81). The odds of preterm birth decreased by 12% (OR 0.88, 95% CI 0.80 to 0.97) and the odds of booking before 25 weeks increased by 23% (OR 1.23, 95% CI 1.09 to 1.38;

see *Appendix 78*). The results were similar regardless of whether the intervention lasted 24, 18, and 30 months, except in the cases of preterm and very preterm births (see *Appendices 78–80*).

Impact of moving the intervention period to 6 months before the real Health in Pregnancy grant period

When evaluating the HiP grant as though it began 6 months before it really began, and maintaining the intervention length at 24 months, the odds of neonatal death increased by 64% during the supposed intervention period (OR 1.64, 95% CI 1.08 to 2.49). However, the odds of preterm birth decreased by 12% (OR 0.88, 95% CI 0.82 to 0.94) and the odds of booking before 25 weeks increased by 16% (OR 1.16, 95% CI 1.06 to 1.27; see *Appendix 81*). The results were similar when the supposed intervention period was shortened to 18 months, although the odds of very preterm birth also decreased by > 50% (OR 0.47, 95% CI 0.38 to 0.58; see *Appendix 82*). Only the odds of booking before 25 weeks were statistically significant when the intervention lasted 30 months (OR 1.15, 95% CI 1.06 to 1.24; see *Appendix 83*).

Impact of moving the intervention period to 6 months after the real Health in Pregnancy grant period

Moving the start of the HiP grant period to 6 months after the real intervention period but maintaining its length at 24 months resulted in a decrease in mean birthweight of 4.7 g (95% CI 0.5 to 8.8 g), and the odds of preterm and very preterm birth increased by 14% (OR 1.14, 95% CI 1.09 to 1.20) and 34% (OR 1.34, 95% CI 1.20 to 1.48), respectively. The odds of booking before 25 weeks increased by 9% during the supposed intervention period (OR 1.09, 95% CI 1.02 to 1.17; see *Appendix 84*). The results were similar when the intervention lasted for 30 months (see *Appendix 88*). However, when the intervention lasted for 18 months, the odds of neonatal death increased by 51% (OR 1.51, 95% CI 1.02 to 2.23; see *Appendix 85*).

Impact of moving the intervention period to 1 year after the real Health in Pregnancy grant period

Moving the start of the HiP grant period to 1 year after the real intervention period and keeping its length at 24 months showed a decrease in mean birthweight of 4.2 g (95% CI 0.1 to 8.2 g), and the odds of preterm and very preterm birth increased by 30% (OR 1.30, 95% CI 1.23 to 1.36) and 69% (OR 1.69, 95% CI 1.51 to 1.88), respectively (see *Appendix 87*). The results were similar when the intervention lasted 18 and 30 months (see *Appendices 88 and 89*).

Summary of results for the main analysis and moving windows

For the primary outcome (birthweight) and five secondary outcomes (gestational age at booking; booking before 25 weeks; preterm delivery; very preterm delivery; and neonatal deaths), the main analysis and moving windows results are summarised in *Figures 3–8*.

Economic analysis results

The HiP intervention period was not associated with any meaningful differences in birthweight outcomes (very low birthweight: –83, 95% CI –223 to 80; low birthweight: 199, 95% CI –189 to 592; normal birthweight: –116, 95% CI –471 to 238), although it trended towards a reduction in births of very low birthweight. The HiP intervention period also led to negligible differences in gestational age outcomes (very preterm: 90, 95% CI –20 to 204; preterm: 28, 95% CI –303 to 355; term: –118, 95% CI –427 to 191). Finally, it also led to negligible differences in maternal outcomes. These results consequently meant that there were negligible differences in index hospitalisation costs from a birthweight approach (–£0.2M, 95% CI –£1.0M to £0.6M); a preterm approach (£0.6M, 95% CI –£0.1M to £1.4M); and a maternal outcomes approach (£0.2M, 95% CI –£0.1M to £0.5M). These figures were in contrast to a HiP grant cost of £20.4M (*Table 26*).




FIGURE 3 Coefficient and 95% CI for birthweight during the HiP grant period and moving windows.




FIGURE 4 Coefficient and 95% CI for gestational age at booking during the HiP grant period and moving windows.




FIGURE 5 Odds ratio and 95% CI for booking before 25 weeks during the HiP grant period and moving windows.




FIGURE 6 Odds ratio and 95% CI for preterm delivery during the HiP grant period and moving windows.




FIGURE 7 Odds ratio and 95% CI for very preterm delivery during the HiP grant period and moving windows.




FIGURE 8 Odds ratio and 95% CI for neonatal death during the HiP grant period and moving windows.

TABLE 26 Incremental outcomes and costs attributable to HiP grant intervention

Outcomes (95% CI)					
Preterm		Birthweight		Pregnancy (maternal)	
Very preterm (< 33 weeks)	90 (–20 to 204)	Very low (< 1500 g)	–83 (–223 to 80)	Ectopic pregnancy	6 (–4 to 15)
Preterm (33–36 weeks)	28 (–303 to 355)	Low (1500–2499 g)	199 (–189 to 592)	Placenta previa	4 (–3 to 11)
Normal (> 36 weeks)	–118 (–427 to 191)	Normal (> 2500 g)	–116 (–471 to 238)	Abruptio placentae	1 (–1 to 3)
				PPROM	37 (–25 to 98)
				Pre-eclampsia	–6 (–17 to 4)
Cost, £ million (95% CI)					
Preterm	0.6 (–0.1 to 1.4)	Birthweight cost	–0.2 (–1.0 to 0.6)	Pregnancy cost	0.2 (–0.1 to 0.5)
HiP	20.4	HiP cost	20.4	HiP cost	20.4
Δcost	21.1 (20.3 to 21.8)	Δcost	20.2 (19.5 to 21.0)	Δcost	20.6 (20.3 to 21.0)
Δcost, change in cost.					

Chapter 4 Discussion

Principal findings

There is no evidence that the HiP grant affected birthweight. The analysis in which we have the most confidence, namely that relating to the analysis of 30 imputed data sets, indicates that singleton births during the eligible period (births to mothers with a due date of delivery between 14 April 2009 and 7 April 2011) had a mean birthweight that was 2.6 g lower than that of babies born during the pre-intervention period, from 1 January 2004 to 30 March 2009 (95% CI –6.9 to 1.7 g). This change in mean birthweight was trivial as well as not significant and reflected a like-for-like comparison through the inclusion of important maternal, obstetric and sociodemographic confounders, as well as the seasonality in birthweight and the secular trend of increasing birthweight.

The results of the complete-case analysis suggest that the HiP grant was associated with a significant decrease in birthweight of 9.0 g (95% CI 3.7 to 14.3 g). The difference between these two results reflects the fact that the complete cases represent a biased sample of the 532,968 singleton births that were available for analysis.

In retrospect, the fact that we found no effect of the HiP grant on birthweight is perhaps not surprising, given that the known modifiable determinants of low birthweight are largely limited to maternal smoking and some specific aspects of nutrition.^{14,23–25,48} To this extent, the choice of birthweight as the primary outcome measure of this study was somewhat optimistic.

Our findings for mean birthweight were supported by other measures of size and weight-for-dates. There was no significant effect on the odds of low birthweight, very low birthweight or high birthweight, suggesting that no part of the birthweight distribution was affected. Similarly, there was no significant effect on the continuous measure of weight-for-dates (z-score) or on the odds of being either SGA or LGA.

There was evidence of a significant effect on head circumference (the mean head circumference of babies associated with the intervention was 0.04 cm smaller than for babies pre intervention; 95% CI 0.03 to 0.05 cm) and crown-to-heel length (the mean length of babies in the intervention was 0.07 cm longer than babies pre intervention, 95% CI 0.04 to 0.10 cm). However, these changes of < 1 mm are too small to be of any clinical relevance and reflect the power available to the study through the use of a large routine data set.

We do see a significant and positive impact on the date of booking. Mean gestational age at booking during the intervention period was 0.35 weeks lower than pre intervention (95% CI 0.29 to 0.41 weeks). This is a small effect, equivalent to a population shift of about 2.5 days, which in itself might be considered unimportant. More important, however, is the increase in the odds of booking before 25 weeks; the HiP grant was associated with a 10% increase in the odds of booking before 25 weeks (OR 1.10, 95% CI 1.02 to 1.18), suggesting that very late bookers were likely to seek help earlier. This effect can be seen in *Table 13*; the crude proportion failing to book before 25 weeks [3.5% over the 10-year study period based on the imputed data (96.5% booked before 25 weeks)] decreased from 3.9% in 2006–8 to 2.8% in 2009–11. A 1.1% absolute increase in the proportion of women seeking antenatal care earlier in their pregnancy represents about 600 women each year. Women who book late in their pregnancy tend to be more disadvantaged than those who book earlier; across the 10-year study period, those booking at 25 weeks or later were more likely to be from a household in which the head of the household had never worked (24% compared with 15% booking before 25 weeks), to be a lone parent (12% vs. 5%) and to have been under the age of 20 years at the time of birth (12% vs. 6%).

The only measure of maternal health behaviour – smoking during pregnancy – was unchanged by the intervention. It is worth noting, however, that the odds of smoking during pregnancy showed strong declines during the study period, with a reduction of 8% per year between 2004 and 2011. Crude (imputed) rates of maternal smoking fell from 25.8% in 2004 to 18.8% in 2013.

The intervention was not associated with a significant effect on elective caesarean sections but it was associated with an increase in emergency caesarean section (OR 1.07, 95% CI 1.03 to 1.10). On its own, it is unclear if an increase in the emergency caesarean section rate is a good or a bad thing. Even if there is no adverse health effect for mother or infant, surgical intervention represents an opportunity cost. However, emergency as opposed to elective caesarean section should indicate a perceived need to intervene for the safety of the mother or infant, and so an increase in this rate may be indicative of something going wrong.

There were adverse outcomes associated with the intervention. Gestational age at delivery showed a small reduction of 0.04 weeks (about 7 hours; 95% CI 0.02 to 0.06 weeks). This small decrease in mean gestational age is accompanied by no significant effect on preterm births and a small (but again not significant) increase in the odds of very preterm births (OR 1.11, 95% CI 0.98 to 1.25). This increase in very preterm deliveries is likely to be associated with the increase in the emergency caesarean section rate noted above (see *Table 5*).

The principal adverse finding is a large increase in the odds of neonatal death associated with the intervention period (OR 1.84, 95% CI 1.22 to 2.78). The crude neonatal mortality rate, averaging 0.07% between 2004 and 2013, was higher between 2009 and 2011 (0.08–0.09%) than in the 2 years before (0.06–0.08%) or after (0.03–0.06%). This increase during the intervention period should be considered against a background of falling neonatal mortality, with the odds of neonatal death falling by 9% per year (95% CI 0% to 17%). There was no significant impact on either the stillbirth rate or the 5-minute Apgar score.

With such limited impact on outcomes, the economic analysis showed that the HiP grant had very little economic effect (positive or negative).

Impact on inequalities

Extensive subgroup analyses were undertaken to enable us to determine whether effects were stronger, or indeed whether they just differed, for the most disadvantaged groups. These could potentially be indications of effects on those with most to gain from the intervention, which are not observed when the whole population is analysed (and with adjustment for measures of disadvantage).

There were no significant effects of the HiP grant on the subgroup of women with diabetes mellitus. For all other subgroups, gestational age at booking was significantly reduced during the intervention period; notably, the effect was more pronounced (i.e. the decrease in gestational age at booking associated with the intervention period was larger) for those women with a BMI at booking of ≥ 35 kg/m², women living in the most deprived 20% of areas, lone mothers, women living in low social class households and teen mothers. Conversely, the effect was less pronounced for women living in the more advantaged areas. Of these subgroups, women with a BMI at booking of ≥ 35 kg/m² and women living in low social class households had increased odds of booking before 25 weeks. These odds were significantly increased relative to the pre-intervention period, but were also larger than those found for all women.

Women living in the most deprived 40% of areas and women living in households in which the head of household had never worked showed significant increases in the odds of emergency caesarean section. However, in each case these odds were lower than those seen for the general population.

For women living in the most deprived 20% of areas, the intervention period was associated with a decrease in mean offspring birthweight of 12 g (95% CI 4 to 21 g). Although this difference itself is probably too small to be important, there was a significant decrease in the odds of high birthweight babies (OR 0.93, 95% CI 0.86 to 1.00) and no significant change in the odds of low birthweight or very low birthweight babies.

Among the subgroup of mothers for whom ethnicity was recorded as a group other than white, the intervention period was associated with a decrease in mean gestational age. This group also saw a significant increase in the odds of having a baby that was small for its gestational age (OR 1.30, 95% CI 1.01 to 1.67).

Robustness and generalisability

We undertook a number of further analyses in an attempt to find evidence for whether or not the relationship between the intervention and the key outcomes was likely to be causal, and to try to understand better how the intervention may have worked. The first of these analyses related to the post-intervention period; following withdrawal of the intervention (for women who reached the 25th week of pregnancy on or after 1 January 2011), the return of an outcome to a pre-intervention level may be seen to strengthen the case that the change in outcome was attributable to the intervention. However, if an outcome was maintained, or if its effect was increased post intervention, then it may be that behaviour change was maintained following withdrawal of the intervention. Alternatively, it could be indicative of macro-level effects unrelated to the intervention. It is also possible that the effect of macro-level activities could be modified by the intervention; the unpredictable nature of such modifications would be difficult to detect with a non-randomised design.

The decrease in mean gestational age at booking seen during the intervention period was extended post intervention; relative to the pre-intervention period, mean gestational age at booking was 0.35 weeks (95% CI 0.29 to 0.41 weeks) lower during the intervention period and 1.10 weeks (95% CI 1.02 to 1.20 weeks) lower post intervention. These decreases were seen over and above the decreasing trends in gestational age at booking and may reflect the introduction and pursuit of Health improvement, Efficiency and governance improvements, Access to services, Treatment appropriate to individuals (HEAT) targets. A Health Improvement Target for 2012/13 was outlined as follows: 'At least 80% of pregnant women in each SIMD quintile will have booked for antenatal care by the 12th week of gestation by March 2015 so as to ensure improvements in breast feeding rates and other important health behaviours'.⁷⁹ Although this was not formally introduced as a target during the intervention period, it is possible that health boards were preparing for its introduction and trying to increase the numbers of women booking by 12 weeks in all deprivation groups. Similarly, eligibility for the Healthy Start vouchers begins at 10 weeks of pregnancy and requires the signature of a health professional, so this would have been an added incentive for the more disadvantaged groups (i.e. those eligible for Healthy Start) to book earlier for antenatal care. However, uptake of Healthy Start vouchers in pregnancy is generally low, and given that the scheme started in 2006 it would have no influence on the analysis that was restricted to the post-smoking ban period (from 2007 onwards). However, it is certainly plausible that the change in mean gestational age at booking was attributable to the HEAT targets rather than to the HiP grant. The same is not true, however, for the increase in the odds of booking before 25 weeks. The target of 25 weeks was related to eligibility for the HiP grants and not the HEAT targets. Following the withdrawal of the HiP grants, there was a small decrease in the odds of booking before 25 weeks (OR 0.91, 95% CI 0.83 to 1.00).

The odds of emergency caesarean section increased following the withdrawal of the HiP grant (OR 1.17, 95% CI 1.12 to 1.23). This meant that the odds of a woman receiving an emergency caesarean section were higher in the post-intervention period than during the intervention, after full adjustment for all covariates. The extent to which this could be attributable to the HiP grant is unclear.

The neonatal mortality rate remained high in the post-intervention period relative to the pre-intervention period, although this difference was not significant (OR 1.52, 95% CI 0.84 to 2.74). It is also the case

that the odds of neonatal mortality in the post-intervention period, although lower than during the intervention, were not significantly lower. The extent to which the increase in the odds of neonatal mortality might be attributable to the HiP grants is, therefore, unclear. It is clear, however, that the odds of both preterm and very preterm births increased significantly in the post-intervention period but not during the intervention, and the higher mortality rate post intervention could be associated with this increase.

Nulliparous women formed a group that would largely be coming into contact with antenatal services for the first time and, as such, their behaviour would not be influenced by previous experience. The results for both mean gestational age at booking and the odds of booking before 25 weeks for this group were very similar to the results for all women. This group, however, had increased odds of elective caesarean section in both the intervention period (OR 1.16, 95% CI 1.08 to 1.26) and post intervention (OR 1.26, 95% CI 1.13 to 1.40). The odds of emergency caesarean section were elevated in the post-intervention period (OR 1.08, 95% CI 1.02 to 1.15) but not during the intervention (OR 1.00, 95% CI 0.96 to 1.05).

The ban on smoking in public places was introduced in Scotland on 26 March 2006. An evaluation of the impact of the ban on pregnancy outcomes found an anticipatory effect, with rates of SGA births, preterm births and spontaneous preterm births all decreasing as of 1 January 2006.⁸⁰ Because of the potentially contaminating effect of the introduction of the smoking ban on the outcomes that we were considering, and, in particular, the effect on the pre-intervention trends, we repeated the main analysis for all outcomes shortening the pre-intervention period by excluding all births before 1 January 2007.

When births from 2004–6 were excluded, we found a reduced, but still significant, reduction in mean gestational age at booking of 0.17 weeks (95% CI 0.06 to 0.28 weeks), and the increase in the odds of booking before 25 weeks was no longer significant (OR 1.05, 95% CI 0.92 to 1.20). Mean gestational age at delivery was significantly lower and the odds of preterm and very preterm births were significantly higher during the intervention period, whereas the odds of emergency caesarean section during the intervention period were elevated, as noted above (OR 1.07, 95% CI 1.01 to 1.15).

To understand the findings when excluding the period before the smoking ban, it is important to understand the nature of the estimates presented. As detailed above (see *Chapter 2, Models fitted and interpretation*), the estimates represent the mean change from the underlying (pre-intervention) trend associated with the intervention period. Using preterm births as an example, the OR of 1.02 (95% CI 0.97 to 1.08) associated with the intervention period given in *Table 18* represents a slight (non-significant) increase over the rate that would have been observed in 2010 had the pre-intervention trend remained in place [the pre-intervention trend, estimated from January 2004 to March 2009, being a small annual increase in the odds of preterm delivery (OR 0.96, 95% CI 0.95 to 0.97)]. The much larger estimate seen in *Table 99* (OR 1.81, 95% CI 1.64 to 2.01) is a departure from a much steeper annual decline pre intervention seen from January 2007 to March 2009 (OR 0.74, 95% CI 0.71 to 0.77). Therefore, a plausible explanation for the increased odds of preterm births when the pre-smoking ban period is excluded is that the introduction of the smoking ban was associated with a rapid but short-lived decrease in preterm births; preterm births during the intervention period were in line with the longer-term trend in such deliveries.

We investigated the effect of allowing the start and end dates (or more accurately the start and duration) of the intervention period to vary for selected outcomes. The purpose of this sensitivity analysis was to ascertain whether or not the actual intervention period represented the strongest 'dose', with a correspondingly greater impact on outcomes than other periods that may have overlapped, but did not completely coincide, with the intervention period. With a non-randomised study design such as ours, it is important to note that there may be several external factors at play. This moving window analysis was designed to overcome the difficulty in adjusting for all the different policies, interventions or events happening at different times in the wider context that may have influenced our outcomes.

The results of this analysis were not conclusive, with a great deal of overlap between estimates and CIs associated with differing hypothetical intervention periods. The extent of the overlap was not surprising

given the overlap between the intervention periods, which can be seen in *Table 8*. We can see from *Figure 4*, however, that smaller decreases in mean gestational age at booking were associated with earlier intervention windows, thereby suggesting that the downwards trend in booking times had started before the intervention period but that further declines were relatively modest following withdrawal of the intervention.

Interpretation

To understand the findings presented here, it is necessary to consider the wider context of the period under study. In particular, we looked for the influence of factors or events that may have impacted on births in Scotland at some stage, whether these be Scotland-wide, UK-wide or more global in nature. Above (see *Robustness and generalisability*), we discussed the introduction of a HEAT target, which was designed to increase the proportion of women from the most disadvantaged areas who booked before the 12th week of pregnancy and concluded that, although this may have contributed to the decrease in the mean gestational age at booking, it was unlikely to have caused the increase in the proportion of women booking before the 25th week during the intervention period. This was both because of the relationship of the 25-week target to the HiP grant, and because the proportion of women booking before 25 weeks fell significantly following withdrawal of the grant.

We undertook a sensitivity analysis relating to the introduction of the smoking ban in public places in Scotland that happened during the pre-intervention period, which was known to be associated with positive outcomes and behaviour change. However, the results of this sensitivity analysis were unclear, given that the exclusion of the period prior to the introduction of the smoking ban may have resulted in an atypical pre-intervention period during which there were rapid changes in some outcomes. This led to our finding of a significant increase in preterm births compared with the short-term (post-smoking-ban) trend, but no significant increase compared with the longer-term trend.

Two other global events are worth some consideration. The first of these is the influenza A virus A/H1N1pdm09 of swine origin (swine flu), which was declared to be a pandemic in June 2009. This virus was known to affect pregnant women and perinatal outcomes adversely, increasing the odds of preterm delivery and perinatal mortality in the UK.^{78,81} The outbreak peaked during the intervention period in July 2009, and again from October to November 2009. It is difficult to know in exactly which stage of pregnancy exposure to the virus had the greatest impact on outcomes. We excluded 5 months of births from July to November 2009, inclusive, as a form of sensitivity analysis to ascertain whether or not excluding the peak months of the pandemic changed any results. Excluding these months left most results unchanged, but did lead to a significant increase in the odds of both preterm (OR 1.07, 95% CI 1.01 to 1.13) and very preterm birth (OR 1.19, 95% CI 1.04 to 1.34). The increased odds of neonatal death remained significant (OR 1.97, 95% CI 1.27 to 3.06). The fact that these effects were larger than those recorded in the main analysis indicates that the months excluded were lower risk than the months included. It may be, therefore, that the months excluded for this sensitivity analysis were not just conservative (in the sense that the peak months of the pandemic only were excluded) but also that the month of delivery was not necessarily the most important factor affecting these outcomes.

Finally, the global financial crisis may have impacted on these results in ways that are difficult to predict. Often considered to have begun with the collapse of the Lehman Brothers bank in September 2008, the crisis resulted in recessions in many countries, including the UK, and the subsequent imposition of austerity measures. There are many plausible mechanisms by which this crisis might have influenced perinatal outcomes. One such route might be through increasing maternal malnutrition caused by economic hardship; certainly, use of food banks has increased in the UK.⁸² Alternatively, it may be that increasing job insecurity, associated with high levels of unemployment or precarious employment, has led to high levels of anxiety and psychosocial stress, and thus that these have influenced outcomes. It is not clear how or when any such effects would manifest themselves; although the poorest groups could be hardest hit, it is also plausible that

there would be some protection for the worse off (such as the long-term unemployed) through the welfare state, whereas those with jobs experience falling salaries and the stress of job insecurity. Therefore, our sensitivity analyses focused not only on the most disadvantaged groups but also on groups from across the spectrum of social advantage and disadvantage, and considered the population as broken down into quintiles of deprivation. The results of these analyses were not, however, able to determine any effect that may be attributable to the global financial crisis.

Strengths and weaknesses

A strength of the study was the very high quality, completeness and coverage of the linked routine maternity hospital discharges and SBR.⁸³ Linked data were available for about 98% of births in Scotland,⁸⁴ with knowledge of all registered births. Such high-quality data are not currently available at a national level for other countries in the UK, which means that it was not possible to extend this evaluation of HiP grants beyond Scotland. To a large extent, the data were complete, with few missing data in most of the key variables considered. This completeness was not universal and data on some variables, such as ethnicity and maternal smoking, were poorly collected for some or all of the study period.

The methods used were appropriate for the analysis of these data. Individual data were used yielding high power for the analyses and enabling data hierarchies of births nested within mothers and of mothers nested within small areas to be taken into account. Multiple imputation was used to account for the fact that the data were not complete. The results of the analysis of the multiply imputed data at times differed from the complete-case analysis, thus suggesting that the data were not missing completely at random but that missing values were patterned in ways that were associated with other (observed) variables. A large number (30) of imputed data sets meant that the variability within the data was preserved through the imputation process.

The study was based on routinely collected data, which meant that there was no information regarding how the money was spent. The HiP grant was an unconditional cash transfer – there was no restriction placed on how the money could be spent – and there is no way of knowing if it was spent in ways that might improve, damage, or have no impact on the health of the mother and fetus.

The study design remains a major limitation. This was essentially an uncontrolled before-and-after study (although unusually there was a period after the withdrawal of the intervention as well as before its introduction to give comparison groups). The interference of changes in the context that occurred during the study period – including, but not necessarily limited to, the introduction of the ban on smoking in public places, the introduction of a HEAT target to increase the proportion of women from the most deprived areas who sought early antenatal advice, the swine flu pandemic and the global financial crisis – may have influenced a number of the outcomes for all women or selected subgroups in ways that are difficult to predict with any certainty. This means that results from this study should be seen as indicative rather than definitive; in the study protocol we acknowledged that this study design meant that it might be difficult to attribute any effects with certainty to the HiP grant and suggested that, in such a case, a randomised controlled trial might be necessary.⁸⁵ It would have been possible to have conceived a randomised design for the original grant when it was introduced. Failing this, another design facilitating evaluation such as a stepped wedge design, as recommended by the House of Commons Health Committee in 2009,⁸⁶ would have satisfied any political requirement to introduce an (untested) intervention across the country. It remains the case that policy interventions are still rarely introduced in such a way as to facilitate rigorous evaluation and we would urge policy-makers to consider the importance of the evaluation of policy and to work with researchers to utilise designs that would facilitate such evaluation, when considering introducing or changing such public health programmes in the future.

Patient and public involvement

This project had no direct patient involvement, as the analysis used anonymised patient records. There would be benefits to the participation of pregnant women in a qualitative component of a future study as a means of understanding whether and how the cash incentive led to behaviour changes including earlier contact with health services. Such research could also explore how the money was spent and whether or not it contributed to a healthier lifestyle. In a retrospective study such as this, evaluating an intervention that has already been withdrawn, the difficulty in and potential bias of recalling such details made this element impractical.

There was little room for the involvement of the public in designing this research project. The intervention had already been designed, delivered and withdrawn. The methodology for the evaluation was determined by the intervention design and best practice in statistics, economics and the evaluation of natural experiments. The project would have benefited from public involvement on the project steering group, particularly from groups focusing on pregnancy and on poverty. Such involvement would have ensured that we were able to allay any fears over the use of confidential data in our analyses and that we reported our results with sufficient sensitivity.

Chapter 5 Conclusions

Implications for health care

We found no effect of the HiP grant on birthweight. Given the difficulty that has been found in changing birthweight, this is probably not surprising, especially given the relatively small sum of money that the grant amounted to.

We found an increase in the odds of booking before 25 weeks to be associated with the HiP grant. We believe that it is likely that this is a direct effect of the £190 cash transfer acting as an incentive; seeking antenatal care before the 25th week was a condition of receiving the money and, following withdrawal of the grant, the odds of booking before 25 weeks fell significantly. This is in line with other examples of health behaviour being influenced by cash incentives,³⁶ and suggests that it is possible to 'nudge' behaviour, including health-care-seeking behaviour. The care provided was normal care, and so the only implication for health service provision was an increased uptake of services. The group of women targeted by such an intervention – those who do not normally present to antenatal services until the 25th week of pregnancy or later – tend to be more disadvantaged than those who present earlier in the pregnancy, with higher proportions of worklessness, lone parents and teen mothers.

However, we did find significant increases in the likelihood of one adverse outcome, namely neonatal mortality. It does not appear likely that this was associated with the intervention for two reasons. First, there is no clear mechanism by which the intervention could have brought about this adverse result. If it were the case that the £190 cash transfer had been spent in ways that led to higher neonatal mortality, then we would expect the effect to be more pronounced in certain subgroups, namely for poorer women for whom £190 might have represented a larger increase in available cash. This does not appear to have been the case for women living in the most deprived areas or for women living in households in which the head of household was a semiskilled or unskilled manual worker, for example. Second, if the payment of £190 associated with the introduction of the HiP grant caused an increase in neonatal mortality then its removal should have brought about an equivalent decrease. The small decrease we found on removal of the grant was far from significant and left the neonatal mortality rate higher than that seen prior to the introduction of HiP. We feel that the impact of extraneous factors, such as the swine flu pandemic and the global financial crises, are more likely to have been the causes of the increase in neonatal mortality. Unfortunately, however, it is not possible to isolate and thereby distinguish the effects of these global phenomena.

It is unclear whether the increase in emergency caesarean sections that we found was an adverse effect (i.e. an unnecessary and expensive surgical intervention) or whether such emergency interventions brought about improvements in maternal and infant health. Given that we found a significant increase in the rate of emergency caesarean sections in the post-intervention period, not only in relation to the pre-intervention period but also in relation to the period during which the HiP grants were in place, it seems unlikely that the HiP grant could have caused such an increase. It is plausible that this outcome and other related outcomes (such as the odds of preterm or very preterm delivery, which were elevated but not significantly so) were also related to the global context including the swine flu pandemic and the global financial crisis.

The outcomes that were used for the analyses contained in this report were restricted to those that are routinely collected and do not include, for example, any measures of maternal wellbeing or mental health. It is possible that such outcomes could have been affected by the cash transfer, and it is important to note that the absence of evidence of an effect is not the same as evidence of the absence of an effect. It is possible that booking shortly before the deadline – say in the 23rd or 24th week of pregnancy – does not leave much time for the effect of any behavioural changes to be realised. It may be that earlier booking would lead to an increased dose of antenatal care, and that either reinforcement of health messages over a longer antenatal

period would lead to behaviour change, or earlier intervention would lead to behaviour change earlier in the pregnancy. Either consequence of earlier booking might improve infant outcomes.

Recommendations for research

It seems likely that the HiP grant was responsible for an increase in the proportion of women booking before 25 weeks, which represents a step in the right direction, but the big question is why this did not translate into an improvement in any of the other outcomes evaluated. We have suggested above (see *Implications for health care*) that this may in part reflect the threshold of 25 weeks being too late in the pregnancy to modify behaviour in any way that would lead to notable differences in birthweight or other outcomes indicating improved infant health. Our first recommendation for further research is, therefore, to test whether a threshold earlier than 25 weeks would lead to increased exposure to antenatal care and advice (increased frequency of antenatal visits), and whether any accompanying change in health behaviour (such as smoking or diet) occurring earlier in the pregnancy would lead to improvements in maternal and infant health outcomes. We recommend evaluation of the economic benefit that can be achieved through such a modified threshold and any consequent improvement in results.

It should be noted that the disadvantaged nature of the approximately 4% of women who do not book before 25 weeks offers an opportunity and a challenge. If the health-seeking behaviour of this group can be modified then this offers an opportunity to provide services to a group with great potential to benefit and, as a result, potentially to reduce inequalities in pregnancy outcomes. However, linking financial incentives to booking targets may result in an effective penalty for those women who are in greatest need of the money but fail to seek professional advice before the deadline, and if the incentive did not lead to behaviour change in this group then this could lead to an increase in inequalities.

Our other recommendations concern the nature of the intervention, and, although these questions are pertinent to such an intervention to improve pregnancy outcomes, they are relevant to many interventions in different fields.

Our second recommendation is to evaluate whether or not this intervention has greater impact, and higher cost-effectiveness, when delivered as a targeted or as a universal intervention. The HiP grant was universal; all women could claim the same cash transfer regardless of personal circumstances. This approach has many benefits, including an easier application process (no need for the complicated form filling that would be required for a means-tested grant) and a lack of stigma or perceived stigma attached to the grant, both of which should lead to higher uptake. There is clearly an opportunity cost; by targeting the payment to those in the greatest need, the payment could be increased or the money saved could be used for other purposes. An increased payment may not lead directly to an improvement in outcomes, but may provide an added incentive to seek advice before the deadline. Targeting the payments also comes with an attached cost, as there is a need to assess the eligibility of claimants.

Our third recommendation for future research is to test whether or not outcomes differ depending on whether the payment is conditional or unconditional. The cash transfer in the HiP grant was unconditional and could be spent as the recipient wished. This means that women were, in theory, able to spend the money received on cigarettes, alcohol or other products that could damage the fetus. An alternative approach would be to issue vouchers rather than cash with restrictions on what can be bought with those vouchers (as happens, e.g., with the Healthy Start voucher scheme⁷⁷). In fact, the two approaches are not as distinct as they might at first appear, because spending a conditional payment on goods that would have been bought anyway will free up cash to be spent as the recipient chooses. Their success depends in part on the retailer enforcing any conditions that are attached, and restricting the retailers that can be used or the goods that can be purchased may prove a disincentive, or may create inequalities between communities with differential access to participating retailers. However, the success of conditional payments will also depend on the acceptability of the restriction of goods to those women included in the scheme.

Our fourth and final recommendation is to investigate the relationship between the size of the payment and subsequent outcomes. The cash payment served two purposes: first, as an incentive to earlier health-care booking in pregnancy, and second, as additional financial support. Varying the size of the payment may not only indicate the optimal payment in terms of cost-effectiveness but may also, in combination with changes to the threshold in the first recommendation above, lead to a better understanding of the separate roles of antenatal care and financial support. For a given booking date a dose–response relationship between the size of the payment and outcomes would emphasise the value of the financial support, whereas improved outcomes associated with earlier antenatal booking at the same level of financial support would highlight the importance of the antenatal care itself.

Research answering these questions would determine whether or not a modification of the HiP grant should be considered as an option for policy-makers looking to improve pregnancy outcomes and to address inequalities in health from the beginning of the life course.

Acknowledgements

Project steering group

Our sincere thanks to the project steering group:

Dr Peter Craig, MRC/CSO Social and Public Health Sciences Unit, University of Glasgow (chairperson).

Dr Mary Hepburn, Consultant Obstetrician and Gynaecologist (retired).

Dr Graham McKenzie, Consultant in Public Health, NHS Lothian.

Mrs Marion McNab, Lead Midwife, NHS Greater Glasgow and Clyde.

Reviewers

We would like to thank the four anonymous reviewers for their thoughtful and helpful comments which have improved our final report.

Contributions of authors

Alastair H Leyland (Associate Director SPHSU, Population Health Statistics) oversaw the project and contributed to all aspects of the design, analysis and interpretation of the results.

Samiratu Ouédraogo (Research Fellow, Epidemiology) led the statistical analysis and contributed to the interpretation of the results.

Julian Nam (Research Fellow, Health Economics) led the economic analysis and contributed to the interpretation of the results.

Lyndal Bond (Principal Research Officer, Social Interventions) contributed to the study design and the interpretation of the results.

Andrew H Briggs (Professor, Health Economics) oversaw the economic analysis and contributed to the study design and the interpretation of the results.

Ron Gray (Senior Clinical Research Fellow, Perinatal Epidemiology) contributed to the study design and the interpretation of the results.

Rachael Wood (Consultant in Public Health Medicine, Public Health) contributed to the interpretation of the results.

Ruth Dundas (Senior Investigator Scientist, Statistics) managed the project, oversaw the statistical analysis and contributed to the study design and the interpretation of the results.

Publications

Dundas R, Ouédraogo S, Bond L, Briggs AH, Chalmers J, Gray R, *et al.* Evaluation of Health in Pregnancy Grants in Scotland: a protocol for a natural experiment. *BMJ Open* 2014;**4**:e006547.

Data sharing statement

The data came from the Scottish maternity and neonatal database held by the ISD at the NHS National Services Scotland. The release of the data for research purposes was subject to agreement (6 May 2014; PAC38A/13) from the Privacy Advisory Committee at NHS National Services Scotland and the Registrar General ([www.nhsnss.org/pages/corporate/privacy_advisory_committee.php](http://www.nhs.uk/nhsnss/pages/corporate/privacy_advisory_committee.php)). Access to the individual data was restricted to the investigators as part of this agreement.

References

1. Goldenberg RL, Culhane JF. Low birth weight in the United States. *Am J Clin Nutr* 2007;**85**:584S–590S.
2. Stein REK, Siegel MJ, Bauman LJ. Are children of moderately low birth weight at increased risk for poor health. A new look at an old question. *Pediatrics* 2006;**118**:217–23.
3. Euro-Peristat project with SCPE and EUROCAT. *European Perinatal Health Report. Health and Care of Pregnant Women and Babies in Europe in 2010*. Paris: Institut national de la santé et de la recherche médicale; 2013.
4. Barker DJ. The fetal and infant origins of adult disease. *BMJ* 1990;**301**:1111. <http://dx.doi.org/10.1136/bmj.301.6761.1111>
5. Barker DJ. In utero programming of chronic disease. *Clin Sci* 1998;**95**:115–28. <http://dx.doi.org/10.1042/cs0950115>
6. Barker DJ. Birth weight and hypertension. *Hypertension* 2006;**48**:357–8. <http://dx.doi.org/10.1161/01.HYP.0000236552.04251.42>
7. Barker DJ, Eriksson JG, Forsén T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. *Int J Epidemiol* 2002;**31**:1235–9. <http://dx.doi.org/10.1093/ije/31.6.1235>
8. Class QA, Rickert ME, Lichtenstein P, D’Onofrio BM. Birth weight, physical morbidity, and mortality: a population-based sibling-comparison study. *Am J Epidemiol* 2014;**179**:550–8. <http://dx.doi.org/10.1093/aje/kwt304>
9. Frankel S, Elwood P, Sweetnam P, Yarnell J, Smith GD. Birthweight, body-mass index in middle age, and incident coronary heart disease. *Lancet* 1996;**348**:1478–80. [http://dx.doi.org/10.1016/S0140-6736\(96\)03482-4](http://dx.doi.org/10.1016/S0140-6736(96)03482-4)
10. Hendryx M, Luo J, Knox SS, Zullig KJ, Cottrell L, Hamilton CW, *et al*. Identifying multiple risks of low birth weight using person-centered modeling. *Womens Health Issues* 2014;**24**:e251–6. <http://dx.doi.org/10.1016/j.whi.2014.01.001>
11. Leon DA, Lithell HO, Vågerö D, Koupilová I, Mohsen R, Berglund L, *et al*. Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915–29. *BMJ* 1998;**317**:241–5. <http://dx.doi.org/10.1136/bmj.317.7153.241>
12. Negrato CA, Gomes MB. Low birth weight: causes and consequences. *Diabetol Metab Syndr* 2013;**5**:49. <http://dx.doi.org/10.1186/1758-5996-5-49>
13. Reyes L, Mañalich R. Long-term consequences of low birth weight. *Kidney Int Suppl* 2005;**97**:S107–11. <http://dx.doi.org/10.1111/j.1523-1755.2005.09718.x>
14. Valero De Bernabé J, Soriano T, Albaladejo R, Juarranz M, Calle ME, Martínez D, Domínguez-Rojas V. Risk factors for low birth weight: a review. *Eur J Obstet Gynecol Reprod Biol* 2004;**116**:3–15. <http://dx.doi.org/10.1016/j.ejogrb.2004.03.007>
15. Abu-Saad K, Fraser D. Maternal nutrition and birth outcomes. *Epidemiol Rev* 2010;**32**:5–25. <http://dx.doi.org/10.1093/epirev/mxq001>
16. Villar J, Meriáldi M, Gulmezoglu AM, Abalos E, Carroli G, Kulier R, *et al*. Nutritional interventions during pregnancy for the prevention or treatment of maternal morbidity and preterm delivery: an overview of randomized controlled trials. *J Nutr* 2003;**133**(Suppl. 2):1606–25.

17. Mason JB, Saldanha LS, Ramakrishnan U, Lowe A, Noznesky EA, Girard AW, *et al.* Opportunities for improving maternal nutrition and birth outcomes: synthesis of country experiences. *Food Nutr Bull* 2012;**33**(Suppl. 2):104–37. <http://dx.doi.org/10.1177/156482651203325107>
18. Wu G, Imhoff-Kunsch B, Girard AW. Biological mechanisms for nutritional regulation of maternal health and fetal development. *Paediatr Perinat Epidemiol* 2012;**26**(Suppl. 1):4–26. <http://dx.doi.org/10.1111/j.1365-3016.2012.01291.x>
19. Delnord M, Blondel B, Zeitlin J. What contributes to disparities in the preterm birth rate in European countries? *Curr Opin Obstet Gynecol* 2015;**27**:133–42. <http://dx.doi.org/10.1097/GCO.0000000000000156>
20. Apgar V. A proposal for a new method of evaluation of the newborn infant. *Curr Res Anesth Analg* 1953;**32**:260–7. <http://dx.doi.org/10.1213/00000539-195301000-00041>
21. Iliodromiti S, Mackay DF, Smith GC, Pell JP, Nelson SM. Apgar score and the risk of cause-specific infant mortality: a population-based cohort study. *Lancet* 2014;**384**:1749–55. [http://dx.doi.org/10.1016/S0140-6736\(14\)61135-1](http://dx.doi.org/10.1016/S0140-6736(14)61135-1)
22. Tweed EJ, Mackay DF, Nelson SM, Cooper SA, Pell JP. Five-minute Apgar score and educational outcomes: retrospective cohort study of 751 369 children. *Arch Dis Child Fetal Neonatal Ed* 2016;**101**:F121–6. <http://dx.doi.org/10.1136/archdischild-2015-308483>
23. Frimmel W, Pruckner GJ. Birth weight and family status revisited: evidence from Austrian register data. *Health Econ* 2014;**23**:426–45. <http://dx.doi.org/10.1002/hec.2923>
24. Huxley R. Smoking, birthweight, and mortality across generations. *Eur Heart J* 2013;**34**:3398–9. <http://dx.doi.org/10.1093/eurheartj/ehs369>
25. Madden D. The relationship between low birth weight and socioeconomic status in Ireland. *J Biosoc Sci* 2014;**46**:248–65. <http://dx.doi.org/10.1017/S0021932013000187>
26. Juárez SP, Merlo J. Revisiting the effect of maternal smoking during pregnancy on offspring birthweight: a quasi-experimental sibling analysis in Sweden. *PLOS ONE* 2013;**8**:e61734. <http://dx.doi.org/10.1371/journal.pone.0061734>
27. Zdravkovic T, Genbacev O, McMaster MT, Fisher SJ. The adverse effects of maternal smoking on the human placenta: a review. *Placenta* 2005;**26**(Suppl. A):81–6. <http://dx.doi.org/10.1016/j.placenta.2005.02.003>
28. Barros FC, Bhutta ZA, Batra M, Hansen TN, Victora CG, Rubens CE, GAPPS Review Group. Global report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions. *BMC Pregnancy Childbirth* 2010;**10**(Suppl. 1):3. <http://dx.doi.org/10.1186/1471-2393-10-S1-S3>
29. Chang HH, Larson J, Blencowe H, Spong CY, Howson CP, Cairns-Smith S, *et al.* Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index. *Lancet* 2013;**381**:223–34. [http://dx.doi.org/10.1016/S0140-6736\(12\)61856-X](http://dx.doi.org/10.1016/S0140-6736(12)61856-X)
30. Fairley L, Leyland AH. Social class inequalities in perinatal outcomes: Scotland 1980–2000. *J Epidemiol Community Health* 2006;**60**:31–6. <http://dx.doi.org/10.1136/jech.2005.038380>
31. Weightman AL, Morgan HE, Shepherd MA, Kitcher H, Roberts C, Dunstan FD. Social inequality and infant health in the UK: systematic review and meta-analyses. *BMJ Open* 2012;**2**:e000964. <http://dx.doi.org/10.1136/bmjopen-2012-000964>
32. Brownell M, Chartier M, Au W, Schultz J. *Evaluation of the Healthy Baby Program*. Winnipeg, MB: Manitoba Centre for Health Policy; 2010.

33. Hollowell J, Kurinczuk JJ, Oakley L, Brocklehurst P, Gray R. *A Systematic Review of the Effectiveness of Antenatal Care Programmes to Reduce Infant Mortality and its Major Causes in Socially Disadvantaged and Vulnerable Women*. Oxford: National Perinatal Epidemiology Unit; 2009.
34. Her Majesty's Revenue and Customs. *Health in Pregnancy Grant Technical Manual*. 2008. URL: www.hmrc.gov.uk/manuals/hipgtmanual/ (accessed 6 September 2015).
35. Marteau TM, Ashcroft RE, Oliver A. Using financial incentives to achieve healthy behaviour. *BMJ* 2009;**338**:b1415. <http://dx.doi.org/10.1136/bmj.b1415>
36. Giles EL, Robalino S, McColl E, Sniehotta FF, Adams J. The effectiveness of financial incentives for health behaviour change: systematic review and meta-analysis. *PLOS ONE* 2014;**9**:e90347. <http://dx.doi.org/10.1371/journal.pone.0090347>
37. Tappin D, Bauld L, Purves D, Boyd K, Sinclair L, MacAskill S, et al. Financial incentives for smoking cessation in pregnancy: randomised controlled trial. *BMJ* 2015;**350**:h134. <http://dx.doi.org/10.1136/bmj.h134>
38. Giles EL, Sniehotta FF, McColl E, Adams J. Acceptability of financial incentives and penalties for encouraging uptake of healthy behaviours: focus groups. *BMC Public Health* 2015;**15**:58. <http://dx.doi.org/10.1186/s12889-015-1409-y>
39. Shaw M, Dorling D, Gordon D, Davey Smith G. *The Widening Gap: Health Inequalities and Policy in Britain*. Bristol: Policy Press, University of Bristol; 1999.
40. Hanlon P, Lawder RS, Buchanan D, Redpath A, Walsh D, Wood R, et al. Why is mortality higher in Scotland than in England and Wales? Decreasing influence of socioeconomic deprivation between 1981 and 2001 supports the existence of a 'Scottish Effect'. *J Public Health* 2005;**27**:199–204. <http://dx.doi.org/10.1093/pubmed/fdi002>
41. Office for National Statistics (ONS). *Ethnicity and National Identity in England and Wales 2011*. London: ONS; 2012.
42. National Records of Scotland. *2011 Census: Key Results on Population, Ethnicity, Identity, Language, Religion, Health, Housing and Accommodation in Scotland - Release 2A*. Edinburgh: National Records of Scotland; 2013.
43. Moser K, Stanfield KM, Leon DA. Birthweight and gestational age by ethnic group, England and Wales 2005: introducing new data on births. *Health Stat Q* 2008;**39**:22–31.
44. Commission on Social Determinants of Health. *Commission on Social Determinants of Health Final Report. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health*. Geneva: World Health Organization; 2008.
45. Shah PS, Zao J, Ali S, Knowledge Synthesis Group of Determinants of preterm/LBW births. Maternal marital status and birth outcomes: a systematic review and meta-analyses. *Matern Child Health J* 2011;**15**:1097–109. <http://dx.doi.org/10.1007/s10995-010-0654-z>
46. Bansal N, Chalmers JW, Fischbacher CM, Steiner MF, Bhopal RS, Scottish Health and Ethnicity Linkage Study. Ethnicity and first birth: age, smoking, delivery, gestation, weight and feeding: Scottish Health and Ethnicity Linkage Study. *Eur J Public Health* 2014;**24**:911–16. <http://dx.doi.org/10.1093/eurpub/cku059>
47. Craig P, Cooper C, Gunnell D, Haw S, Lawson K, Macintyre S, et al. Using natural experiments to evaluate population health interventions: new Medical Research Council guidance. *J Epidemiol Community Health* 2012;**66**:1182–6. <http://dx.doi.org/10.1136/jech-2011-200375>
48. Grieger JA, Clifton VL. A review of the impact of dietary intakes in human pregnancy on infant birthweight. *Nutrients* 2015;**7**:153–78. <http://dx.doi.org/10.3390/nu7010153>

49. Carlson SE. Docosahexaenoic acid supplementation in pregnancy and lactation. *Am J Clin Nutr* 2009;**89**:678–84S. <http://dx.doi.org/10.3945/ajcn.2008.26811E>
50. Wells JL, James DK, Luxton R, Pennock CA. Maternal leucocyte zinc deficiency at start of third trimester as a predictor of fetal growth retardation. *Br Med J* 1987;**294**:1054–6. <http://dx.doi.org/10.1136/bmj.294.6579.1054>
51. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW, Nutrition Impact Model Study Group (anaemia). Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. *BMJ* 2013;**346**:f3443. <http://dx.doi.org/10.1136/bmj.f3443>
52. Conter V, Cortinovis I, Rogari P, Riva L. Weight growth in infants born to mothers who smoked during pregnancy. *BMJ* 1995;**310**:768–71. <http://dx.doi.org/10.1136/bmj.310.6982.768>
53. Johnson CD, Jones S, Paranjothy S. Reducing low birth weight: prioritizing action to address modifiable risk factors [published online ahead of print 16 February 2016]. *J Public Health* 2016. <http://dx.doi.org/10.1093/pubmed/fdv212>
54. Suzuki K, Shinohara R, Sato M, Otawa S, Yamagata Z. Association between maternal smoking during pregnancy and birth weight: an appropriately adjusted model from the Japan Environment and Children's Study. *J Epidemiol* 2016;**26**:371–7. <http://dx.doi.org/10.2188/jea.JE20150185>
55. Scottish Government. *Smoking, Health and Social Care (Scotland) Act 2005 (asp 13)*. Edinburgh: The Stationery Office Limited; 2005.
56. Einarsdóttir K, Kemp A, Haggard FA, Moorin RE, Gunnell AS, Preen DB, et al. Increase in caesarean deliveries after the Australian Private Health Insurance Incentive policy reforms. *PLOS ONE* 2012;**7**:e41436. <http://dx.doi.org/10.1371/journal.pone.0041436>
57. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. *Int J Technol Assess Health Care* 2003;**19**:613–23. <http://dx.doi.org/10.1017/S0266462303000576>
58. Fairley L. Changing patterns of inequality in birthweight and its determinants: a population-based study, Scotland 1980–2000. *Paediatr Perinat Epidemiol* 2005;**19**:342–51. <http://dx.doi.org/10.1111/j.1365-3016.2005.00665.x>
59. Shadish WR, Cook TD, Campbell DT. *Experimental and Quasi-Experimental Designs for Generalized Causal Inference*. 2nd edn. New York, NY: Houghton Mifflin Company; 2001.
60. Administrative Data Liaison Service. *Maternity and Neonatal Linked Database*. URL: www.adls.ac.uk/nhs-scotland/maternity-andneonatal-linked-database/?detail (accessed 15 August 2015).
61. Administrative Data Liaison Service. *Scottish Birth Records*. URL: www.adls.ac.uk/nhs-scotland/sbr-scottish-birth-record/?detail (accessed 15 August 2015).
62. Scottish Government. *Scottish Index of Multiple Deprivation 2009 General Report*. Edinburgh: Scottish Government; 2009.
63. Office for National Statistics. *The National Statistics Socio-economic Classification (NS-SEC rebased on the SOC2010)*. URL: www.ons.gov.uk/ons/guide-method/classifications/current-standard-classifications/soc2010/soc2010-volume-3-ns-sec-rebased-on-soc2010-user-manual/index.html (accessed 10 June 2014).
64. NHS National Services Scotland. *Privacy Advisory Committee at NHS National Services Scotland and the Registrar General*. 2015. URL: www.nhs.uk/scot.nhs.uk/pages/corporate/privacy_advisory_committee.php (accessed 29 June 2016).
65. Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. *BMJ* 2012;**344**:e2088. <http://dx.doi.org/10.1136/bmj.e2088>

66. Alwan NA, Greenwood DC, Simpson NA, McArdle HJ, Godfrey KM, Cade JE. Dietary iron intake during early pregnancy and birth outcomes in a cohort of British women. *Hum Reprod* 2011;**26**:911–19. <http://dx.doi.org/10.1093/humrep/der005>
67. Bonellie S, Chalmers J, Gray R, Greer I, Jarvis S, Williams C. Centile charts for birthweight for gestational age for Scottish singleton births. *BMC Pregnancy Childbirth* 2008;**8**:5. <http://dx.doi.org/10.1186/1471-2393-8-5>
68. Knight M, Kurinczuk JJ, Spark P, Brocklehurst P, on behalf of the UK Obstetric Surveillance System. Extreme obesity in pregnancy in the United Kingdom. *Obstet Gynecol* 2010;**115**:989–97. <http://dx.doi.org/10.1097/AOG.0b013e3181da8f09>
69. Tukey JW. *Exploratory Data Analysis*. Reading, MA: Addison-Wesley; 1977.
70. StataCorp. *Stata 13 Base Reference Manual*. College Station, TX: Stata Press; 2013.
71. Royston P, White IR. Multiple Imputation by Chained Equations (MICE): Implementation in Stata. *J Stat Software* 2011;**45**:20. <http://dx.doi.org/10.18637/jss.v045.i04>
72. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med* 2011;**30**:377–99. <http://dx.doi.org/10.1002/sim.4067>
73. Curtis L. *Unit Costs of Health and Social Care 2012*. Canterbury: Personal Social Services Research Unit, University of Kent; 2012.
74. Godfrey C, Pickett KE, Parrott S, Mdege ND, Eapen D. *Estimating the Costs to the NHS of Smoking in Pregnancy for Pregnant Women and Infants. Public Health Research Consortium Project Final Report*. York: Department of Health Sciences, University of York; 2010.
75. Petrou S, Kupek E. Socioeconomic differences in childhood hospital inpatient service utilisation and costs: prospective cohort study. *J Epidemiol Community Health* 2005;**59**:591–7. <http://dx.doi.org/10.1136/jech.2004.025395>
76. Department of Health. *NHS Reference Costs 2009–10*. 2011. URL: www.gov.uk/government/publications/nhs-reference-costs-2009-10 (accessed 6 April 2016).
77. National Health Service. *Healthy Start*. URL: www.healthystart.nhs.uk/ (accessed 3 September 2015).
78. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M, UKOSS. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. *BMJ* 2011;**342**:d3214. <http://dx.doi.org/10.1136/bmj.d3214>
79. NHS Scotland Performance and Business Management. *HEAT Archive Report 2013/14*. Edinburgh: The Scottish Government; 2015.
80. Mackay DF, Nelson SM, Haw SJ, Pell JP. Impact of Scotland's smoke-free legislation on pregnancy complications: retrospective cohort study. *PLOS Med* 2012;**9**:e1001175. <http://dx.doi.org/10.1371/journal.pmed.1001175>
81. Yates L, Pierce M, Stephens S, Mill AC, Spark P, Kurinczuk JJ, et al. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. *Health Technol Assess* 2010;**14**(34). <http://dx.doi.org/10.3310/hta14340-02>
82. Loopstra R, Reeves A, Taylor-Robinson D, Barr B, McKee M, Stuckler D. Austerity, sanctions, and the rise of food banks in the UK. *BMJ* 2015;**350**:h1775.
83. Information Services Division. *Data Quality Assurance. Assessment of Maternity Data (SMR02) 2008–9*. Edinburgh: NHS National Services Scotland; 2010.
84. Information Services Division. *Births in Scottish Hospitals*. URL: www.isdscotland.org/Health-Topics/Maternity-and-Births/Births/Background.asp?Co=Y (accessed 13 September 2015).

85. Dundas R, Ouédraogo S, Bond L, Briggs AH, Chalmers J, Gray R, *et al.* Evaluation of health in pregnancy grants in Scotland: a protocol for a natural experiment. *BMJ Open* 2014;**4**:e006547. <http://dx.doi.org/10.1136/bmjopen-2014-006547>
86. House of Commons Health Committee. *Health Inequalities. Third Report of Session 2008–09. Volume 1*. London: The Stationery Office; 2009.
87. Snijders TAB, Bosker RJ. *Multilevel Analysis*. London: Sage, 1999.

Appendix 1 Models specification (adjusted on gestational age at booking and maternal smoking)

TABLE 27 Models specification (adjusted on gestational age at booking and maternal smoking)

[illegible]

Covariates	Birthweight				Booking status		Measures of stage						Measures of size		Other birth outcomes					
	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD EIC	EmC	SB	5 ApS	ND	Maternal smoking
Months																				
January	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
February																				
March																				
April																				
May																				
June																				
July																				
August																				
September																				
October																				
November																				
December																				
Sex																				
Male	Ref	Ref	Ref	Ref			Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	
Female																				

continued

TABLE 27 Models specification (adjusted on gestational age at booking and maternal smoking) (*continued*)

[illegible]

	Birthweight				Booking status		Measures of stage						Measures of size		Other birth outcomes					Maternal smoking
Covariates	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD		SB	5 ApS	ND	
															EIC	EmC				
Age (years) group																				
< 20	Ref	Ref	Ref	Ref	Ref	Ref		Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
20–24																				
25–29																				
30–34																				
35–39																				
≥ 40																				
BMI at booking (kg/m²)	X	X	X	X	X	X		X	X	X	X	X	X	X	X	X		X	X	
Quadratic term BMI at booking (kg/m²)	X	X		X	X	X		X	X	X	X	X			X	X				
Height (cm)	X	X	X	X				X	X	X	X	X	X	X	X	X		X	X	
Quadratic term height (cm)	X	X		X				X	X		X		X		X	X				
Parity																				
0	Ref	Ref	Ref	Ref	Ref	Ref		Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
1																				
2																				
3+																				

continued

continued

TABLE 27 Models specification (adjusted on gestational age at booking and maternal smoking) (continued)

[illegible]

Covariates	Birthweight				Booking status		Measures of stage						Measures of size		Other birth outcomes					Maternal smoking
	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD	EmC	SB	5 ApS	ND	
3																				
4																				
5: least deprived																				
Gestational age at booking (weeks)																				
0–12	Ref	Ref	Ref	Ref	Ref	Ref		Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
13–24																				
25+																				
Smoking status at booking																				
Never smoked	Ref	Ref	Ref	Ref	Ref	Ref		Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Current smoker																				
Former smoker																				
Smoking status during pregnancy																				
No	Ref	Ref	Ref	Ref	Ref	Ref		Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Yes																				
Previous caesarean section																				
No																Ref	Ref			
Yes																				
Statistical models																				
3-level linear regression (area, maternal and baby level)	+				+		+			+			+	+						

continued

continued

TABLE 27 Models specification (adjusted on gestational age at booking and maternal smoking) (*continued*)

Covariates	Birthweight				Booking status		Measures of stage						Measures of size		Other birth outcomes					
	BW	LBW	Very LBW	HBW	GB	Bb425W	GD	Preterm	Very preterm	z-score	SGA	LGA	HC	CHL	MD EIC	EmC	SB	5 ApS	ND	Maternal smoking
3-level binomial logistic regression (area, maternal and baby level)		+		+		+		+			+	+			+	+		+		+
2-level multinomial logistic regression (area and baby level)			+						+								+		+	

X, variables considered for adjustment in the statistical analysis; +, statistical models; 5 ApS, 5-minute Apgar score; Bb425W, booking before 25 weeks; BW, birthweight; CHL, crown-to-heel length; EIC, elective caesarean; EmC, emergency caesarean; GB, gestational age at booking; GD, gestational age at delivery; HBW, high birthweight; HC, head circumference; MD, mode of delivery; LBW, low birthweight; MS, maternal smoking during pregnancy; ND, neonatal death; Ref, reference; SB, stillbirth.

Appendix 2 Results of the analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: maternal behaviour

TABLE 28 Complete cases unadjusted for gestational age at booking and maternal smoking: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.60 (−0.70 to 0.50)	1.05 (0.96 to 1.15)	0.98 (0.94 to 1.02)
Period 3 ^c	−1.50 (−1.60 to 1.40)	0.93 (0.82 to 1.05)	1.06 (1.00 to 1.12)
Global test 1 ^d	–	–	–
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.13 (−0.15 to 0.12)	1.10 (1.08 to 1.12)	0.94 (0.93 to 0.95)
Interaction 2 ^g	−0.82 (−0.87 to 0.76)	1.25 (1.16 to 1.35)	0.93 (0.90 to 0.96)
Interaction 3 ^h	−0.27 (−0.30 to 0.23)	0.94 (0.89 to 0.98)	0.99 (0.97 to 1.02)
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Note

Dashes indicate that no data were available.

Appendix 3 The results of analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: measures of size

TABLE 29 Complete cases unadjusted for gestational age at booking and maternal smoking: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm) coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	1.06 (0.78 to 1.45)	1.08 (0.99 to 1.17)	0.93 (0.90 to 0.98)	−0.03 (−0.05 to 0.02)	0.10 (0.09 to 0.20)
Period 3 ^c	1.18 (0.75 to 1.84)	1.14 (1.01 to 1.29)	0.90 (0.85 to 0.95)	−0.10 (−0.14 to 0.07)	0.33 (0.27 to 0.39)
Global test 1 ^d	0.70	0.09	0.002		
Trend					
All years ^e	0.96 (0.89 to 1.03)	0.97 (0.95 to 0.99)	1.02 (1.01 to 1.03)		
Interactions					
Interaction 1 ^f				0.008 (0.004 to 0.01)	0.005 (−0.005 to 0.02)
Interaction 2 ^g				−0.03 (−0.04 to 0.01)	0.11 (0.08 to 0.14)
Interaction 3 ^h				−0.05 (−0.06 to 0.04)	0.03 (0.01 to 0.05)
Global test 2 ⁱ	0.80	0.07	0.05	< 0.0001	< 0.0001
HBW, high birthweight; LBW, low birthweight.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 4 The results of analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: measures of stage

TABLE 30 Complete cases unadjusted for gestational age at booking and maternal smoking: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.03 (−0.06 to 0.005)	1.05 (0.98 to 1.12)	1.10 (0.93 to 1.30)	−0.02 (−0.03 to 0.008)	1.01 (0.95 to 1.08)	0.96 (0.91 to 1.00)
Period 3 ^c	−0.14 (−0.18 to 0.11)	1.26 (1.14 to 1.39)	1.45 (1.16 to 1.81)	−0.03 (−0.05 to 0.01)	1.04 (0.95 to 1.14)	0.95 (0.88 to 1.01)
Global test 1 ^d				0.001	0.60	0.20
Trend						
All years ^e				0.010 (0.008 to 0.013)	0.97 (0.95 to 0.98)	1.00 (0.99 to 1.02)
Interactions						
Interaction 1 ^f	0.018 (0.012 to 0.024)	0.96 (0.95 to 0.98)	0.94 (0.91 to 0.98)			
Interaction 2 ^g	0.14 (0.13 to 0.16)	0.71 (0.68 to 0.75)	0.59 (0.55 to 0.66)			
Interaction 3 ^h	0.04 (0.02 to 0.05)	0.87 (0.84 to 0.90)	0.72 (0.67 to 0.78)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.20	0.50	0.40
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 5 The results of analysis for the secondary outcomes using the complete cases unadjusted for gestational age at booking and maternal smoking: birth outcomes

TABLE 31 Complete cases unadjusted for gestational age at booking and maternal smoking: birth outcomes

Parameter	Birth outcomes				
	Mode of delivery				
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	1.00
Period 2 ^b	1.04 (0.99 to 1.10)	1.03 (0.99 to 1.08)	0.95 (0.78 to 1.16)	0.87 (0.77 to 0.98)	2.17 (1.28 to 3.69)
Period 3 ^c	1.17 (1.08 to 1.26)	1.02 (0.93 to 1.12)	0.88 (0.66 to 1.17)	0.82 (0.70 to 0.97)	1.76 (0.81 to 3.80)
Global test 1 ^d	< 0.0001		0.60	0.05	0.003
Trend					
All years ^e	1.04 (1.03 to 1.05)		0.97 (0.93 to 1.02)	1.01 (0.99 to 1.04)	0.86 (0.77 to 0.97)
Interactions					
Interaction 1 ^f		0.99 (0.98 to 1.00)			
Interaction 2 ^g		0.99 (0.96 to 1.02)			
Interaction 3 ^h		1.00 (0.98 to 1.02)			
Global test 2 ⁱ	0.40	0.90	0.20	0.90	0.02
<p>^a Pre-intervention period. ^b Intervention HiP grant. ^c Post-intervention period. ^d Global test for the periods in which the interactions were not significant. ^e Trend over the study period 2004–13. ^f Trend pre intervention. ^g Trend during the HiP grant period. ^h Trend post intervention. ⁱ Global test for the interactions.</p>					

Appendix 6 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: maternal behaviour

TABLE 32 Complete cases and adjusting the model for gestational age at booking and maternal smoking: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.60 (−0.70 to 0.50)	1.06 (0.96 to 1.16)	0.99 (0.95 to 1.04)
Period 3 ^c	−1.50 (−1.60 to 1.40)	0.94 (0.83 to 1.06)	0.96 (0.90 to 1.02)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.14 (−0.15 to 0.12)	1.10 (1.08 to 1.12)	0.93 (0.92 to 0.94)
Interaction 2 ^g	−0.82 (−0.87 to 0.77)	1.26 (1.17 to 1.35)	0.94 (0.91 to 0.98)
Interaction 3 ^h	−0.29 (−0.32 to 0.26)	0.97 (0.92 to 1.02)	1.00 (0.98 to 1.02)
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001
^a Pre-intervention period. ^b Intervention HiP grant. ^c Post-intervention period. ^d Global test for the periods in which the interactions were not significant. ^e Trend over the study period 2004–13. ^f Trend pre intervention. ^g Trend during the HiP grant period. ^h Trend post intervention. ⁱ Global test for the interactions.			

Appendix 7 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of size

TABLE 33 Complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	1.08 (0.76 to 1.53)	1.08 (0.98 to 1.19)	0.95 (0.90 to 0.99)	−0.05 (−0.07 to 0.03)	0.20 (0.15 to 0.25)
Period 3 ^c	1.17 (0.71 to 1.91)	1.20 (1.05 to 1.38)	0.91 (0.85 to 0.97)	−0.13 (−0.16 to 0.11)	0.53 (0.46 to 0.60)
Global test 1 ^d	0.80	0.02	0.007		
Trend					
All years ^e	0.97 (0.90 to 1.05)	0.99 (0.96 to 1.01)	1.01 (1.00 to 1.02)		
Interactions					
Interaction 1 ^f				0.0097 (0.005 to 0.014)	−0.04 (−0.05 to 0.03)
Interaction 2 ^g				−0.04 (−0.05 to 0.02)	0.08 (0.05 to 0.1)
Interaction 3 ^h				−0.055 (−0.064 to 0.045)	0.04 (0.02 to 0.07)
Global test 2 ⁱ	0.80	0.047	0.06	< 0.0001	< 0.0001
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 8 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of stage

TABLE 34 Complete cases and adjusting the model for gestational age at booking and maternal smoking: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.03 (−0.06 to 0.003)	1.06 (0.98 to 1.14)	1.10 (0.91 to 1.32)	−0.02 (−0.03 to 0.008)	1.03 (0.96 to 1.11)	0.97 (0.92 to 1.02)
Period 3 ^c	−0.10 (−0.14 to 0.06)	1.21 (1.09 to 1.35)	1.32 (1.03 to 1.70)	−0.04 (−0.06 to 0.02)	1.10 (1.00 to 1.22)	0.95 (0.88 to 1.02)
Global test 1 ^d				0.0001	0.07	0.40
Trend						
All years ^e				0.004 (0.0008 to 0.007)	0.98 (0.96 to 0.99)	0.99 (0.98 to 1.00)
Interactions						
Interaction 1 ^f	0.01 (0.008 to 0.02)	0.97 (0.95 to 0.98)	0.96 (0.93 to 1.00)			
Interaction 2 ^g	0.14 (0.12 to 0.16)	0.72 (0.68 to 0.76)	0.61 (0.54 to 0.69)			
Interaction 3 ^h	0.04 (0.03 to 0.05)	0.87 (0.84 to 0.90)	0.74 (0.69 to 0.80)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.01	0.90	0.30
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 9 The results of analysis for the secondary outcomes using the complete cases and adjusting the model for gestational age at booking and maternal smoking: birth outcomes

TABLE 35 Complete cases and adjusting the model for gestational age at booking and maternal smoking: birth outcomes

Parameter	Birth outcomes, OR (95% CI)				
	Mode of delivery				Neonatal death
	Elective caesarean	Emergency caesarean	Stillbirth	5-minute Apgar score	
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	1.00
Period 2 ^b	1.06 (1.00 to 1.12)	1.02 (0.97 to 1.08)	0.99 (0.78 to 1.26)	0.88 (0.77 to 1.01)	2.58 (1.38 to 4.82)
Period 3 ^c	1.17 (1.08 to 1.28)	1.08 (1.01 to 1.16)	0.99 (0.72 to 1.38)	0.81 (0.67 to 0.98)	1.97 (0.79 to 4.90)
Global test 1 ^d	0.0001				
Trend					
All years ^e	1.03 (1.02 to 1.05)		0.97 (0.92 to 1.02)	1.02 (0.99 to 1.05)	0.87 (0.75 to 0.99)
Interactions					
Interaction 1 ^f		0.99 (0.98 to 1.01)			
Interaction 2 ^g		0.98 (0.95 to 1.01)			
Interaction 3 ^h		0.99 (0.97 to 1.02)			
Global test 2 ⁱ	0.30	0.70	0.30	0.90	0.20
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>					

Appendix 10 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: maternal behaviour

TABLE 36 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: maternal behaviour

Other parameter estimates	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Months			
January	0.00	1.00	1.00
February	−0.02 (−0.09 to 0.05)	0.98 (0.91 to 1.06)	1.00 (0.96 to 1.04)
March	−0.09 (−0.20 to 0.02)	1.03 (0.95 to 1.12)	0.96 (0.92 to 0.99)
April	−0.10 (−0.20 to 0.03)	0.98 (0.90 to 1.06)	0.95 (0.91 to 0.99)
May	−0.06 (−0.10 to 0.01)	0.94 (0.87 to 1.02)	0.93 (0.89 to 0.97)
June	−0.05 (−0.10 to 0.02)	0.97 (0.90 to 1.05)	0.94 (0.90 to 0.98)
July	0.10 (0.04 to 0.20)	0.96 (0.89 to 1.04)	0.92 (0.88 to 0.96)
August	0.10 (0.05 to 0.20)	0.97 (0.90 to 1.04)	0.90 (0.87 to 0.94)
September	−0.05 (−0.10 to 0.02)	0.95 (0.88 to 1.02)	0.91 (0.88 to 0.95)
October	−0.10 (−0.20 to 0.04)	0.98 (0.91 to 1.06)	0.90 (0.86 to 0.94)
November	−0.09 (−0.20 to 0.02)	0.96 (0.89 to 1.04)	0.92 (0.88 to 0.96)
December	−0.20 (−0.3 to 0.10)	1.01 (0.93 to 1.09)	0.92 (0.88 to 0.95)
Global test	< 0.0001	0.60	< 0.0001
Age (years) group			
< 20	0.00	1.00	1.00
20–24	−0.53 (−0.60 to 0.46)	1.19 (1.12 to 1.27)	0.90 (0.87.88 to 0.93)
25–29	−0.76 (−0.83 to 0.69)	1.46 (1.37 to 1.56)	0.76 (0.74 to 0.79)
30–34	−0.80 (−0.90 to 0.70)	1.67 (1.55 to 1.79)	0.70 (0.67 to 0.72)
35–39	−0.70 (−0.80 to 0.60)	1.74 (1.61 to 1.88)	0.68 (0.65 to 0.70)
40+	−0.40 (−0.50 to 0.30)	1.63 (1.47 to 1.82)	0.61 (0.58 to 0.65)
Global test	< 0.0001	< 0.0001	< 0.0001
BMI (kg/m²)			
BMI at booking	0.11 (0.08 to 0.13)	0.89 (0.87 to 0.91)	
Quadratic term BMI at booking	−0.0016 (−0.0020 to 0.0013)	1.00 (1.00 to 1.00)	

continued

TABLE 36 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: maternal behaviour (*continued*)

Other parameter estimates	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Height (cm)			
Height			
Quadratic term height			
Parity			
0	0.00	1.00	1.00
1	-0.05 (-0.08 to 0.02)	1.28 (1.24 to 1.33)	1.27 (1.24 to 1.29)
2	0.25 (0.20 to 0.29)	1.15 (1.09 to 1.21)	1.80 (1.76 to 1.85)
3+	0.83 (0.77 to 0.90)	0.79 (0.75 to 0.85)	2.59 (2.51 to 2.68)
Global test	< 0.0001	< 0.0001	< 0.0001
Marital status			
Married to each other	0.00	1.00	1.00
Joint registration: same address	0.02 (-0.01 to 0.06)	1.12 (1.07 to 1.17)	3.30 (3.22 to 3.37)
Joint registration: different address	0.22 (0.16 to 0.27)	1.06 (0.99 to 1.12)	4.30 (4.18 to 4.43)
Sole registration	1.47 (1.40 to 1.54)	0.52 (0.49 to 0.55)	5.33 (5.11 to 5.57)
Global test	< 0.0001	< 0.0001	< 0.0001
Primary household social classes			
Managerial and professional	0.00	1.00	1.00
Intermediate	-0.13 (-0.17 to 0.09)	1.14 (1.09 to 1.20)	1.44 (1.40 to 1.48)
Working	-0.16 (-0.19 to 0.12)	1.22 (1.17 to 1.28)	2.46 (2.40 to 2.53)
Never worked/ long-term unemployed	0.52 (0.46 to 0.57)	0.74 (0.70 to 0.78)	2.87 (2.78 to 2.96)
Global test	< 0.0001	< 0.0001	< 0.0001
Diabetes mellitus			
No	0.00	1.00	1.00
Yes	-0.5 (-0.6 to 0.4)	1.10 (0.95 to 1.27)	0.89 (0.83 to 0.96)
Income domains of the SIMD			
1: most deprived	0.00	1.00	1.00
2	-0.40 (-0.50 to 0.30)	1.05 (0.99 to 1.11)	0.87 (0.84 to 0.89)
3	-0.30 (-0.40 to 0.20)	0.87 (0.81 to 0.92)	0.70 (0.68 to 0.72)
4	-0.30 (-0.40 to 0.20)	0.85 (0.80 to 0.91)	0.54 (0.52 to 0.56)
5: least deprived	-0.40 (-0.50 to 0.30)	0.86 (0.81 to 0.92)	0.41 (0.39 to 0.43)
Global test	< 0.0001	< 0.0001	< 0.0001
Blank cells indicate that terms were not included in the models.			

Appendix 11 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of size

TABLE 37 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of size

Other parameter estimates	Measures of size					
	Birthweight (g), coefficient (95% CI)	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Months	0.00					
January	4.90 (−0.60 to 10.40)	1.00	1.00	1.00	0.00	0.00
February	4.60 (−0.80 to 10.00)	0.95 (0.70 to 1.28)	1.01 (0.93 to 1.10)	1.04 (0.99 to 1.09)	−0.01 (−0.03 to 0.002)	−0.02 (−0.06 to 0.02)
March	11.90 (6.40 to 17.50)	0.90 (0.67 to 1.21)	1.06 (0.98 to 1.15)	1.02 (0.98 to 1.06)	−0.01 (−0.03 to 0.004)	−0.004 (−0.04 to 0.03)
April	10.30 (4.80 to 15.70)	0.89 (0.66 to 1.18)	0.96 (0.89 to 1.05)	1.08 (1.03 to 1.12)	−0.02 (−0.04 to −0.009)	−0.02 (−0.06 to 0.02)
May	10.60 (5.20 to 16.10)	0.99 (0.74 to 1.33)	1.01 (0.93 to 1.10)	1.06 (1.02 to 1.11)	−0.04 (−0.05 to 0.02)	−0.04 (−0.07 to 0.003)
June	14.90 (9.50 to 20.20)	1.03 (0.77 to 1.38)	0.96 (0.88 to 1.04)	1.07 (1.03 to 1.12)	−0.04 (−0.06 to 0.02)	−0.02 (−0.06 to 0.02)
July	18.70 (13.30 to 24.00)	1.11 (0.83 to 1.49)	0.95 (0.88 to 1.03)	1.08 (1.03 to 1.13)	−0.04 (−0.06 to 0.02)	−0.03 (−0.07 to 0.005)
August	18.60 (13.20 to 24.00)	0.93 (0.69 to 1.25)	0.94 (0.87 to 1.03)	1.09 (1.05 to 1.14)	−0.04 (−0.05 to 0.02)	0.04 (0.002 to 0.08)
September	18.80 (13.40 to 24.20)	0.95 (0.71 to 1.28)	0.99 (0.91 to 1.08)	1.11 (1.07 to 1.16)	−0.02 (−0.04 to 0.004)	0.01 (−0.03 to 0.05)
October	16.60 (11.10 to 22.10)	1.03 (0.77 to 1.38)	0.92 (0.85 to 1.00)	1.13 (1.08 to 1.17)	−0.02 (−0.03 to 0.0002)	0.01 (−0.03 to 0.05)
November	5.50 (0.01 to 11.00)	0.74 (0.54 to 1.00)	0.98 (0.90 to 1.07)	1.11 (1.07 to 1.16)	−0.01 (−0.03 to 0.002)	0.0002 (−0.04 to 0.04)
December	< 0.0001	0.82 (0.60 to 1.11)	1.00 (0.92 to 1.09)	1.02 (0.97 to 1.06)	−0.001 (−0.02 to 0.02)	0.07 (0.03 to 0.1)
Global test		0.40	0.07	< 0.0001	< 0.0001	< 0.0001
Sex	0.00					
Male	−133.10 (−135.30 to 130.90)	1.00	1.00	1.00	0.00	0.00
Female	519.40 (508.90 to 530.00)	1.83 (1.62 to 2.07)	1.67 (1.61 to 1.72)	0.53 (0.52 to 0.54)	−0.38 (−0.39 to 0.38)	−0.31 (−0.33 to 0.29)

Other parameter estimates	Measures of size					
	Birthweight (g), coefficient (95% CI)	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Gestational age at delivery (weeks)						
Gestational age at delivery	−4.50 (−4.70 to 4.40)	0.33 (0.32 to 0.34)	0.359 (0.355 to 0.363)	33.13 (22.24 to 49.36)	0.28 (0.24 to 0.33)	1.10 (1.00 to 1.20)
Quadratic term gestational age at delivery				0.96 (0.96 to 0.97)	−0.0026 (−0.0032 to 0.0020)	−0.011 (−0.014 to 0.010)
Birthweight (g)						
Birthweight					0.00279 (0.00274 to 0.00285)	0.0063 (0.0061 to 0.0064)
Quadratic term birthweight					−1.51e-07 (−1.59e-07 to −1.43e-07)	−4.19e-07 (−4.40e-07 to −3.98e-07)
Age (years) group						
< 20	0.00	1.00	1.00	1.00	0.00	0.00
20–24	−43.70 (−48.90 to 38.40)	1.27 (0.99 to 1.63)	1.36 (1.26 to 1.46)	0.88 (0.84 to 0.92)	−0.01 (−0.02 to 0.006)	0.02 (−0.01 to 0.06)
25–29	−54.90 (−60.40 to 49.40)	1.54 (1.19 to 1.99)	1.49 (1.38 to 1.60)	0.89 (0.85 to 0.93)	−0.005 (−0.02 to 0.01)	0.06 (0.02 to 0.1)
30–34	−57.30 (−63.00 to 51.50)	1.49 (1.14 to 1.96)	1.68 (1.56 to 1.82)	0.90 (0.86 to 0.93)	0.03 (0.01 to 0.04)	0.10 (0.08 to 0.2)
35–39	−60.90 (−67.10 to 54.70)	1.98 (1.48 to 2.64)	1.88 (1.72 to 2.04)	0.90 (0.86 to 0.95)	0.06 (0.04 to 0.07)	0.15 (0.10 to 0.19)
≥ 40	−73.10 (−81.50 to 64.80)	2.13 (1.45 to 3.13)	2.07 (1.85 to 2.32)	0.85 (0.80 to 0.91)	0.99 (0.08 to 0.12)	0.23 (0.18 to 0.29)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BMI (kg/m²)						
BMI at booking	38.80 (37.00 to 40.70)	0.99 (0.98 to 1.01)	0.81 (0.79 to 0.83)	1.20 (1.19 to 1.22)	0.0113 (0.0106 to 0.0119)	0.0003 (−0.001 to 0.002)
Quadratic term BMI at booking	−0.45 (−0.48 to −0.41)		1.00 (1.00 to 1.00)	1.00 (1.00 to 1.00)		
Height (cm)						
Height	24.00 (16.80 to 31.30)	0.97 (0.96 to 0.98)	0.79 (0.72 to 0.87)	1.14 (1.08 to 1.21)	−0.04 (−0.06 to 0.02)	0.019 (0.018 to 0.021)
Quadratic term height	−0.03 (−0.05 to 0.009)		1.00 (1.00 to 1.00)	1.00 (1.00 to 1.00)	0.0001 (0.00008 to 0.0002)	

continued

TABLE 37 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of size (*continued*)

Other parameter estimates	Measures of size					
	Birthweight (g), coefficient (95% CI)	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Parity						
0	0.00	1.00	1.00	1.00	0.00	0.00
1	116.90 (114.40 to 119.40)	0.74 (0.64 to 0.86)	0.66 (0.64 to 0.69)	1.63 (1.59 to 1.66)	0.01 (0.007 to 0.02)	-0.08 (-0.10 to 0.06)
2	129.00 (125.40 to 132.60)	0.70 (0.58 to 0.86)	0.68 (0.64 to 0.71)	1.76 (1.72 to 1.81)	0.02 (0.01 to 0.03)	-0.11 (-0.14 to 0.09)
3+	117.80 (112.70 to 122.90)	0.47 (0.37 to 0.59)	0.70 (0.65 to 0.75)	1.79 (1.72 to 1.85)	0.03 (0.01 to 0.04)	-0.09 (-0.10 to 0.05)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
Marital status						
Married to each other	0.00	1.00	1.00	1.00	0.00	0.00
Joint registration: same address	-43.90 (-46.90 to 40.80)	01.26 (1.08 to 1.46)	1.35 (1.29 to 1.41)	0.87 (0.85 to 0.89)	-0.01 (-0.02 to 0.005)	-0.06 (-0.08 to 0.04)
Joint registration: different address	-66.80 (-71.30 to 62.30)	1.24 (1.01 to 1.52)	1.51 (1.43 to 1.60)	0.79 (0.76 to 0.82)	-0.005 (-0.02 to 0.008)	-0.07 (-0.10 to 0.03)
Sole registration	-97.50 (-103.20 to 91.80)	1.28 (0.99 to 1.64)	1.81 (1.69 to 1.95)	0.71 (0.67 to 0.74)	-0.003 (-0.02 to 0.01)	-0.10 (-0.10 to 0.07)
Global test	< 0.0001	0.03	< 0.0001	< 0.0001	0.01	< 0.0001
Primary household social class						
Managerial and professional	0.00	1.00	1.00	1.00	0.00	0.00
Intermediate	-6.30 (-9.80 to 2.80)	1.04 (0.86 to 1.27)	1.10 (1.04 to 1.16)	1.00 (0.98 to 1.03)	-0.001 (-0.01 to 0.009)	-0.02 (-0.04 to 0.005)
Working	-36.50 (-39.70 to 33.20)	1.03 (0.87 to 1.23)	1.37 (1.31 to 1.44)	0.90 (0.88 to 0.92)	-0.045 (-0.054 to 0.036)	-0.04 (-0.07 to 0.02)
Never worked/ long-term unemployed	-64.90 (-69.40 to 60.40)	1.02 (0.82 to 1.27)	1.64 (1.54 to 1.74)	0.80 (0.78 to 0.83)	-0.05 (-0.06 to 0.04)	-0.08 (-0.10 to 0.05)
Global test	< 0.0001	0.90	< 0.0001	< 0.0001	< 0.0001	< 0.0001

Other parameter estimates	Measures of size					
	Birthweight (g), coefficient (95% CI)	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Diabetes mellitus						
No	0.00	1.00	1.00	1.00	0.00	0.00
Yes	258.60 (248.80 to 268.40)	0.40 (0.28 to 0.59)	0.26 (0.22 to 0.30)	3.42 (3.21 to 3.66)	−0.05 (−0.07 to 0.02)	−0.02 (−0.09 to 0.04)
Income domains of the SIMD						
1: most deprived	0.00	1.00	1.00	1.00	0.00	0.00
2	24.50 (20.20 to 28.70)	1.04 (0.88 to 1.23)	0.88 (0.84 to 0.93)	1.12 (1.09 to 1.15)	−0.01 (−0.02 to 0.004)	−0.01 (−0.10 to 0.08)
3	36.00 (31.60 to 40.40)	0.87 (0.72 to 1.05)	0.82 (0.78 to 0.87)	1.13 (1.10 to 1.16)	−0.02 (−0.03 to 0.006)	−0.10 (−0.30 to 0.08)
4	51.70 (47.10 to 56.30)	0.82 (0.66 to 1.00)	0.71 (0.67 to 0.76)	1.20 (1.16 to 1.23)	−0.03 (−0.05 to 0.02)	−0.30 (−0.40 to 0.20)
5: least deprived	59.10 (54.30 to 63.90)	0.82 (0.65 to 1.02)	0.65 (0.61 to 0.70)	1.21 (1.17 to 1.25)	−0.01 (−0.03 to 0.002)	−0.30 (−0.40 to 0.20)
Global test	< 0.0001	0.07	< 0.0001	< 0.0001	0.0001	< 0.0001
HBW, high birthweight; LBW, low birthweight. Blank cells indicate that terms were not included in the models.						

Appendix 12 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of stage

TABLE 38 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of stage

Other parameter estimates	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Months						
January	0.00	1.00	1.00	0.00	1.00	1.00
February	0.03 (0.009 to 0.06)	0.96 (0.90 to 1.02)	1.04 (0.91 to 1.19)	0.01 (−0.001 to 0.02)	0.95 (0.89 to 1.01)	1.02 (0.97 to 1.07)
March	0.05 (0.02 to 0.07)	0.94 (0.88 to 0.99)	1.10 (0.97 to 1.25)	0.01 (−0.001 to 0.02)	0.97 (0.91 to 1.03)	0.99 (0.95 to 1.05)
April	−0.03 (−0.06 to 0.009)	1.06 (1.00 to 1.12)	1.17 (1.03 to 1.33)	0.03 (0.02 to 0.04)	0.93 (0.87 to 0.99)	1.08 (1.03 to 1.13)
May	0.07 (0.05 to 0.10)	0.88 (0.83 to 0.93)	0.92 (0.81 to 1.05)	0.02 (0.01 to 0.03)	0.96 (0.91 to 1.03)	1.03 (0.98 to 1.08)
June	0.08 (0.05 to 0.10)	0.88 (0.83 to 0.93)	0.91 (0.79 to 1.04)	0.02 (0.01 to 0.04)	0.95 (0.89 to 1.01)	1.06 (1.01 to 1.11)
July	0.07 (0.05 to 0.10)	0.87 (0.82 to 0.93)	0.85 (0.74 to 0.97)	0.03 (0.02 to 0.04)	0.94 (0.89 to 1.01)	1.07 (1.02 to 1.12)
August	0.08 (0.06 to 0.11)	0.89 (0.84 to 0.95)	0.85 (0.75 to 0.98)	0.04 (0.03 to 0.05)	0.94 (0.88 to 1.00)	1.08 (1.02 to 1.12)
September	0.09 (0.06 to 0.11)	0.82 (0.77 to 0.87)	0.84 (0.73 to 0.96)	0.04 (0.03 to 0.05)	0.92 (0.86 to 0.98)	1.10 (1.05 to 1.16)
October	0.09 (0.06 to 0.11)	0.89 (0.84 to 0.94)	0.90 (0.79 to 1.03)	0.04 (0.03 to 0.05)	0.91 (0.85 to 0.97)	1.08 (1.03 to 1.13)
November	0.08 (0.06 to 0.10)	0.85 (0.80 to 0.90)	0.83 (0.73 to 0.96)	0.04 (0.02 to 0.05)	0.93 (0.87 to 0.99)	1.08 (1.03 to 1.13)
December	0.08 (0.06 to 0.10)	0.83 (0.78 to 0.88)	0.79 (0.69 to 0.90)	0.01 (−0.0004 to 0.02)	0.96 (0.90 to 1.02)	1.01 (0.96 to 1.06)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.30	< 0.0001
Sex						
Male	0.00	1.00	1.00	0.00	1.00	1.00
Female	0.06 (0.05 to 0.07)	0.86 (0.84 to 0.88)	0.81 (0.77 to 0.86)	−0.296 (−0.30 to 0.291)	1.74 (1.69 to 1.79)	0.54 (0.52 to 0.55)
Gestational age at delivery (weeks)						
Gestational age at delivery				−0.14 (−0.20 to 0.12)		
Quadratic term gestational age at delivery				0.002 (0.001 to 0.002)		

Other parameter estimates	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Age (years) group						
< 20	0.00	1.00	1.00	0.00	1.00	1.00
20–24	−0.06 (−0.09 to 0.04)	1.07 (1.01 to 1.12)	1.07 (0.96 to 1.20)	−0.09 (−0.10 to 0.08)	1.39 (1.32 to 1.46)	0.86 (0.81 to 0.90)
25–29	−0.12 (−0.14 to 0.10)	1.17 (1.11 to 1.24)	1.16 (1.03 to 1.30)	−0.12 (−0.13 to 0.11)	1.52 (1.44 to 1.60)	0.89 (0.84 to 0.94)
30–34	−0.15 (−0.18 to 0.13)	1.27 (1.20 to 1.34)	1.25 (1.10 to 1.41)	−0.12 (−0.14 to 0.11)	1.72 (1.62 to 1.82)	0.90 (0.85 to 0.95)
35–39	−0.24 (−0.25 to 0.20)	1.39 (1.30 to 1.47)	1.45 (1.27 to 1.65)	−0.13 (−0.15 to 0.12)	1.96 (1.84 to 2.09)	0.92 (0.87 to 0.98)
≥ 40	−0.38 (−0.41 to 0.34)	1.53 (1.41 to 1.66)	1.56 (1.30 to 1.86)	−0.16 (−0.18 to 0.14)	2.123 (1.94 to 2.33)	0.88 (0.81 to 0.94)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
BMI (kg/m²)						
BMI at booking	0.08 (0.07 to 0.08)	0.91 (0.90 to 0.93)	0.91 (0.88 to 0.95)	0.086 (0.082 to 0.09)	0.82 (0.80 to 0.83)	1.23 (1.21 to 1.25)
Quadratic term BMI at booking	−0.0011 (−0.0013 to 0.0011)	1.00 (1.00 to 1.00)	1.00 (1.00 to 1.00)	−0.001 (−0.001 to 0.0009)	1.00 (1.00 to 1.00)	0.998 (0.997 to 0.998)
Height (cm)						
Height	0.15 (0.12 to 0.18)	0.88 (0.82 to 0.94)	0.97 (0.96 to 0.97)	0.05 (0.04 to 0.07)	0.86 (0.80 to 0.93)	1.07 (1.06 to 1.07)
Quadratic term height	−0.0004 (−0.0005 to 0.0003)	1.00 (1.00 to 1.00)		−0.00007 (−0.0001 to 0.00002)	1.00 (1.00 to 1.00)	
Parity						
0	0.00	1.00	1.00	0.00	1.00	1.00
1	−0.11 (−0.12 to 0.10)	0.74 (0.72 to 0.76)	0.65 (0.60 to 0.69)	0.25 (0.24 to 0.25)	0.57 (0.55 to 0.59)	1.61 (1.58 to 1.65)
2	−0.22 (−0.23 to 0.20)	0.86 (0.82 to 0.89)	0.78 (0.72 to 0.86)	0.27 (0.26 to 0.28)	0.59 (0.56 to 0.61)	1.76 (1.71 to 1.82)
3+	−0.34 (−0.37 to 0.32)	1.10 (1.04 to 1.15)	1.02 (0.92 to 1.14)	0.25 (0.24 to 0.26)	0.63 (0.59 to 0.66)	1.77 (1.70 to 1.84)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001

continued

TABLE 38 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: measures of stage (*continued*)

Other parameter estimates	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Marital status						
Married to each other	0.00	1.00	1.00	0.00	1.00	1.00
Joint registration: same address	0.01 (−0.001 to 0.02)	1.13 (1.09 to 1.16)	1.22 (1.14 to 1.31)	−0.093 (−0.01 to 0.086)	1.37 (1.33 to 1.42)	0.87 (0.85 to 0.90)
Joint registration: different address	−0.08 (−0.10 to 0.06)	1.29 (1.24 to 1.35)	1.67 (1.52 to 1.83)	−0.14 (−0.15 to 0.13)	1.52 (1.45 to 1.59)	0.79 (0.76 to 0.83)
Sole registration	−0.07 (−0.10 to 0.05)	1.34 (1.27 to 1.41)	1.62 (1.45 to 1.82)	−0.21 (−0.22 to 0.20)	1.82 (1.73 to 1.92)	0.68 (0.65 to 0.72)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
Primary household social classes						
Managerial and professional	0.00	1.00	1.00	0.00	1.00	1.00
Intermediate	−0.04 (−0.06 to 0.03)	1.07 (1.03 to 1.11)	1.12 (1.02 to 1.21)	−0.01 (−0.02 to 0.007)	1.11 (1.07 to 1.16)	0.98 (0.96 to 1.01)
Working	−0.08 (−0.10 to 0.07)	1.18 (1.14 to 1.22)	1.23 (1.14 to 1.33)	−0.08 (−0.09 to 0.07)	1.38 (1.33 to 1.43)	0.89 (0.87 to 0.92)
Never worked/ long-term unemployed	−0.17 (−0.19 to 0.15)	1.29 (1.24 to 1.35)	1.39 (1.26 to 1.53)	−0.14 (−0.15 to 0.13)	1.62 (1.54 to 1.70)	0.79 (0.76 to 0.82)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001

Other parameter estimates	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Diabetes mellitus						
No	0.00	1.00	1.00	0.00	1.00	1.00
Yes	-1.38 (-1.43 to -1.33)	3.43 (3.21 to 3.67)	2.90 (2.48 to 3.39)	0.55 (0.53 to 0.57)	0.38 (0.32 to 0.45)	3.48 (3.29 to 3.67)
Income domains of the SIMD						
1: most deprived	0.00	1.00	1.00	0.00	1.00	1.00
2	0.09 (0.08 to 0.11)	0.90 (0.87 to 0.93)	0.90 (0.83 to 0.97)	0.05 (0.04 to 0.06)	0.88 (0.84 to 0.91)	1.11 (1.07 to 1.14)
3	0.12 (0.10 to 0.14)	0.86 (0.83 to 0.90)	0.87 (0.80 to 0.94)	0.08 (0.07 to 0.09)	0.80 (0.77 to 0.84)	1.10 (1.07 to 1.14)
4	0.17 (0.15 to 0.19)	0.78 (0.75 to 0.81)	0.80 (0.73 to 0.87)	0.11 (0.10 to 0.12)	0.70 (0.67 to 0.73)	1.16 (1.12 to 1.20)
5: least deprived	0.16 (0.14 to 0.18)	0.81 (0.77 to 0.84)	0.79 (0.72 to 0.87)	0.13 (0.12 to 0.14)	0.64 (0.60 to 0.67)	1.20 (1.16 to 1.24)
Global test	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
Blank cells indicate that terms were not included in the models.						

Appendix 13 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: birth outcomes

TABLE 39 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: birth outcomes

Other covariates	Birth outcomes, OR (95% CI)				
	Mode of delivery			5-minute Apgar score	Neonatal death
	Elective caesarean	Emergency caesarean	Stillbirth		
Months					
January	1.00	1.00	1.00	1.00	1.00
February	1.05 (1.00 to 1.11)	0.97 (0.94 to 1.01)	0.83 (0.67 to 1.03)	1.03 (0.91 to 1.15)	1.03 (0.63 to 1.68)
March	1.11 (1.05 to 1.17)	1.02 (0.98 to 1.06)	0.85 (0.69 to 1.06)	1.03 (0.92 to 1.16)	0.74 (0.44 to 1.25)
April	1.11 (1.05 to 1.17)	1.00 (0.96 to 1.04)	0.97 (0.79 to 1.20)	1.00 (0.89 to 1.13)	0.57 (0.32 to 0.99)
May	1.05 (1.00 to 1.11)	1.01 (0.97 to 1.05)	0.85 (0.68 to 1.05)	1.04 (0.93 to 1.17)	1.24 (0.78 to 1.96)
June	1.09 (1.03 to 1.15)	0.99 (0.95 to 1.03)	0.84 (0.68 to 1.04)	1.01 (0.90 to 1.14)	1.03 (0.64 to 1.66)
July	1.05 (0.99 to 1.00)	0.99 (0.96 to 1.03)	0.83 (0.67 to 1.03)	1.01 (0.90 to 1.134)	1.02 (0.63 to 1.65)
August	1.07 (1.01 to 1.13)	1.01 (0.97 to 1.05)	0.76 (0.61 to 0.95)	0.97 (0.86 to 1.09)	0.81 (0.49 to 1.34)
September	1.08 (1.02 to 1.14)	1.00 (0.96 to 1.04)	0.78 (0.63 to 0.98)	0.98 (0.88 to 1.11)	0.96 (0.59 to 1.56)
October	1.06 (1.01 to 1.12)	1.02 (0.98 to 1.06)	0.85 (0.69 to 1.05)	0.99 (0.88 to 1.11)	0.98 (0.61 to 1.60)
November	1.05 (0.99 to 1.11)	1.01 (0.97 to 1.05)	0.79 (0.64 to 0.99)	0.98 (0.87 to 1.10)	0.86 (0.52 to 1.42)
December	1.10 (1.04 to 1.16)	0.96 (0.92 to 1.00)	0.77 (0.62 to 0.96)	1.02 (0.91 to 1.14)	0.75 (0.44 to 1.27)
Global test	0.006	0.06	0.30	0.90	0.30
Sex					
Male	1.00	1.00	1.00	1.00	1.00
Female	1.08 (1.05 to 1.10)	0.81 (0.80 to 0.82)	1.07 (0.98 to 1.17)	0.79 (0.75 to 0.83)	0.79 (0.64 to 0.97)
Gestational age at delivery (weeks)					
Gestational age at delivery			1.42 (1.19 to 1.70)	0.53 (0.45 to 0.62)	0.82 (0.77 to 0.86)
Quadratic term gestational age at delivery			0.99 (0.99 to 0.99)	1.01 (1.01 to 1.01)	

Other covariates	Birth outcomes, OR (95% CI)				
	Mode of delivery				
	Elective caesarean	Emergency caesarean	Stillbirth	5-minute Apgar score	Neonatal death
Birthweight (g)					
Birthweight				1.00 (1.00 to 1.00)	1.00 (1.00 to 1.00)
Quadratic term birthweight				1.00 (1.00 to 1.00)	
Modes of delivery					
Vaginal				1.00	1.00
Elective caesarean				0.61 (0.55 to 0.68)	1.32 (0.92 to 1.89)
Emergency caesarean				2.25 (2.13 to 2.38)	1.91 (1.51 to 2.43)
Global test				< 0.0001	< 0.0001
Previous caesarean section					
No	1.00	1.00			
Yes	22.45 (21.87 to 23.05)	3.09 (3.01 to 3.17)			
Age (years) group					
< 20	1.00	1.00	1.00	1.00	1.00
20–24	1.62 (1.49 to 1.75)	1.38 (1.33 to 1.43)	1.10 (0.91 to 1.34)	1.02 (0.92 to 1.13)	0.91 (0.57 to 1.45)
25–29	2.14 (1.98 to 2.32)	1.82 (1.75 to 1.90)	1.06 (0.88 to 1.28)	0.98 (0.88 to 1.09)	0.97 (0.61 to 1.55)
30–34	2.73 (2.52 to 2.96)	2.29 (2.20 to 2.38)	1.02 (0.84 to 1.24)	1.03 (0.92 to 1.15)	0.89 (0.54 to 1.46)
35–39	3.49 (3.21 to 3.79)	2.72 (2.60 to 2.84)	1.24 (1.01 to 1.53)	1.06 (0.94 to 1.20)	1.01 (0.60 to 1.69)
≥ 40	4.79 (4.37 to 5.25)	3.40 (3.22 to 3.60)	1.44 (1.09 to 1.90)	1.21 (1.03 to 1.42)	0.98 (0.50 to 1.93)
Global test	< 0.0001	< 0.0001	0.010	0.030	0.90
BMI (kg/m²)					
BMI at booking	1.029 (1.027 to 1.03)	1.12 (1.11 to 1.14)		1.01 (0.98 to 1.04)	1.02 (1.00 to 1.04)
Quadratic term BMI at booking		1.00 (1.00 to 1.00)		1.00 (1.00 to 1.00)	

continued

TABLE 39 Other parameter estimates for the primary and secondary outcomes using the imputed data and unadjusted for gestational age at booking and maternal smoking: birth outcomes (*continued*)

Other covariates	Birth outcomes, OR (95% CI)				
	Mode of delivery			5-minute Apgar score	Neonatal death
	Elective caesarean	Emergency caesarean	Stillbirth		
Height (cm)					
Height	0.84 (0.79 to 0.90)	0.82 (0.78 to 0.86)		1.00 (1.00 to 1.00)	1.02 (1.00 to 1.03)
Quadratic term height	1.00 (1.00 to 1.00)	1.00 (1.00 to 1.00)			
Parity					
0	1.00	1.00	1.00	1.00	1.00
1	1.06 (1.03 to 1.09)	0.234 (0.229 to 0.239)	0.78 (0.70 to 0.87)	0.87 (0.82 to 0.93)	0.81 (0.62 to 1.05)
2	0.92 (0.89 to 0.96)	0.166 (0.161 to 0.172)	0.87 (0.75 to 1.00)	0.95 (0.88 to 1.03)	1.13 (0.82 to 1.55)
3+	0.60 (0.57 to 0.63)	0.165 (0.158 to 0.172)	0.93 (0.79 to 1.11)	1.05 (0.95 to 1.16)	0.95 (0.63 to 1.42)
Global test	< 0.0001	< 0.0001	0.0002	< 0.0001	0.20
Marital status					
Married to each other	1.00	1.00		1.00	1.00
Joint registration: same address	0.92 (0.90 to 0.95)	1.11 (1.09 to 1.13)		1.10 (1.03 to 1.17)	0.86 (0.78 to 1.45)
Joint registration: different address	0.94 (0.88 to 0.96)	1.14 (1.10 to 1.17)		1.14 (1.04 to 1.24)	0.68 (0.67 to 1.19)
Sole registration	0.94 (0.89 to 1.00)	1.10 (1.06 to 1.15)		1.27 (1.14 to 1.41)	0.91 (0.79 to 1.67)
Global test	< 0.0001	< 0.0001		< 0.0001	0.30
Primary household social classes					
Managerial and professional	1.00	1.00		1.00	1.00
Intermediate	1.00 (0.97 to 1.04)	0.99 (0.97 to 1.01)		0.99 (0.92 to 1.07)	1.06 (0.78 to 1.45)
Working	1.00 (0.97 to 1.03)	0.97 (0.95 to 0.99)		1.07 (1.00 to 1.14)	0.89 (0.67 to 1.19)
Never worked/long-term unemployed	0.96 (0.92 to 1.00)	0.94 (0.91 to 0.97)		1.13 (1.04 to 1.24)	1.15 (0.79 to 1.67)
Global test	0.10	0.002		0.01	0.40

	Birth outcomes, OR (95% CI)				
	Mode of delivery			5-minute Apgar score	Neonatal death
Other covariates	Elective caesarean	Emergency caesarean	Stillbirth		
<i>Diabetes mellitus</i>					
No	1.00	1.00	1.00	1.00	1.00
Yes	2.06 (1.92 to 2.22)	1.61 (1.52 to 1.71)	0.99 (0.74 to 1.31)	1.07 (0.90 to 1.28)	0.46 (0.19 to 1.14)
<i>Income domains of the SIMD</i>					
1: most deprived	1.00	1.00	1.00	1.00	1.00
2	0.97 (0.93 to 1.01)	0.95 (0.93 to 0.98)	0.96 (0.84 to 1.09)	1.11 (1.03 to 1.19)	0.99 (0.74 to 1.33)
3	1.01 (0.97 to 1.05)	0.90 (0.88 to 0.93)	0.97 (0.85 to 1.11)	1.20 (1.11 to 1.29)	0.88 (0.63 to 1.21)
4	1.03 (0.99 to 1.08)	0.88 (0.86 to 0.91)	0.86 (0.74 to 1.00)	1.08 (0.99 to 1.17)	1.04 (0.75 to 1.45)
5: least deprived	1.08 (1.03 to 1.12)	0.88 (0.86 to 0.91)	0.77 (0.66 to 0.90)	1.16 (1.06 to 1.26)	0.88 (0.61 to 1.27)
Global test	< 0.0001	< 0.0001	0.01	0.0001	0.83
Blank cells indicate that terms were not included in the models.					

Appendix 14 Variances and standard errors for the final models for each outcome

TABLE 40 Variances and standard errors for the final models for each outcome

Model ^a	Level 3			Level 2			Level 1		
	Data zone			Mother			Baby		
	Variance	SE	% total variance	Variance	SE	% total variance	Variance	SE	% total variance
Three-level models									
Birthweight (g)	725.60	56.30	0.40	86659.10	519	48.10	92807.80	433.90	51.50
LBW ^b	0.0181	0.0078	0.50	0.348	0.036	9.50	–	–	90.00
HBW ^b	0.008	0.0023	0.20	0.454	0.015	12.10	–	–	87.70
Gestational age at booking (weeks)	1.294	0.0301	5.50	3.39	0.926	14.30	19.004	0.0978	80.20
Booking before 25 weeks ^b	0.2199	0.011	5.80	0.298	0.046	7.80	–	–	86.40
Gestational age at delivery (weeks)	0.0143	0.001	0.50	1.086	0.0098	34.20	2.073	0.0092	65.30
Preterm ^b	0.0136	0.0042	0.40	0.538	0.032	14.00	–	–	85.60
z-score	0.0033	0.0003	0.40	0.416	0.0025	48.00	0.448	0.0021	51.70
SGA ^b	0.0254	0.005	0.70	0.48	0.0338	12.60	–	–	86.70
LGA ^b	0.0047	0.0027	0.10	0.5216	0.0194	13.70	–	–	86.20
Head circumference (cm)	0.011	0.00048	1.00	0.152	0.0042	14.20	0.904	0.0046	84.70
Crown-to-heel length (cm)	0.971	0.022	18.00	0.366	0.0213	6.80	4.055	0.0233	75.20
Elective caesarean section ^b	0.0517	0.0043	1.40	0.3233	0.0209	8.80	–	–	89.80
Emergency caesarean section ^b	0.0114	0.002	0.30	0.0863	0.0135	2.50	–	–	97.10
5-minute Apgar score ^b	0.0637	0.0165	1.80	0.208	0.0944	5.80	–	–	92.40
Maternal smoking ^b	0.069	0.0032	1.70	0.625	0.013	15.70	–	–	82.60
Two-level models^c									
Very low birthweight ^b	0.163	0.076	4.70				–	–	95.30
Very preterm ^b	0.0512	0.0197	1.50				–	–	98.50
Stillbirth ^b	0.0001	0.00	0.003				–	–	99.997
Neonatal death ^b	0.433	0.257	11.60				–	–	88.40

HBW, high birthweight; LBW, low birthweight; SE, standard error.

a The final models are those reported in *Tables 15–19* for the imputed data not adjusting for gestational age at booking and maternal smoking.

b For multilevel logistic regression, the level 1 (baby) variance is approximated by $\pi^2/3 = 3.29$ as per Snijders and Bosker.⁸⁷

c For the two-level models, it was not possible to fit the mother as a level.

Note

Dashes reinforce the lack of direct estimates (with approximations used instead).

Appendix 15 Results of the analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – maternal behaviour

TABLE 41 Subgroup of mothers living in the most deprived areas (SIMD1): maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.50 (−0.60 to 0.40)	1.04 (0.91 to 1.19)	1.03 (0.98 to 1.10)
Period 3 ^c	−1.40 (−1.60 to 1.30)	0.96 (0.81 to 1.14)	1.19 (1.09 to 1.28)
Global test 1 ^d			< 0.0001
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.06 (−0.08 to 0.03)	1.08 (1.07 to 1.11)	0.92 (0.91 to 0.93)
Interaction 2 ^g	−0.40 (−0.50 to 0.30)	1.04 (0.93 to 1.16)	0.94 (0.90 to 0.99)
Interaction 3 ^h	−0.17 (−0.23 to 0.11)	0.85 (0.79 to 0.92)	0.96 (0.93 to 0.99)
Global test 2 ⁱ	< 0.0001	< 0.0001	0.02
^a Pre-intervention period. ^b Intervention HiP grant. ^c Post-intervention period. ^d Global test for the periods in which the interactions were not significant. ^e Trend over the study period 2004–13. ^f Trend pre intervention. ^g Trend during the HiP grant period. ^h Trend post intervention. ⁱ Global test for the interactions.			

Appendix 16 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – measures of size

TABLE 42 Subgroup of mothers living in the most deprived areas (SIMD1): measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.91 (0.60 to 1.38)	1.07 (0.96 to 1.20)	0.93 (0.86 to 0.995)	−0.02 (−0.05 to 0.005)	0.04 (−0.04 to 0.1)
Period 3 ^c	0.97 (0.54 to 1.74)	1.23 (1.05 to 1.44)	0.91 (0.82 to 1.01)	−0.10 (−0.14 to 0.06)	0.40 (0.20 to 0.60)
Global test 1 ^d	0.90	0.02	0.10		
Trend					
All years ^e	1.00 (0.91 to 1.09)	0.95 (0.93 to 0.98)	1.02 (1.01 to 1.04)		
Interactions					
Interaction 1 ^f				0.01 (0.005 to 0.02)	0.06 (0.04 to 0.07)
Interaction 2 ^g				−0.03 (−0.05 to 0.005)	0.05 (−0.01 to 0.1)
Interaction 3 ^h				−0.03 (−0.05 to 0.01)	0.001 (−0.04 to 0.05)
Global test 2 ⁱ	0.30	0.04	0.60	< 0.0001	0.08
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 17 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – measures of stage

TABLE 43 Subgroup of mothers living in the most deprived areas (SIMD1): measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.04 (−0.08 to 0.0007)	1.01 (0.92 to 1.12)	1.05 (0.85 to 1.31)	−0.03 (−0.05 to 0.01)	1.07 (0.98 to 1.17)	0.93 (0.86 to 1.01)
Period 3 ^c	−0.19 (−0.24, −0.13)	1.23 (1.08 to 1.39)	1.34 (0.95 to 1.88)	−0.05 (−0.08 to 0.03)	1.19 (1.05 to 1.34)	0.92 (0.83 to 1.04)
Global test 1 ^d				0.0006	0.02	0.20
Trend						
All years ^e				0.015 (0.011 to 0.019)	0.94 (0.93 to 0.96)	0.99 (0.97 to 1.02)
Interactions						
Interaction 1 ^f	0.03 (0.02 to 0.04)	0.95 (0.93 to 0.97)	0.92 (0.88 to 0.96)			
Interaction 2 ^g	0.17 (0.13 to 0.20)	0.76 (0.70 to 0.82)	0.60 (0.51 to 0.72)			
Interaction 3 ^h	0.05 (0.03 to 0.08)	0.87 (0.82 to 0.92)	0.80 (0.71 to 0.90)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.02	0.03	0.20
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>						

Appendix 18 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the most deprived areas (SIMD1) – birth outcomes

TABLE 44 Subgroup of mothers living in the most deprived areas (SIMD1): birth outcomes

Parameter	Mode of delivery		Other birth outcomes		
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	1.00
Period 2 ^b	1.00 (0.91 to 1.09)	1.10 (1.03 to 1.18)	0.79 (0.58 to 1.09)	1.02 (0.85 to 1.23)	1.54 (0.72 to 3.28)
Period 3 ^c	0.98 (0.86 to 1.11)	1.17 (1.07 to 1.29)	0.58 (0.37 to 0.91)	1.01 (0.78 to 1.30)	1.32 (0.45 to 3.92)
Global test 1 ^d	0.90		0.05	0.90	0.40
Trend					
All years ^e	1.06 (1.04 to 1.08)		1.03 (0.96 to 1.10)	1.00 (0.96 to 1.04)	0.94 (0.80 to 1.10)
Interactions					
Interaction 1 ^f		0.99 (0.97 to 1.00)			
Interaction 2 ^g		1.00 (0.95 to 1.05)			
Interaction 3 ^h		1.01 (0.97 to 1.04)			
Global test 2 ⁱ	0.30	0.50	0.01	0.10	0.07
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>					

Appendix 19 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – maternal behaviour

TABLE 45 Subgroup of mothers living in SIMD2 areas: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.32 (−0.45 to 0.19)	1.15 (0.98 to 1.35)	0.96 (0.90 to 1.04)
Period 3 ^c	−1.10 (−1.30 to 0.90)	1.37 (0.94 to 1.98)	1.10 (1.00 to 1.21)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.15 (−0.18 to 0.12)	1.09 (1.06 to 1.12)	0.93 (0.91 to 0.94)
Interaction 2 ^g	−0.53 (−0.64 to 0.43)	1.19 (1.14 to 1.36)	0.95 (0.90 to 1.00)
Interaction 3 ^h	−0.27 (−0.33 to 0.20)	0.91 (0.83 to 0.99)	0.98 (0.94 to 1.02)
Global test 2 ⁱ	< 0.0001	0.0006	0.03
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 20 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – measures of size

TABLE 46 Subgroup of mothers living in SIMD2 areas: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.73 (0.44 to 1.21)	1.04 (0.90 to 1.20)	1.01 (0.94 to 1.09)	−0.04 (−0.07 to 0.006)	0.03 (−0.05 to 0.10)
Period 3 ^c	0.95 (0.47 to 1.90)	1.01 (0.83 to 1.24)	0.95 (0.85 to 1.06)	−0.12 (−0.16 to 0.08)	0.10 (0.03 to 0.2)
Global test 1 ^d	0.20	0.80	0.20		
Trend					
All years ^e	0.99 (0.89 to 1.10)	0.98 (0.95 to 1.01)	1.01 (0.99 to 1.03)		
Interactions					
Interaction 1 ^f				0.008 (0.001 to 0.01)	0.04 (0.02 to 0.05)
Interaction 2 ^g				−0.02 (−0.04 to 0.005)	0.07 (0.009 to 0.10)
Interaction 3 ^h				−0.02 (−0.04 to 0.006)	0.02 (−0.02 to 0.06)
Global test 2 ⁱ	0.90	0.50	0.80	0.0006	0.40
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 21 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – measures of stage

TABLE 47 Subgroup of mothers living in SIMD2 areas: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.04 (−0.09 to 0.001)	1.05 (0.94 to 1.19)	1.02 (0.78 to 1.33)	−0.004 (−0.02 to 0.02)	0.98 (0.88 to 1.09)	0.97 (0.89 to 1.06)
Period 3 ^c	−0.16 (−0.22 to 0.10)	1.23 (1.05 to 1.43)	1.34 (0.95 to 1.88)	−0.02 (−0.05 to 0.009)	0.94 (0.80 to 1.09)	0.92 (0.82 to 1.04)
Global test 1 ^d				0.20	0.60	0.30
Trend						
All years ^e				0.009 (0.005 to 0.01)	0.98 (0.96 to 1.00)	1.01 (0.99 to 1.02)
Interactions						
Interaction 1 ^f	0.02 (0.01 to 0.03)	0.96 (0.94 to 0.98)	0.95 (0.90 to 1.00)			
Interaction 2 ^g	0.16 (0.12 to 0.19)	0.72 (0.66 to 0.79)	0.57 (0.46 to 0.70)			
Interaction 3 ^h	0.04 (0.02 to 0.07)	0.89 (0.83 to 0.95)	0.68 (0.59 to 0.78)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.40	0.60	0.90
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 22 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD2 areas – birth outcomes

TABLE 48 Subgroup of mothers living in SIMD2 areas: birth outcomes

	Other birth outcomes, OR (95% CI)				
	Mode of delivery				
Parameter	Elective caesarean	Emergency caesarean	Stillbirth	5-minute Apgar score	Neonatal death
Periods					IGLS algorithm failed to converge
Period 1 ^a	1.00	1.00	1.00	1.00	
Period 2 ^b	1.03 (0.93 to 1.13)	1.08 (1.00 to 1.17)	1.20 (0.81 to 1.77)	0.86 (0.70 to 1.05)	
Period 3 ^c	1.08 (0.94 to 1.24)	1.18 (1.07 to 1.31)	1.11 (0.64 to 1.93)	0.81 (0.61 to 1.07)	
Global test 1 ^d	0.50		0.60	0.30	
Trend					
All years ^e	1.05 (1.02 to 1.07)		0.92 (0.85 to 1.00)	1.02 (0.98 to 1.06)	
Interactions					
Interaction 1 ^f		0.98 (0.97 to 1.00)			
Interaction 2 ^g		1.02 (0.96 to 1.09)			
Interaction 3 ^h		1.01 (0.97 to 1.06)			
Global test 2 ⁱ	0.10	0.20	0.09	0.70	
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 23 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – maternal behaviour

TABLE 49 Subgroup of mothers living in SIMD3 areas: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.34 (−0.48 to 0.20)	1.24 (1.06 to 1.45)	1.10 (1.01 to 1.20)
Period 3 ^c	−1.03 (−1.20 to 0.84)	1.03 (0.84 to 1.25)	1.24 (1.10 to 1.38)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.19 (−0.22 to 0.17)	1.09 (1.06 to 1.12)	0.91 (0.89 to 0.92)
Interaction 2 ^g	−0.57 (−0.68 to 0.46)	1.13 (0.98 to 1.30)	0.91 (0.85 to 0.97)
Interaction 3 ^h	−0.17 (−0.25 to 0.10)	0.89 (0.80 to 0.97)	0.97 (0.92 to 1.02)
Global test 2 ⁱ	< 0.0001	0.0002	0.04
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 24 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – measures of size

TABLE 50 Subgroup of mothers living in SIMD3 areas: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.89 (0.50 to 1.57)	1.05 (0.90 to 1.24)	0.97 (0.89 to 1.05)	−0.06 (−0.10 to 0.03)	0.08 (0.003 to 0.20)
Period 3 ^c	0.72 (0.32 to 1.60)	1.12 (0.90 to 1.40)	0.98 (0.87 to 1.09)	−0.10 (−0.20 to 0.08)	0.30 (0.20 to 0.40)
Global test 1 ^d	0.7	0.6	0.7		
Trend					
All years ^e	1.01 (0.89 to 1.15)	0.97 (0.94 to 1.00)	1.01 (0.99 to 1.02)		
Interactions					
Interaction 1 ^f				0.008 (0.002 to 0.01)	0.009 (−0.007 to 0.03)
Interaction 2 ^g				−0.03 (−0.05 to 0.001)	0.08 (0.02 to 0.10)
Interaction 3 ^h				−0.03 (−0.05 to 0.01)	0.08 (0.03 to 0.10)
Global test 2 ⁱ	0.30	0.90	0.90	0.0001	0.002
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>					

Appendix 25 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – measures of stage

TABLE 51 Subgroup of mothers living in SIMD3 areas: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.04 (−0.08 to 0.01)	1.03 (0.90 to 1.17)	1.15 (0.85 to 1.56)	−0.006 (−0.03 to 0.02)	1.00 (0.89 to 1.13)	0.99 (0.90 to 1.08)
Period 3 ^c	−0.17 (−0.24 to −0.11)	1.30 (1.10 to 1.54)	1.73 (1.18 to 2.54)	−0.006 (−0.03 to 0.03)	1.00 (0.85 to 1.19)	1.02 (0.90 to 1.15)
Global test 1 ^d				0.70	0.90	0.70
Trend						
All years ^e				0.005 (0.0006 to 0.01)	0.97 (0.95 to 1.00)	1.00 (0.98 to 1.02)
Interactions						
Interaction 1 ^f	0.03 (0.02 to 0.04)	0.96 (0.93 to 0.98)	0.91 (0.86 to 0.97)			
Interaction 2 ^g	0.16 (0.12 to 0.19)	0.72 (0.65 to 0.80)	0.57 (0.45 to 0.72)			
Interaction 3 ^h	0.07 (0.05 to 0.10)	0.84 (0.78 to 0.90)	0.66 (0.56 to 0.77)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.90	0.50	0.60
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 26 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD3 areas – birth outcomes

TABLE 52 Subgroup of mothers living in SIMD3 areas: birth outcomes

Parameter	Mode of delivery				Neonatal death, OR (95% CI)
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	
Periods					IGLS algorithm failed to converge
Period 1 ^a	1.00	1.00	1.00	1.00	
Period 2 ^b	0.99 (0.90 to 1.10)	1.05 (0.97 to 1.14)	1.11 (0.74 to 1.66)	0.86 (0.70 to 1.07)	
Period 3 ^c	1.05 (0.92 to 1.21)	1.18 (1.06 to 1.31)	0.77 (0.43 to 1.38)	0.80 (0.60 to 1.07)	
Global test 1 ^d	0.40		0.10		
Trend					
All years ^e	1.05 (1.03 to 1.07)		1.01 (0.92 to 1.10)	1.01 (0.96 to 1.05)	
Interactions					
Interaction 1 ^f		0.98 (0.96 to 1.00)			
Interaction 2 ^g		1.04 (0.97 to 1.10)			
Interaction 3 ^h		1.00 (0.96 to 1.04)			
Global test 2 ⁱ	0.60	0.30	0.90	0.80	

IGLS, iterative generalised least squares.

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Appendix 27 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – maternal behaviour

TABLE 53 Subgroup of mothers living in SIMD4 areas: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.24 (−0.39 to −0.10)	1.09 (0.92 to 1.29)	0.99 (0.89 to 1.10)
Period 3 ^c	−0.86 (−1.04 to −0.67)	0.85 (0.68 to 1.05)	1.13 (0.99 to 1.29)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.22 (−0.25 to −0.19)	1.12 (1.09 to 1.16)	0.92 (0.90 to 0.94)
Interaction 2 ^g	−0.62 (−0.73 to −0.50)	1.11 (0.96 to 1.29)	0.91 (0.84 to 0.99)
Interaction 3 ^h	−0.26 (−0.33 to −0.18)	0.87 (0.78 to 0.96)	1.05 (0.99 to 1.12)
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 28 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – measures of size

TABLE 54 Subgroup of mothers living in SIMD4 areas: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	1.07 (0.54 to 2.13)	0.87 (0.72 to 1.04)	0.98 (0.91 to 1.06)	−0.04 (−0.08 to −0.01)	0.02 (−0.06 to 0.09)
Period 3 ^c	1.23 (0.47 to 3.20)	0.79 (0.61 to 1.02)	0.99 (0.88 to 1.10)	−0.11 (−0.15 to −0.06)	0.20 (0.1 to 0.30)
Global test 1 ^d	0.90	0.20	0.90		
Trend					
All years ^e	0.94 (0.81 to 1.09)	1.03 (0.99 to 1.08)	1.00 (0.98 to 1.02)		
Interactions					
Interaction 1 ^f				0.005 (−0.002 to 0.01)	0.02 (0.007 to 0.04)
Interaction 2 ^g				−0.04 (−0.06 to −0.01)	0.09 (0.03 to 0.20)
Interaction 3 ^h				−0.04 (−0.05 to −0.02)	0.07 (0.03 to 0.10)
Global test 2 ⁱ	0.90	0.50	0.10	< 0.0001	0.0007
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 29 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – measures of stage

TABLE 55 Subgroup of mothers living in SIMD4 areas: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient 95% CI	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.01 (−0.06 to 0.03)	0.97 (0.84 to 1.11)	1.35 (0.97 to 1.88)	0.008 (−0.01 to 0.03)	0.91 (0.80 to 1.05)	1.02 (0.93 to 1.11)
Period 3 ^c	−0.10 (−0.20 to −0.05)	1.07 (0.89 to 1.28)	1.56 (1.02 to 2.40)	0.01 (−0.02 to 0.04)	0.83 (0.69 to 1.01)	0.98 (0.87 to 1.11)
Global test 1 ^d				0.70	0.20	0.70
Trend						
All years ^e				0.002 (−0.003 to 0.006)	1.00 (0.97 to 1.03)	0.99 (0.98 to 1.01)
Interactions						
Interaction 1 ^f	0.02 (0.007 to 0.03)	0.98 (0.95 to 1.00)	0.91 (0.86 to 0.978)			
Interaction 2 ^g	0.14 (0.11 to 0.18)	0.69 (0.62 to 0.78)	0.71 (0.55 to 0.91)			
Interaction 3 ^h	0.05 (0.03 to 0.08)	0.82 (0.76 to 0.89)	0.66 (0.55 to 0.79)			
Global test 2 ⁱ	< 0.0001	< 0.0001	0.001		0.20	0.30
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 30 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in SIMD4 areas – birth outcomes

TABLE 56 Subgroup of mothers living in SIMD4 areas: birth outcomes

Parameter	Birth outcomes				Neonatal death, OR (95% CI)
	Mode of delivery			5-minute Apgar score, OR (95% CI)	
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)		
Periods					IGLS algorithm failed to converge
Period 1 ^a	1.00	1.00	1.00	1.00	
Period 2 ^b	1.00 (0.91 to 1.11)	1.02 (0.93 to 1.10)	1.17 (0.73 to 1.90)	0.92 (0.73 to 1.16)	
Period 3 ^c	1.03 (0.89 to 1.18)	1.09 (0.98 to 1.22)	1.55 (0.80 to 3.00)	0.96 (0.70 to 1.33)	
Global test 1 ^d	0.90		0.40	0.70	
Trend					
All years ^e			0.91 (0.83 to 1.01)	0.99 (0.94 to 1.04)	
Interactions	1.06 (1.04 to 1.08)				
Interaction 1 ^f		0.99 (0.97 to 1.01)			
Interaction 2 ^g		1.01 (0.95 to 1.08)			
Interaction 3 ^h		0.99 (0.94 to 1.04)			
Global test 2 ⁱ	0.40	0.80	0.60	0.20	
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 31 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – maternal behaviour

TABLE 57 Subgroup of mothers living in the least deprived areas: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.20 (−0.40 to 0.10)	1.02 (0.85 to 1.22)	0.98 (0.86 to 1.11)
Period 3 ^c	−1.00 (−1.10 to 0.80)	0.76 (0.61 to 0.96)	1.16 (0.98 to 1.37)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.13 (−0.16 to 0.10)	1.10 (1.06 to 1.13)	0.91 (0.89 to 0.94)
Interaction 2 ^g	−0.80 (−0.90 to 0.70)	1.12 (0.96 to 1.31)	0.81 (0.73 to 0.90)
Interaction 3 ^h	−0.16 (−0.24 to 0.08)	0.88 (0.80 to 0.97)	1.05 (0.97 to 1.13)
Global test 2 ⁱ	< 0.0001	0.0003	0.0001
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 32 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – measures of size

TABLE 58 Subgroup of mothers living in the least deprived areas: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.68 (0.33 to 1.37)	1.01 (0.83 to 1.24)	1.00 (0.92 to 1.09)	−0.04 (−0.08 to 0.01)	0.20 (0.10 to 0.30)
Period 3 ^c	0.97 (0.37 to 2.55)	0.99 (0.75 to 1.30)	0.99 (0.88 to 1.10)	−0.09 (−0.10 to 0.04)	0.40 (0.30 to 0.50)
Global test 1 ^d	0.30	0.90	0.90		
Trend					
All years ^e	1.04 (0.89 to 1.20)	1.00 (0.96 to 1.05)	1.00 (0.98 to 1.02)		
Interactions					
Interaction 1 ^f				0.004 (−0.003 to 0.01)	−0.01 (−0.03 to 0.006)
Interaction 2 ^g				−0.009 (−0.03 to 0.02)	0.09 (0.03 to 0.20)
Interaction 3 ^h				−0.05 (−0.07 to 0.03)	0.03 (−0.01 to 0.08)
Global test 2 ⁱ	0.30	0.90	0.04	< 0.0001	0.002
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 33 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – measures of stage

TABLE 59 Subgroup of mothers living in the least deprived areas: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	0.10 (0.02 to 0.20)	1.03 (0.89 to 1.19)	1.07 (0.77 to 1.49)	0.001 (−0.02 to 0.02)	1.04 (0.90 to 1.22)	1.06 (0.96 to 1.16)
Period 3 ^c	−0.20 (−0.30 to 0.10)	1.25 (1.04 to 1.51)	1.11 (0.72 to 1.72)	−0.0007 (−0.03 to 0.03)	1.06 (0.86 to 1.32)	1.08 (0.95 to 1.22)
Global test 1 ^d				0.90	0.80	0.40
Trend						
All years ^e				0.0004 (−0.004 to 0.005)	0.99 (0.96 to 1.02)	0.98 (0.96 to 1.00)
Interactions						
Interaction 1 ^f	0.03 (0.02 to 0.04)	0.96 (0.93 to 0.99)	0.96 (0.90 to 1.03)			
Interaction 2 ^g	0.11 (0.07 to 0.15)	0.76 (0.67 to 0.85)	0.70 (0.54 to 0.91)			
Interaction 3 ^h	0.05 (0.02 to 0.08)	0.85 (0.78 to 0.92)	0.65 (0.53 to 0.80)			
Global test 2 ⁱ	0.0001	< 0.0001	0.0002	0.30	0.50	0.040
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 34 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in the least deprived areas – birth outcomes

TABLE 60 Subgroup of mothers living in the least deprived areas: birth outcomes

Parameter	Birth outcomes, OR (95% CI)				
	Mode of delivery				Neonatal death
	Elective caesarean	Emergency caesarean	Stillbirth	5-minute Apgar score	
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	
Period 2 ^b	1.02 (0.93 to 1.13)	1.05 (0.96 to 1.15)	1.00 (0.59 to 1.69)	0.91 (0.72 to 1.15)	
Period 3 ^c	1.23 (1.07 to 1.41)	1.23 (1.10 to 1.38)	1.32 (0.65 to 2.67)	0.84 (0.60 to 1.16)	
Global test 1 ^d	0.0002		0.50	0.60	
Trend					IGLS algorithm failed to converge
All years ^e	1.05 (1.03 to 1.07)		0.97 (0.87 to 1.08)	1.02 (0.97 to 1.07)	
Interactions					
Interaction 1 ^f		0.98 (0.95 to 0.99)			
Interaction 2 ^g		1.03 (0.96 to 1.10)			
Interaction 3 ^h		0.98 (0.94 to 1.03)			
Global test 2 ⁱ	0.90	0.30	0.80	0.01	
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 35 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – maternal behaviour

TABLE 61 Subgroup of mothers with diabetes mellitus (before or during pregnancy): maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00		1.00
Period 2 ^b	−0.10 (−0.70 to 0.50)		1.23 (0.88 to 1.73)
Period 3 ^c	−0.60 (−1.40 to 0.10)		1.30 (0.81 to 2.08)
Global test 1 ^d			
Trend		IGLS algorithm failed to converge	
All years ^e			
Interactions			
Interaction 1 ^f	−0.10 (−0.30 to 0.02)		0.91 (0.84 to 0.98)
Interaction 2 ^g	−0.30 (−0.70 to 0.10)		0.93 (0.75 to 1.17)
Interaction 3 ^h	−0.20 (−0.40 to 0.03)		0.99 (0.86 to 1.13)
Global test 2 ⁱ	0.70		0.60

IGLS, iterative generalised least squares.

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Appendix 36 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – measures of size

TABLE 62 Subgroup of mothers with diabetes mellitus (before or during pregnancy): measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a		1.00	1.00	0.00	0.00
Period 2 ^b		0.98 (0.55 to 1.76)	0.82 (0.64 to 1.04)	−0.02 (−0.14 to 0.11)	0.10 (−0.30 to 0.50)
Period 3 ^c		0.81 (0.36 to 1.86)	0.64 (0.46 to 0.90)	−0.02 (−0.20 to 0.20)	0.10 (−0.40 to 0.70)
Global test 1 ^d		0.70	0.03		
Trend					
	IGLS algorithm failed to converge				
All years ^e		0.99 (0.87 to 1.12)	0.97 (0.92 to 1.03)		
Interactions					
Interaction 1 ^f				0.005 (−0.03 to 0.04)	0.002 (−0.08 to 0.09)
Interaction 2 ^g				0.02 (−0.08 to 0.10)	0.20 (−0.10 to 0.40)
Interaction 3 ^h				0.004 (−0.05 to 0.06)	0.04 (−0.10 to 0.20)
Global test 2 ⁱ		0.20	0.0005	0.90	0.50
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 37 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – measures of stage

TABLE 63 Subgroup of mothers with diabetes mellitus (before or during pregnancy): measures of stage

	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Parameter						
Periods						
Period 1 ^a	0.00	1.00		0.00	1.00	1.00
Period 2 ^b	−0.04 (−0.30 to 0.20)	1.14 (0.84 to 1.54)		−0.40 (−0.60 to 0.10)	1.14 (0.54 to 2.39)	1.07 (0.86 to 1.33)
Period 3 ^c	−0.07 (−0.40 to 0.20)	1.00 (0.67 to 1.50)		−0.20 (−0.50 to 0.10)	0.78 (0.26 to 2.36)	0.85 (0.62 to 1.16)
Global test 1 ^d	< 0.0001			0.03	0.40	0.03
Trend			IGLS algorithm failed to converge			
All years ^e				−0.02 (−0.04 to 0.004)	1.07 (0.90 to 1.28)	0.95 (0.91 to 0.999)
Interactions						
Interaction 1 ^f	0.04 (−0.01 to 0.09)	0.95 (0.89 to 1.01)				
Interaction 2 ^g	0.08 (−0.09 to 0.20)	0.87 (0.70 to 1.07)				
Interaction 3 ^h	0.10 (0.02 to 0.20)	0.78 (0.68 to 0.89)				
Global test 2 ⁱ	0.40	0.03		0.0001	0.10	0.002
IGLS, iterative generalised least squares.						
a Pre-intervention period.						
b Intervention HiP grant.						
c Post-intervention period.						
d Global test for the periods in which the interactions were not significant.						
e Trend over the study period 2004–13.						
f Trend pre intervention.						
g Trend during the HiP grant period.						
h Trend post intervention.						
i Global test for the interactions.						

Appendix 38 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers with diabetes mellitus (before or during pregnancy) – birth outcomes

TABLE 64 Subgroup of mothers with diabetes mellitus (before or during pregnancy): birth outcomes

Parameter	Birth outcomes, OR (95% CI)				
	Mode of delivery			5-minute Apgar score	Neonatal death
	Elective caesarean	Emergency caesarean	Stillbirth		
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	
Period 2 ^b	0.96 (0.73 to 1.26)	0.92 (0.54 to 1.59)	2.35 (0.72 to 7.69)	0.87 (0.44 to 1.71)	
Period 3 ^c	1.08 (0.73 to 1.58)	1.08 (0.73 to 1.58)	4.57 (0.89 to 23.52)	0.51 (0.18 to 1.41)	
Global test 1 ^d	0.50		0.20	0.20	
Trend					IGLS algorithm failed to converge
All years ^e	1.00 (0.95 to 1.07)		0.76 (0.59 to 0.97)	1.10 (0.93 to 1.29)	
Interactions					
Interaction 1 ^f		0.96 (0.90 to 1.02)			
Interaction 2 ^g		0.87 (0.72 to 1.04)			
Interaction 3 ^h		0.99 (0.89 to 1.10)			
Global test 2 ⁱ	0.40	0.50	0.70	0.90	
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 39 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m²) – maternal behaviour

TABLE 65 Subgroup of obese mothers (BMI ≥ 35 kg/m²): maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.70 (−0.90 to 0.40)	1.35 (1.05 to 1.72)	1.00 (0.88 to 1.14)
Period 3 ^c	−1.50 (−1.90 to 1.10)	1.11 (0.81 to 1.52)	1.18 (0.99 to 1.41)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.10 (−0.20 to 0.09)	1.08 (1.03 to 1.13)	0.94 (0.92 to 0.97)
Interaction 2 ^g	−0.70 (−0.90 to 0.50)	1.09 (0.88 to 1.35)	0.92 (0.83 to 1.03)
Interaction 3 ^h	−0.10 (−0.30 to 0.02)	0.92 (0.80 to 1.06)	0.96 (0.90 to 1.02)
Global test 2 ⁱ	< 0.0001	0.10	0.80
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 40 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m²) – measures of size

TABLE 66 Subgroup of obese mothers (BMI ≥ 35 kg/m²): measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.63 (0.23 to 1.70)	1.10 (0.82 to 1.48)	0.92 (0.82 to 1.03)	−0.02 (−0.08 to 0.03)	0.20 (0.03 to 0.30)
Period 3 ^c	0.73 (0.18 to 2.91)	1.32 (0.87 to 1.99)	0.80 (0.67 to 0.94)	−0.10 (−0.20 to 0.03)	0.40 (0.20 to 0.60)
Global test 1 ^d	0.60	0.30	0.01		
Trend					
All years ^e	1.09 (0.87 to 1.37)	0.99 (0.93 to 1.06)	1.01 (0.98 to 1.03)		
Interactions					
Interaction 1 ^f				0.01 (0.001 to 0.02)	−0.01 (−0.04 to 0.02)
Interaction 2 ^g				0.003 (−0.04 to 0.04)	0.06 (−0.05 to 0.2)
Interaction 3 ^h				−0.02 (−0.05 to 0.005)	0.04 (−0.03 to 0.1)
Global test 2 ⁱ	0.90	0.30	0.20	0.01	0.20
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 41 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m²) – measures of stage

TABLE 67 Subgroup of obese mothers (BMI ≥ 35 kg/m²): measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.03 (−0.1 to 0.05)	1.01 (0.82 to 1.23)	1.27 (0.82 to 1.97)	−0.03 (−0.07 to 0.01)	1.16 (0.91 to 1.50)	0.94 (0.84 to 1.06)
Period 3 ^c	−0.20 (−0.30 to 0.05)	1.26 (0.97 to 1.64)	1.59 (0.90 to 2.83)	−0.09 (−0.20 to 0.03)	1.41 (1.00 to 2.00)	0.85 (0.72 to 1.01)
Global test 1 ^d				0.004	0.10	0.10
Trend						
All years ^e				0.002 (−0.007 to 0.01)	0.96 (0.91 to 1.01)	0.99 (0.97 to 1.02)
Interactions						
Interaction 1 ^f	0.02 (−0.002 to 0.04)	0.96 (0.92 to 1.00)	0.93 (0.85 to 1.01)			
Interaction 2 ^g	0.10 (0.06 to 0.20)	0.75 (0.64 to 0.87)	0.79 (0.57 to 1.09)			
Interaction 3 ^h	0.06 (0.02 to 0.10)	0.84 (0.76 to 0.92)	0.69 (0.55 to 0.85)			
Global test 2 ⁱ	0.001	0.0006	0.04	0.006	0.40	0.05

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Appendix 42 Results of analysis for the secondary outcomes using the imputed data: subgroup of obese mothers (BMI ≥ 35 kg/m²) – birth outcomes

TABLE 68 Subgroup of obese mothers (BMI ≥ 35 kg/m²): birth outcomes

	Birth outcomes, OR (95% CI)				
	Mode of delivery			5-minute Apgar score	Neonatal death
Parameter	Elective caesarean	Emergency caesarean	Stillbirth		
Periods					
Period 1 ^a	1.00	1.00		1.00	
Period 2 ^b	1.01 (0.88 to 1.17)	1.11 (0.98 to 1.25)		0.85 (0.61 to 1.20)	
Period 3 ^c	1.12 (0.92 to 1.38)	1.21 (1.02 to 1.44)		0.70 (0.43 to 1.13)	
Global test 1 ^d	0.20			0.30	
Trend			IGLS algorithm failed to converge		IGLS algorithm failed to converge
All years ^e	1.05 (1.02 to 1.08)			1.03 (0.96 to 1.12)	
Interactions					
Interaction 1 ^f		0.97 (0.95 to 1.00)			
Interaction 2 ^g		1.03 (0.94 to 1.12)			
Interaction 3 ^h		0.99 (0.93 to 1.05)			
Global test 2 ⁱ	0.90	0.50		0.70	
IGLS, iterative generalised least squares. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 43 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – maternal behaviour

TABLE 69 Subgroup of lone mothers: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.40 (−0.70 to −0.06)	0.97 (0.79 to 1.19)	1.03 (0.92 to 1.14)
Period 3 ^c	−1.20 (−1.60 to −0.70)	0.89 (0.68 to 1.16)	1.18 (1.02 to 1.37)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.17 (−0.23 to −0.11)	1.09 (1.05 to 1.13)	0.94 (0.92 to 0.96)
Interaction 2 ^g	−0.50 (−0.70 to −0.20)	0.97 (0.82 to 1.14)	0.92 (0.85 to 1.01)
Interaction 3 ^h	−0.20 (−0.40 to −0.02)	0.94 (0.83 to 1.07)	0.98 (0.91 to 1.04)
Global test 2 ⁱ	0.10	0.049	0.50
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 44 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – measures of size

TABLE 70 Subgroup of lone mothers: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.94 (0.39 to 2.25)	1.15 (0.91 to 1.44)	0.98 (0.83 to 1.16)	−0.04 (−0.10 to 0.02)	0.03 (−0.10 to 0.20)
Period 3 ^c	0.75 (0.22 to 2.58)	1.13 (0.82 to 1.55)	0.81 (0.64 to 1.02)	−0.09 (−0.2 to −0.007)	0.20 (−0.02 to 0.4)
Global test 1 ^d	0.90	0.50	0.03		
Trend					
All years ^e	1.10 (0.91 to 1.33)	0.96 (0.91 to 1.00)	1.03 (1.00 to 1.07)		
Interactions					
Interaction 1 ^f				0.01 (−0.002 to 0.02)	0.03 (−0.009 to 0.06)
Interaction 2 ^g				−0.007 (−0.06 to 0.04)	0.09 (−0.03 to 0.20)
Interaction 3 ^h				−0.01 (−0.05 to 0.03)	0.20 (0.07 to 0.30)
Global test 2 ⁱ	0.50	0.70	0.90	0.50	0.02
HBW, high birthweight; LBW, low birthweight. a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.					

Appendix 45 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – measures of stage

TABLE 71 Subgroup of lone mothers: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.10 (−0.20 to 0.008)	1.16 (0.95 to 1.41)	0.92 (0.60 to 1.43)	−0.01 (−0.05 to 0.03)	1.12 (0.94 to 1.33)	0.91 (0.75 to 1.10)
Period 3 ^c	−0.30 (−0.40 to 0.20)	1.44 (1.11 to 1.87)	1.51 (0.88 to 2.59)	−0.06 (−0.1 to 0.003)	1.17 (0.92 to 1.49)	0.74 (0.56 to 0.96)
Global test 1 ^d				0.06	0.40	0.047
Trend						
All years ^e				0.01 (0.003 to 0.02)	0.95 (0.92 to 0.98)	1.02 (0.98 to 1.07)
Interactions						
Interaction 1 ^f	0.04 (0.02 to 0.06)	0.94 (0.90 to 0.97)	0.91 (0.84 to 0.99)			
Interaction 2 ^g	0.10 (0.07 to 0.20)	0.80 (0.68 to 0.94)	0.55 (0.38 to 0.79)			
Interaction 3 ^h	0.09 (0.03 to 0.10)	0.77 (0.68 to 0.86)	0.65 (0.51 to 0.84)			
Global test 2 ⁱ	0.02	0.002	0.002	0.70	0.60	0.50
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>						

Appendix 46 Results of analysis for the secondary outcomes using the imputed data: subgroup of lone mothers – birth outcomes

TABLE 72 Subgroup of lone mothers: birth outcomes

	Birth outcomes, OR (95% CI)				
	Mode of delivery				
Parameter	Elective caesarean	Emergency caesarean	Stillbirth	5-minute Apgar score	Neonatal death
Periods					
Period 1 ^a	1.00	1.00		1.00	
Period 2 ^b	0.94 (0.76 to 1.17)	1.11 (0.95 to 1.29)		1.09 (0.76 to 1.56)	
Period 3 ^c	0.97 (0.72 to 1.31)	1.20 (0.98 to 1.47)		1.06 (0.64 to 1.74)	
Global test 1 ^d	0.80			0.90	
Trend			IGLS algorithm failed to converge	IGLS algorithm failed to converge	IGLS algorithm failed to converge
All years ^e	1.07 (1.02 to 1.12)			1.01 (0.94 to 1.09)	
Interactions					
Interaction 1 ^f		0.99 (0.96 to 1.02)			
Interaction 2 ^g		0.90 (0.80 to 1.02)			
Interaction 3 ^h		0.96 (0.88 to 1.05)			
Global test 2 ⁱ	0.90	0.30		0.90	
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 47 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – maternal behaviour

TABLE 73 Subgroup of mothers living in households where the head is in the group of working-class people: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.50 (−0.60 to 0.40)	1.19 (1.04 to 1.35)	1.03 (0.97 to 1.09)
Period 3 ^c	−1.26 (−1.39 to 1.12)	1.00 (0.85 to 1.18)	1.17 (1.09 to 1.26)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.13 (−0.15 to 0.11)	1.09 (1.06 to 1.11)	0.92 (0.91 to 0.93)
Interaction 2 ^g	−0.60 (−0.70 to 0.50)	1.12 (1.00 to 1.25)	0.91 (0.87 to 0.95)
Interaction 3 ^h	−0.24 (−0.29 to 0.19)	0.87 (0.80 to 0.94)	0.98 (0.95 to 1.01)
Global test 2 ⁱ	< 0.0001	< 0.0001	0.0007
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 48 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – measures of size

TABLE 74 Subgroup of mothers living in households where the head is in the group of working-class people: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.76 (0.51 to 1.14)	1.04 (0.93 to 1.16)	0.94 (0.89 to 1.00)	−0.05 (−0.07 to 0.03)	0.03 (−0.02 to 0.10)
Period 3 ^c	0.92 (0.53 to 1.60)	1.10 (0.95 to 1.28)	0.92 (0.84 to 1.00)	−0.11 (−0.14 to 0.08)	0.20 (0.10 to 0.30)
Global test 1 ^d	0.20	0.40	0.10		
Trend					
All years ^e	1.00 (0.92 to 1.09)	0.97 (0.95 to 0.99)	1.02 (1.01 to 1.03)		
Interactions					
Interaction 1 ^f				0.008 (0.003 to 0.01)	0.02 (0.01 to 0.04)
Interaction 2 ^g				−0.03 (−0.05 to 0.01)	0.08 (0.03 to 0.10)
Interaction 3 ^h				−0.03 (−0.04 to 0.01)	0.05 (0.01 to 0.08)
Global test 2 ⁱ	0.50	0.90	0.20	< 0.0001	0.03

HBW, high birthweight; LBW, low birthweight.

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Appendix 49 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – measures of stage

TABLE 75 Subgroup of mothers living in households where the head is in the group of working-class people: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.04 (−0.07 to 0.0007)	1.05 (0.96 to 1.15)	1.14 (0.92 to 1.40)	−0.01 (−0.03 to 0.002)	1.02 (0.94 to 1.11)	0.95 (0.89 to 1.01)
Period 3 ^c	−0.18 (−0.23 to 0.13)	1.31 (1.16 to 1.47)	1.55 (1.19 to 2.03)	−0.03 (−0.05 to 0.008)	1.06 (0.94 to 1.19)	0.92 (0.83 to 1.00)
Global test 1 ^d				0.02	0.60	0.20
Trend						
All years ^e				0.011 (0.008 to 0.014)	0.96 (0.94 to 0.98)	1.01 (0.99 to 1.02)
Interactions						
Interaction 1 ^f	0.037 (0.020 to 0.030)	0.95 (0.93 to 0.96)	0.92 (0.89 to 0.96)			
Interaction 2 ^g	0.16 (0.13 to 0.19)	0.72 (0.67 to 0.78)	0.60 (0.51 to 0.71)			
Interaction 3 ^h	0.08 (0.06 to 0.10)	0.85 (0.81 to 0.89)	0.67 (0.59 to 0.75)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.50	0.80	0.40
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 50 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of working-class people – birth outcomes

TABLE 76 Subgroup of mothers living in households where the head is in the group of working-class people: birth outcomes

Parameter	Birth outcomes, OR (95% CI)				
	Mode of delivery				
	Elective caesarean	Emergency caesarean	Stillbirth	5-minute Apgar score	Neonatal death
Periods					
Period 1 ^a	1.00	1.00		1.00	1.00
Period 2 ^b	0.98 (0.91 to 1.06)	1.02 (0.96 to 1.08)		0.91 (0.77 to 1.06)	1.33 (0.66 to 2.68)
Period 3 ^c	1.03 (0.92 to 1.14)	1.09 (1.01 to 1.19)		0.83 (0.67 to 1.03)	0.87 (0.32 to 2.39)
Global test 1 ^d	0.30			0.20	0.30
Trend			IGLS algorithm failed to converge		
All years ^e	1.07 (1.05 to 1.08)			1.01 (0.97 to 1.04)	0.96 (0.83 to 1.12)
Interactions					
Interaction 1 ^f		0.99 (0.98 to 1.00)			
Interaction 2 ^g		1.00 (0.95 to 1.05)			
Interaction 3 ^h		0.99 (0.96 to 1.02)			
Global test 2 ⁱ	0.30	0.90		0.50	0.70
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 51 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – maternal behaviour

TABLE 77 Subgroup of mothers living in households where the head is in the group of people who have never worked: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.30 (−0.50 to 0.10)	1.03 (0.90 to 1.19)	1.06 (0.99 to 1.14)
Period 3 ^c	−1.10 (−1.40 to 0.90)	0.95 (0.79 to 1.14)	1.25 (1.14 to 1.38)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.15 (−0.19 to 0.11)	1.08 (1.05 to 1.11)	0.93 (0.91 to 0.94)
Interaction 2 ^g	−0.50 (−0.60 to 0.30)	1.05 (0.93 to 1.19)	0.96 (0.91 to 1.01)
Interaction 3 ^h	−0.20 (−0.30 to 0.10)	0.85 (0.78 to 0.92)	0.97 (0.94 to 1.01)
Global test 2 ⁱ	0.0001	< 0.0001	0.05
a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.			

Appendix 52 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – measures of size

TABLE 78 Subgroup of mothers living in households where the head is in the group of people who have never worked: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	0.80 (0.47 to 1.36)	1.02 (0.89 to 1.18)	1.03 (0.93 to 1.13)	−0.02 (−0.06 to 0.01)	0.06 (−0.04 to 0.10)
Period 3 ^c	0.67 (0.32 to 1.40)	1.12 (0.92 to 1.36)	1.05 (0.92 to 1.21)	−0.10 (−0.15 to 0.06)	0.20 (0.03 to 0.30)
Global test 1 ^d	0.60	0.40	0.70		
Trend					
All years ^e	1.06 (0.95 to 1.19)	0.97 (0.94 to 1.00)	1.00 (0.98 to 1.02)		
Interactions					
Interaction 1 ^f				0.008 (0.0008 to 0.02)	0.04 (0.02 to 0.06)
Interaction 2 ^g				−0.03 (−0.05 to 0.001)	0.08 (0.008 to 0.10)
Interaction 3 ^h				−0.03 (−0.05 to 0.01)	0.05 (−0.003 to 0.10)
Global test 2 ⁱ	0.80	0.01	0.40	0.0001	0.60

HBW, high birthweight; LBW, low birthweight.

a Pre-intervention period.

b Intervention HiP grant.

c Post-intervention period.

d Global test for the periods in which the interactions were not significant.

e Trend over the study period 2004–13.

f Trend pre intervention.

g Trend during the HiP grant period.

h Trend post intervention.

i Global test for the interactions.

Appendix 53 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – measures of stage

TABLE 79 Subgroup of mothers living in households where the head is in the group of people who have never worked: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.05 (−0.10 to 0.006)	1.10 (0.97 to 1.25)	1.22 (0.93 to 1.59)	−0.005 (−0.03 to 0.02)	1.02 (0.91 to 1.14)	0.95 (0.85 to 1.06)
Period 3 ^c	−0.20 (−0.28 to 0.12)	1.33 (1.13 to 1.56)	1.58 (1.12 to 2.24)	−0.03 (−0.06 to 0.009)	1.07 (0.92 to 1.24)	1.01 (0.86 to 1.18)
Global test 1 ^d				0.20		0.30
Trend						
All years ^e				0.008 (0.002 to 0.01)	0.97 (0.95 to 0.99)	0.99 (0.96 to 1.01)
Interactions						
Interaction 1 ^f	0.03 (0.02 to 0.04)	0.95 (0.92 to 0.97)	0.91 (0.87 to 0.96)			
Interaction 2 ^g	0.17 (0.13 to 0.22)	0.75 (0.68 to 0.83)	0.68 (0.56 to 0.84)			
Interaction 3 ^h	0.06 (0.03 to 0.10)	0.83 (0.78 to 0.89)	0.77 (0.67 to 0.89)			
Global test 2 ⁱ	< 0.0001	< 0.0001	0.004	0.30	0.60	0.30
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>						

Appendix 54 Results of analysis for the secondary outcomes using the imputed data: subgroup of mothers living in households where the head is in the group of people who have never worked – birth outcomes

TABLE 80 Subgroup of mothers living in households where the head is in the group of people who have never worked: birth outcomes

	Birth outcomes, OR (95% CI)				
	Mode of delivery			5-minute Apgar score	Neonatal death
Parameter	Elective caesarean	Emergency caesarean	Stillbirth		
Periods					
Period 1 ^a	1.00	1.00		1.00	
Period 2 ^b	1.01 (0.89 to 1.15)	1.12 (1.01 to 1.24)		1.03 (0.82 to 1.30)	
Period 3 ^c	1.01 (0.84 to 1.21)	1.24 (1.09 to 1.42)		1.05 (0.77 to 1.44)	
Global test 1 ^d	0.90			0.90	
Trend			IGLS algorithm failed to converge		IGLS algorithm failed to converge
All years ^e	1.05 (1.02 to 1.08)			0.99 (0.94 to 1.04)	
Interactions					
Interaction 1 ^f		0.98 (0.96 to 1.00)			
Interaction 2 ^g		1.02 (0.94 to 1.10)			
Interaction 3 ^h		1.02 (0.97 to 1.07)			
Global test 2 ⁱ	0.10	0.30		0.30	
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 55 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – maternal behaviour

TABLE 81 Subgroup of teen mothers (< 20 years old): maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.50 (−0.80 to 0.20)	1.08 (0.89 to 1.33)	0.92 (0.84 to 1.02)
Period 3 ^c	−1.30 (−1.60 to 0.90)	0.97 (0.75 to 1.27)	0.94 (0.82 to 1.07)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.16 (−0.22 to 0.11)	1.07 (1.03 to 1.12)	0.97 (0.95 to 0.99)
Interaction 2 ^g	−0.60 (−0.82 to 0.38)	1.07 (0.90 to 1.27)	1.00 (0.92 to 1.08)
Interaction 3 ^h	−0.30 (−0.51 to 0.18)	0.88 (0.77 to 1.01)	1.02 (0.96 to 1.08)
Global test 2 ⁱ	< 0.0001	0.03	0.30
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 56 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – measures of size

TABLE 82 Subgroup of teen mothers (< 20 years old): measures of size

	Measures of size				
Parameter	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a		1.00		0.00	0.00
Period 2 ^b		1.05 (0.84 to 1.33)		−0.01 (−0.07 to 0.04)	0.05 (−0.09 to 0.20)
Period 3 ^c		1.45 (1.06 to 1.99)		−0.10 (−0.20 to 0.03)	0.10 (−0.08 to 0.30)
Global test 1 ^d		0.01			
Trend	IGLS algorithm failed to converge		IGLS algorithm failed to converge		
All years ^e		0.93 (0.89 to 0.98)			
Interactions					
Interaction 1 ^f				0.002 (−0.008 to 0.01)	0.04 (0.02 to 0.07)
Interaction 2 ^g				−0.02 (−0.06 to 0.02)	0.05 (−0.06 to 0.20)
Interaction 3 ^h				−0.03 (−0.06 to 0.007)	0.05 (−0.04 to 0.10)
Global test 2 ⁱ		0.20		0.20	0.90
HBW, high birthweight; IGLS, iterative generalised least squares; LBW, low birthweight.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 57 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – measures of stage

TABLE 83 Subgroup of teen mothers (< 20 years old): measures of stage

Parameter	Measures of stage				
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI) LGA, OR (95% CI)
Periods					
Period 1 ^a	0.00	1.00		0.00	1.00 1.00
Period 2 ^b	−0.09 (−0.20 to 0.0006)	1.07 (0.89 to 1.29)		−0.006 (−0.04 to 0.03)	1.09 (0.92 to 1.29) 0.92 (0.77 to 1.10)
Period 3 ^c	−1.30 (−1.60 to 1.10)	1.33 (1.04 to 1.69)		−0.03 (−0.08 to 0.02)	1.26 (1.01 to 1.59) 1.03 (0.80 to 1.32)
Global test 1 ^d				0.30	0.10 0.30
Trend			IGLS algorithm failed to converge		
All years ^e				0.01 (0.004 to 0.02)	0.94 (0.91 to 0.97) 1.01 (0.97 to 1.05)
Interactions					
Interaction 1 ^f	0.05 (0.03 to 0.07)	0.93 (0.90 to 0.97)			
Interaction 2 ^g	0.20 (0.09 to 0.20)	0.72 (0.62 to 0.84)			
Interaction 3 ^h	0.03 (0.09 to 0.20)	0.86 (0.77 to 0.97)			
Global test 2 ⁱ	0.005	0.004		0.20	0.70 0.10
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 58 Results of analysis for the secondary outcomes using the imputed data: subgroup of teen mothers (< 20 years old) – birth outcomes

TABLE 84 Subgroup of teen mothers (< 20 years old): birth outcomes

Parameter	Birth outcomes, OR (95% CI)				
	Mode of delivery			5-minute Apgar score	Neonatal death
	Elective caesarean	Emergency caesarean	Stillbirth		
Periods					
Period 1 ^a	1.00	1.00	1.00		
Period 2 ^b	1.03 (0.77 to 1.38)	1.09 (0.95 to 1.25)	1.07 (0.56 to 2.05)		
Period 3 ^c	1.33 (0.89 to 1.98)	0.95 (0.76 to 1.20)	1.12 (0.45 to 2.77)		
Global test 1 ^d	0.20		0.90		
Trend				IGLS algorithm failed to converge	IGLS algorithm failed to converge
All years ^e	0.99 (0.93 to 1.05)		0.94 (0.83 to 1.08)		
Interactions					
Interaction 1 ^f		0.99 (0.96 to 1.02)			
Interaction 2 ^g		1.00 (0.89 to 1.11)			
Interaction 3 ^h		1.07 (0.98 to 1.17)			
Global test 2 ⁱ	0.20	0.20	0.20		
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 59 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – maternal behaviour

TABLE 85 Subgroup of non-white mothers: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.70 (−1.10 to 0.20)	1.10 (0.82 to 1.48)	0.82 (0.54 to 1.25)
Period 3 ^c	−1.70 (−2.40 to 1.00)	1.20 (0.79 to 1.84)	1.15 (0.62 to 2.11)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.02 (−0.10 to 0.10)	1.00 (0.93 to 1.08)	0.90 (0.81 to 0.99)
Interaction 2 ^g	−0.70 (−1.04 to 0.50)	1.11 (0.92 to 1.34)	0.97 (0.70 to 1.34)
Interaction 3 ^h	−0.10 (−0.30 to 0.04)	0.88 (0.78 to 0.99)	1.09 (0.91 to 1.31)
Global test 2 ⁱ	< 0.0001	0.07	0.20
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 60 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – measures of size

TABLE 86 Subgroup of non-white mothers: measures of size

Parameter	Measures of size				
	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods					
Period 1 ^a		1.00	1.00	0.00	0.00
Period 2 ^b		0.93 (0.66 to 1.30)	0.97 (0.76 to 1.24)	−0.06 (−0.10 to 0.03)	0.20 (−0.04 to 0.40)
Period 3 ^c		1.28 (0.79 to 2.07)	1.04 (0.72 to 1.49)	−0.20 (−0.30 to 0.05)	0.40 (0.03 to 0.70)
Global test 1 ^d		0.05	0.70		
Trend					
All years ^e	IGLS algorithm failed to converge	0.94 (0.87 to 1.01)	1.00 (0.94 to 1.06)		
Interactions					
Interaction 1 ^f				0.03 (0.004 to 0.05)	0.0006 (−0.05 to 0.06)
Interaction 2 ^g				−0.02 (−0.07 to 0.04)	0.06 (−0.08 to 0.20)
Interaction 3 ^h				−0.03 (−0.06 to 0.003)	0.03 (−0.06 to 0.10)
Global test 2 ⁱ		0.80	0.90	0.02	0.70
HBW, high birthweight; IGLS, iterative generalised least squares; LBW, low birthweight.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 61 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – measures of stage

TABLE 87 Subgroup of non-white mothers: measures of stage

	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)					
Parameter		Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00		0.00	1.00	1.00
Period 2 ^b	−0.04 (−0.20 to 0.08)	1.05 (0.75 to 1.46)		−0.02 (−0.07 to 0.03)	1.30 (1.01 to 1.67)	1.07 (0.81 to 1.40)
Period 3 ^c	−0.20 (−0.30 to 0.02)	1.23 (0.77 to 1.96)		−0.05 (−0.10 to 0.03)	1.45 (1.01 to 2.08)	0.97 (0.65 to 1.45)
Global test 1 ^d				0.30	0.10	0.50
Trend			IGLS algorithm failed to converge			
All years ^e				0.02 (0.004 to 0.03)	0.90 (0.85 to 0.96)	1.01 (0.94 to 1.08)
Interactions						
Interaction 1 ^f	0.04 (0.008 to 0.07)	0.93 (0.86 to 1.01)				
Interaction 2 ^g	0.20 (0.10 to 0.30)	0.72 (0.58 to 0.89)				
Interaction 3 ^h	0.06 (0.01 to 0.10)	0.91 (0.80 to 1.04)				
Global test 2 ⁱ	0.0002	0.08		0.30	0.60	0.80
IGLS, iterative generalised least squares.						
a Pre-intervention period.						
b Intervention HiP grant.						
c Post-intervention period.						
d Global test for the periods in which the interactions were not significant.						
e Trend over the study period 2004–13.						
f Trend pre intervention.						
g Trend during the HiP grant period.						
h Trend post intervention.						
i Global test for the interactions.						

Appendix 62 Results of analysis for the secondary outcomes using the imputed data: subgroup of non-white mothers – birth outcomes

TABLE 88 Subgroup of non-white mothers: birth outcomes

	Birth outcomes, OR (95% CI)				
	Mode of delivery		Stillbirth	5-minute Apgar score	Neonatal death
Parameter	Elective caesarean	Emergency caesarean			
Periods					
Period 1 ^a	1.00	1.00			
Period 2 ^b	1.02 (0.78 to 1.31)	1.05 (0.86 to 1.29)			
Period 3 ^c	1.10 (0.76 to 1.60)	0.94 (0.70 to 1.26)			
Global test 1 ^d	0.70				
Trend			IGLS algorithm failed to converge	IGLS algorithm failed to converge	IGLS algorithm failed to converge
All years ^e	1.09 (1.02 to 1.16)				
Interactions					
Interaction 1 ^f		1.00 (0.95 to 1.06)			
Interaction 2 ^g		0.90 (0.80 to 1.02)			
Interaction 3 ^h		1.10 (1.01 to 1.19)			
Global test 2 ⁱ	0.80	0.02			
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 63 Results of the main analysis for the secondary outcomes adjusted for ethnicity and using the complete cases: maternal behaviour

TABLE 89 Secondary outcomes adjusted for ethnicity and using the complete cases: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	-1.07 (-1.20 to 1.00)	1.36 (1.17 to 1.58)	0.94 (0.88 to 1.01)
Period 3 ^c	-2.40 (-2.60 to 2.30)	1.56 (1.25 to 1.94)	1.15 (0.62 to 2.11)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	0.02 (-0.01 to 0.05)	1.01 (0.97 to 1.05)	0.97 (0.95 to 0.99)
Interaction 2 ^g	-1.00 (-1.02 to 0.90)	1.24 (1.13 to 1.37)	0.96 (0.92 to 1.00)
Interaction 3 ^h	-0.31 (-0.35 to 0.27)	0.96 (0.91 to 1.02)	1.01 (0.98 to 1.03)
Global test 2 ⁱ	< 0.0001	< 0.0001	0.20
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>			

Appendix 64 Results of the main analysis for the primary and secondary outcomes adjusted for ethnicity and using the complete cases: measures of size

TABLE 90 Primary and secondary outcomes adjusted for ethnicity and using the complete cases: measures of size

		Measures of size				
Parameter	Birthweight (g), coefficient (95% CI)	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	−12.80 (−20.90 to −4.60)	1.34 (0.83 to 2.17)	1.12 (0.98 to 1.28)	0.95 (0.89 to 1.02)	−0.01 (−0.04 to 0.02)	0.16 (0.09 to 0.23)
Period 3 ^c	−16.50 (−28.60 to 4.50)	1.89 (0.94 to 3.81)	1.23 (1.01 to 1.49)	0.94 (0.85 to 1.04)	−0.08 (−0.10 to 0.04)	0.30 (0.20 to 0.40)
Global test 1 ^d	0.009	0.20	0.05			
Trend						
All years ^e	5.90 (3.80 to 8.00)	0.88 (0.78 to 0.99)	0.95 (0.92 to 0.99)	1.01 (0.99 to 1.03)		
Interactions						
Interaction 1 ^f					0.003 (−0.005 to 0.01)	0.01 (−0.009 to 0.03)
Interaction 2 ^g					−0.01 (−0.03 to 0.004)	0.11 (0.07 to 0.15)
Interaction 3 ^h					−0.07 (−0.08 to 0.06)	0.03 (0.01 to 0.05)
Global test 2 ⁱ	0.30	0.70	0.07	0.30	< 0.0001	0.0001
HBW, high birthweight; LBW, low birthweight.						
a Pre-intervention period.						
b Intervention HiP grant.						
c Post-intervention period.						
d Global test for the periods in which the interactions were not significant.						
e Trend over the study period 2004–13.						
f Trend pre intervention.						
g Trend during the HiP grant period.						
h Trend post intervention.						
i Global test for the interactions.						

Appendix 65 Results of the main analysis for the secondary outcomes adjusted for ethnicity and using the complete cases: measures of stage

TABLE 91 Secondary outcomes adjusted for ethnicity and using the complete cases: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.03 (−0.06 to 0.005)	1.03 (0.91 to 1.16)	1.11 (0.84 to 1.47)	−0.03 (−0.05 to 0.01)	1.09 (0.98 to 1.20)	0.97 (0.90 to 1.04)
Period 3 ^c	−0.14 (−0.18 to 0.11)	1.26 (1.06 to 1.51)	1.54 (1.03 to 2.31)	−0.04 (−0.06 to 0.01)	1.16 (1.00 to 1.34)	0.96 (0.86 to 1.08)
Global test 1 ^d				0.009	0.20	0.70
Trend						
All years ^e				0.01 (0.008 to 0.02)	0.95 (0.92 to 0.97)	1.00 (0.98 to 1.02)
Interactions						
Interaction 1 ^f	0.018 (0.012 to 0.024)	0.96 (0.93 to 0.99)	0.93 (0.87 to 1.00)			
Interaction 2 ^g	0.14 (0.13 to 0.16)	0.70 (0.65 to 0.75)	0.57 (0.49 to 0.66)			
Interaction 3 ^h	0.04 (0.02 to 0.05)	0.86 (0.83 to 0.89)	0.71 (0.65 to 0.77)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.10	0.80	0.70
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 66 Results of the main analysis for the secondary outcomes adjusted for ethnicity and using the complete cases: birth outcomes

TABLE 92 Secondary outcomes adjusted for ethnicity and using the complete cases: birth outcomes

Parameter	Birth outcomes				
	Mode of delivery				
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	1.00
Period 2 ^b	1.03 (0.96 to 1.12)	1.00 (0.93 to 1.08)	0.91 (0.69 to 1.21)	0.86 (0.72 to 1.03)	2.84 (1.26 to 6.38)
Period 3 ^c	1.03 (0.92 to 1.15)	1.12 (1.05 to 1.19)	0.80 (0.53 to 1.20)	0.79 (0.61 to 1.03)	2.74 (0.85 to 8.86)
Global test 1 ^d	0.60		0.50	0.20	0.002
Trend					
All years ^e	1.06 (1.03 to 1.08)		0.92 (0.86 to 0.99)	1.02 (0.97 to 1.07)	0.78 (0.64 to 0.94)
Interactions					
Interaction 1 ^f		1.00 (0.98 to 1.02)			
Interaction 2 ^g		0.94 (0.91 to 0.99)			
Interaction 3 ^h		1.00 (0.98 to 1.03)			
Global test 2 ⁱ	0.50	0.90	0.50	0.60	0.03
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>					

Appendix 67 Results of analysis for the secondary outcomes using the imputed data: subgroup of nulliparous mothers – maternal behaviour

TABLE 93 Subgroup of nulliparous mothers: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.33 (−0.43 to 0.23)	1.08 (0.98 to 1.19)	1.01 (0.90 to 1.13)
Period 3 ^c	−1.01 (−1.14 to 0.88)	0.87 (0.77 to 0.98)	1.17 (1.10 to 1.25)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.15 (−0.17 to 0.13)	1.09 (1.07 to 1.11)	0.92 (0.91 to 0.93)
Interaction 2 ^g	−0.53 (−0.60 to 0.45)	1.03 (0.95 to 1.11)	0.92 (0.88 to 0.96)
Interaction 3 ^h	−0.19 (−0.24 to 0.14)	0.87 (0.82 to 0.92)	1.02 (0.99 to 1.05)
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001
a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.			

Appendix 68 Results of analysis for the primary and secondary outcomes using the imputed data: subgroup of nulliparous mothers – measures of size

TABLE 94 Subgroup of nulliparous mothers: measures of size

		Measures of size				
Parameter	Birthweight (g), coefficient (95% CI)	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference (cm), coefficient (95% CI)	Crown-to-heel length (cm), coefficient (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	−0.20 (−6.80 to 6.40)	0.74 (0.54 to 1.03)	0.98 (0.90 to 1.08)	0.98 (0.90 to 1.08)	−0.05 (−0.07 to 0.03)	0.07 (0.02 to 0.10)
Period 3 ^c	1.30 (−7.90 to 10.60)	0.74 (0.47 to 1.16)	1.00 (0.88 to 1.13)	1.00 (0.88 to 1.13)	−0.12 (−0.14 to 0.09)	0.20 (0.10 to 0.30)
Global test 1 ^d	0.90	0.20	0.90	0.90		
Trend						
All years ^e	1.92 (0.50 to 3.34)	1.04 (0.97 to 1.12)	0.99 (0.97 to 1.01)	0.99 (0.97 to 1.01)		
Interactions						
Interaction 1 ^f					0.004 (−0.0004 to 0.008)	0.03 (0.02 to 0.04)
Interaction 2 ^g					−0.03 (−0.05 to 0.01)	0.06 (0.02 to 0.10)
Interaction 3 ^h					−0.04 (−0.05 to 0.02)	0.07 (0.04 to 0.09)
Global test 2 ⁱ	0.90	0.90	0.20	0.20	< 0.0001	0.02
HBW, high birthweight; LBW, low birthweight.						
a Pre-intervention period.						
b Intervention HiP grant.						
c Post-intervention period.						
d Global test for the periods in which the interactions were not significant.						
e Trend over the study period 2004–13.						
f Trend pre intervention.						
g Trend during the HiP grant period.						
h Trend post intervention.						
i Global test for the interactions.						

Appendix 69 Results of analysis for the secondary outcomes using the imputed data: subgroup of nulliparous mothers – measures of stage

TABLE 95 Subgroup of nulliparous mothers: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.07 (−0.10 to 0.04)	1.02 (0.94 to 1.10)	1.11 (0.93 to 1.31)	−0.002 (−0.02 to 0.01)	0.96 (0.90 to 1.03)	0.98 (0.92 to 1.04)
Period 3 ^c	−0.24 (−0.29 to 0.20)	1.23 (1.11 to 1.35)	1.56 (1.25 to 1.94)	−0.001 (−0.02 to 0.02)	0.98 (0.90 to 1.08)	1.00 (0.91 to 1.09)
Global test 1 ^d				0.90	0.30	0.60
Trend						
All years ^e				0.005 (0.001 to 0.008)	0.98 (0.97 to 0.99)	1.00 (0.98 to 1.01)
Interactions						
Interaction 1 ^f	0.04 (0.03 to 0.05)	0.96 (0.94 to 0.97)	0.92 (0.89 to 0.96)			
Interaction 2 ^g	0.17 (0.15 to 0.20)	0.72 (0.68 to 0.77)	0.60 (0.52 to 0.68)			
Interaction 3 ^h	0.06 (0.04 to 0.08)	0.86 (0.82 to 0.90)	0.73 (0.67 to 0.80)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.90	0.50	0.20
<p>a Pre-intervention period. b Intervention HiP grant. c Post-intervention period. d Global test for the periods in which the interactions were not significant. e Trend over the study period 2004–13. f Trend pre intervention. g Trend during the HiP grant period. h Trend post intervention. i Global test for the interactions.</p>						

Appendix 70 Results of analysis for the secondary outcomes using the imputed data: subgroup of nulliparous mothers – birth outcomes

TABLE 96 Subgroup of nulliparous mothers: birth outcomes

Parameter	Birth outcomes				
	Mode of delivery			5-minute Apgar score OR (95% CI)	Neonatal death OR (95% CI)
	Elective caesarean OR (95% CI)	Emergency caesarean OR (95% CI)	Stillbirth OR (95% CI)		
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	
Period 2 ^b	1.20 (1.11 to 1.30)	1.00 (0.95 to 1.04)	1.01 (0.79 to 1.30)	0.87 (0.77 to 0.99)	
Period 3 ^c	1.38 (1.24 to 1.1.54)	1.06 (1.00 to 1.12)	1.01 (0.71 to 1.44)	0.81 (0.68 to 0.97)	
Global test 1 ^d	< 0.0001		0.90	0.06	
Trend					IGLS algorithm failed to converge
All years ^e	0.97 (0.95 to 0.98)		0.98 (0.93 to 1.03)	1.03 (1.00 to 1.06)	
Interactions					
Interaction 1 ^f		1.01 (1.00 to 1.02)			
Interaction 2 ^g		1.05 (1.01 to 1.08)			
Interaction 3 ^h		1.02 (1.00 to 1.04)			
Global test 2 ⁱ	0.20	0.10	0.10	0.60	
IGLS, iterative generalised least squares.					
a Pre-intervention period.					
b Intervention HiP grant.					
c Post-intervention period.					
d Global test for the periods in which the interactions were not significant.					
e Trend over the study period 2004–13.					
f Trend pre intervention.					
g Trend during the HiP grant period.					
h Trend post intervention.					
i Global test for the interactions.					

Appendix 71 Impact of restricting the pre-intervention period to the period after the smoking ban: maternal behaviour

TABLE 97 Impact of restricting the pre-intervention period to the period after the smoking ban: maternal behaviour

Parameter	Maternal behaviour		
	Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Maternal smoking during this pregnancy, OR (95% CI)
Periods			
Period 1 ^a	0.00	1.00	1.00
Period 2 ^b	−0.17 (−0.28 to 0.06)	1.05 (0.92 to 1.20)	1.01 (0.95 to 1.08)
Period 3 ^c	−0.80 (−1.00 to 0.60)	0.84 (0.67 to 1.06)	1.16 (1.03 to 1.30)
Global test 1 ^d			
Trend			
All years ^e			
Interactions			
Interaction 1 ^f	−0.22 (−0.27 to 0.18)	1.11 (1.06 to 1.17)	0.92 (0.90 to 0.94)
Interaction 2 ^g	−0.58 (−0.64 to 0.55)	1.11 (1.05 to 1.18)	0.92 (0.90 to 0.95)
Interaction 3 ^h	−0.21 (−0.24 to 0.18)	0.88 (0.84 to 0.91)	0.99 (0.97 to 1.01)
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>			

Appendix 72 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of size

TABLE 98 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of size

		Measures of size				
Parameter	Birthweight (g), coefficient (95% CI)	Very LBW, OR (95% CI)	LBW, OR (95% CI)	HBW, OR (95% CI)	Head circumference, coefficient (95% CI)	Crown-to-heel length, coefficient (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	1.00	0.00	0.00
Period 2 ^b	−0.80 (−6.10 to 4.50)	0.93 (0.69 to 1.25)	1.06 (0.98 to 1.15)	0.99 (0.95 to 1.03)	0.008 (−0.02 to 0.03)	0.09 (0.03 to 0.20)
Period 3 ^c	−0.10 (−9.50 to 9.30)	1.09 (0.65 to 1.82)	1.16 (1.00 to 1.34)	1.00 (0.93 to 1.08)	−0.02 (−0.06 to 0.03)	0.30 (0.20 to 0.40)
Global test 1 ^d	0.90	0.40	0.10	0.80		
Trend						
All years ^e	2.40 (0.40 to 4.40)	0.96 (0.86 to 1.07)	0.96 (0.93 to 0.99)	1.00 (0.98 to 1.01)		
Interactions						
Interaction 1 ^f					−0.01 (−0.02 to 0.004)	0.009 (−0.02 to 0.03)
Interaction 2 ^g					−0.03 (−0.04 to 0.01)	0.07 (0.05 to 0.1)
Interaction 3 ^h					−0.034 (−0.042 to 0.026)	0.04 (0.02 to 0.06)
Global test 2 ⁱ	0.30	0.50	0.07	0.70	0.007	0.001
HBW, high birthweight; LBW, low birthweight.						
a Pre-intervention period.						
b Intervention HiP grant.						
c Post-intervention period.						
d Global test for the periods in which the interactions were not significant.						
e Trend over the study period 2004–13.						
f Trend pre intervention.						
g Trend during the HiP grant period.						
h Trend post intervention.						
i Global test for the interactions.						

Appendix 73 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of stage

TABLE 99 Impact of restricting the pre-intervention period to the period after the smoking ban: measures of stage

Parameter	Measures of stage					
	Gestational age at delivery (weeks), coefficient (95% CI)	Preterm, OR (95% CI)	Very preterm, OR (95% CI)	z-score, coefficient (95% CI)	SGA, OR (95% CI)	LGA, OR (95% CI)
Periods						
Period 1 ^a	0.00	1.00	1.00	0.00	1.00	1.00
Period 2 ^b	−0.40 (−0.44 to 0.36)	1.81 (1.64 to 2.01)	3.80 (2.96 to 4.87)	−0.003 (−0.01 to 0.009)	1.01 (0.94 to 1.07)	1.00 (0.95 to 1.05)
Period 3 ^c	−0.87 (−0.94 to 0.80)	3.69 (3.10 to 4.40)	15.27 (10.03 to 23.25)	−0.002 (−0.02 to 0.02)	1.01 (0.91 to 1.13)	1.01 (0.93 to 1.10)
Global test 1 ^d				0.80	0.90	0.80
Trend						
All years ^e				0.004 (0.0006 to 0.009)	0.97 (0.95 to 0.997)	0.99 (0.97 to 1.01)
Interactions						
Interaction 1 ^f	0.19 (0.18 to 0.21)	0.74 (0.71 to 0.77)	0.54 (0.49 to 0.59)			
Interaction 2 ^g	0.17 (0.15 to 0.18)	0.72 (0.69 to 0.75)	0.59 (0.53 to 0.65)			
Interaction 3 ^h	0.06 (0.05 to 0.07)	0.85 (0.83 to 0.88)	0.70 (0.65 to 0.74)			
Global test 2 ⁱ	< 0.0001	< 0.0001	< 0.0001	0.20	0.30	0.30
<p>a Pre-intervention period.</p> <p>b Intervention HiP grant.</p> <p>c Post-intervention period.</p> <p>d Global test for the periods in which the interactions were not significant.</p> <p>e Trend over the study period 2004–13.</p> <p>f Trend pre intervention.</p> <p>g Trend during the HiP grant period.</p> <p>h Trend post intervention.</p> <p>i Global test for the interactions.</p>						

Appendix 74 Impact of restricting the pre-intervention period to the period after the smoking ban: birth outcomes

TABLE 100 Impact of restricting the pre-intervention period to the period after the smoking ban: birth outcomes

Imputed	Birth outcomes				
	Mode of delivery				
	Elective caesarean, OR (95% CI)	Emergency caesarean, OR (95% CI)	Stillbirth, OR (95% CI)	5-minute Apgar score, OR (95% CI)	Neonatal death, OR (95% CI)
Periods					
Period 1 ^a	1.00	1.00	1.00	1.00	1.00
Period 2 ^b	1.06 (1.01 to 1.12)	1.12 (1.05 to 1.19)	1.08 (0.86 to 1.35)	0.94 (0.84 to 1.05)	2.08 (1.26 to 3.44)
Period 3 ^c	1.19 (1.09 to 1.31)	1.28 (1.14 to 1.44)	1.08 (0.73 to 1.60)	0.93 (0.76 to 1.14)	2.08 (0.86 to 5.04)
Global test 1 ^d	0.0001		0.70	0.50	0.004
Trend					
All years ^e	1.03 (1.01 to 1.05)		0.93 (0.86 to 1.01)	0.99 (0.95 to 1.04)	0.84 (0.69 to 1.01)
Interactions					
Interaction 1 ^f		0.96 (0.94 to 0.99)			
Interaction 2 ^g		1.02 (0.99 to 1.05)			
Interaction 3 ^h		1.00 (0.98 to 1.02)			
Global test 2 ⁱ	0.04	0.005	0.30	0.80	0.10
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>					

Appendix 75 Impact of moving the real Health in Pregnancy grant period: restriction to 18 months

TABLE 101 Impact of moving the real HiP grant period: restriction to 18 months

Imputed	Birthweight (g), coefficient 95% CI	Booking status		Measures of stage, OR (95% CI)		Other birth outcomes, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	1.00
Period 2 ^b	−1.80 (−6.10 to 2.50)	−0.25 (−0.32 to 0.17)	1.12 (1.03 to 1.22)	0.90 (0.84 to 0.96)	0.93 (0.80 to 1.08)	1.98 (1.31 to 2.98)
Period 3 ^c	−5.10 (−10.70 to 0.50)	−1.07 (−1.20 to 1.00)	0.90 (0.82 to 0.98)	1.17 (1.09 to 1.25)	1.34 (1.15 to 1.57)	1.90 (1.09 to 3.29)
Global test 1 ^d	0.20					0.005
Trend						
All years ^e	3.30 (2.40 to 4.20)					0.89 (0.82 to 0.97)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.13)	1.09 (1.08 to 1.11)	0.96 (0.95 to 0.97)	0.93 (0.91 to 0.96)	
Interaction 2 ^g		−0.47 (−0.54 to 0.39)	1.13 (1.04 to 1.24)	0.68 (0.64 to 0.72)	0.57 (0.49 to 0.65)	
Interaction 3 ^h		−0.28 (−0.31 to 0.26)	0.92 (0.89 to 0.95)	0.88 (0.86 to 0.90)	0.75 (0.71 to 0.79)	
Global test 2 ⁱ	0.20	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.04
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 76 Impact of moving the real Health in Pregnancy grant period: extension to 30 months

TABLE 102 Impact of moving the real HiP grant period: extension to 30 months

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Other birth outcomes, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	1.00
Period 2 ^b	−3.00 (−7.40 to 1.30)	−0.37 (−0.44 to −0.31)	1.10 (1.03 to 1.17)	1.10 (1.04 to 1.16)	1.28 (1.14 to 1.44)	1.76 (1.16 to 2.66)
Period 3 ^c	−7.20 (−13.60 to 0.90)	−1.15 (−1.24 to 1.06)	0.92 (0.84 to 1.02)	1.30 (1.21 to 1.39)	1.30 (1.21 to 1.39)	1.26 (0.68 to 2.34)
Global test 1 ^d	0.06					0.001
Trend						
All years ^e	3.50 (2.6 to 4.4)					0.93 (0.85 to 1.01)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.13)	1.09 (1.08 to 1.11)	0.96 (0.95 to 0.97)	0.93 (0.91 to 0.96)	
Interaction 2 ^g		−0.62 (−0.66 to 0.59)	1.11 (1.06 to 1.16)	0.83 (0.81 to 0.86)	0.78 (0.73 to 0.84)	
Interaction 3 ^h		−0.10 (−0.20 to 0.09)	0.86 (0.82 to 0.91)	0.77 (0.74 to 0.80)	0.59 (0.54 to 0.65)	
Global test 2 ⁱ	0.70	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.20
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 77 Impact of moving the real Health in Pregnancy grant period: exclusion of births that occurred during the 2009 swine flu outbreak

TABLE 103 Impact of moving the real HiP grant period: exclusion of births that occurred during the 2009 swine flu outbreak

Imputed	Birthweight (g), coefficient 95% CI	Booking status		Measures of stage, OR (95% CI)		Other birth outcomes, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	1.00
Period 2 ^b	−4.40 (−9.00 to 0.20)	−0.36 (−0.43 to 0.30)	1.09 (1.02 to 1.17)	1.07 (1.01 to 1.13)	1.19 (1.04 to 1.34)	1.97 (1.27 to 3.06)
Period 3 ^c	−6.40 (−12.50 to 0.30)	−1.10 (−1.20 to 1.00)	0.90 (0.83 to 1.00)	1.22 (1.14 to 1.31)	1.46 (1.24 to 1.71)	1.56 (0.86 to 2.84)
Global test 1 ^d	0.10					0.003
Trend						
All years ^e	3.40 (2.40 to 4.30)					0.91 (0.83 to 0.99)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.13)	1.09 (1.08 to 1.11)	0.96 (0.95 to 0.97)	0.93 (0.91 to 0.95)	
Interaction 2 ^g		−0.54 (−0.60 to 0.48)	1.13 (1.04 to 1.22)	0.62 (0.59 to 0.65)	0.45 (0.40 to 0.51)	
Interaction 3 ^h		−0.21 (−0.24 to 0.17)	0.88 (0.84 to 0.91)	0.86 (0.83 to 0.88)	0.71 (0.66 to 0.76)	
Global test 2 ⁱ	0.30	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.09
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 78 Impact of moving the start of the intervention period to one year before the real Health in Pregnancy grant period: 24-month intervention period

TABLE 104 Impact of moving the start of the intervention period to 1 year before the real HiP grant period: 24-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	2.20 (−2.10 to 6.50)	−0.20 (−0.30 to 0.07)	1.23 (1.09 to 1.38)	0.88 (0.80 to 0.97)	0.82 (0.66 to 1.01)	1.85 (1.22 to 2.81)
Period 3 ^c	−1.70 (−8.30 to 5.00)	−1.23 (−1.35 to 1.11)	0.99 (0.88 to 1.12)	1.41 (1.27 to 1.56)	1.91 (1.52 to 2.41)	2.11 (1.10 to 4.03)
Global test 1 ^d	0.07					0.02
Trend						
All years ^e	2.8 (1.80 to 3.9)					0.88 (0.79 to 0.97)
Interactions						
Interaction 1 ^f		−0.11 (−0.13 to 0.10)	1.08 (1.06 to 1.10)	0.93 (0.92 to 0.95)	0.89 (0.86 to 0.92)	
Interaction 2 ^g		−0.16 (−0.21 to 0.11)	1.15 (1.09 to 1.22)	0.72 (0.69 to 0.75)	0.57 (0.52 to 0.63)	
Interaction 3 ^h		−0.37 (−0.39 to 0.35)	0.94 (0.92 to 0.97)	0.92 (0.90 to 0.93)	0.82 (0.79 to 0.85)	
Global test 2 ⁱ	0.90	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.10
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 79 Impact of moving the start of the intervention period to 1 year before the real Health in Pregnancy grant period: 18-month intervention period

TABLE 105 Impact of moving the start of the intervention period to 1 year before the real HiP grant period: 18-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	1.00
Period 2 ^b	3.10 (−1.10 to 7.30)	−0.030 (−0.20 to 0.10)	1.17 (1.00 to 1.38)	0.79 (0.70 to 0.90)	0.67 (0.50 to 0.88)	1.88 (1.25 to 2.83)
Period 3 ^c	−1.50 (−7.40 to 4.40)	−1.20 (−1.30 to 1.10)	0.99 (0.88 to 1.12)	1.37 (1.24 to 1.51)	1.81 (1.44 to 2.28)	2.78 (1.56 to 4.95)
Global test 1 ^d	0.03					0.002
Trend						
All years ^e	2.80 (1.90 to 3.80)					0.84 (0.77 to 0.92)
Interactions						
Interaction 1 ^f		−0.12 (−0.13 to 0.10)	1.08 (1.06 to 1.10)	0.94 (0.92 to 0.95)	0.89 (0.86 to 0.92)	
Interaction 2 ^g		−0.07 (−0.10 to 0.002)	1.12 (1.03 to 1.22)	0.71 (0.67 to 0.75)	0.54 (0.47 to 0.63)	
Interaction 3 ^h		−0.43 (−0.45 to 0.42)	0.96 (0.94 to 0.98)	0.92 (0.91 to 0.94)	0.85 (0.82 to 0.88)	
Global test 2 ⁱ	0.50	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.30
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 80 Impact of moving the start of the intervention period to 1 year before the real Health in Pregnancy grant period: 30-month intervention period

TABLE 106 Impact of moving the start of the intervention period to 1 year before the real HiP grant period: 30-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	2.50 (−2.00 to 6.90)	−0.30 (−0.40 to 0.20)	1.21 (1.09 to 1.34)	1.05 (0.97 to 1.14)	1.20 (0.99 to 1.43)	1.97 (1.28 to 3.05)
Period 3 ^c	0.20 (−6.90 to 7.30)	−1.20 (−1.40 to 1.10)	1.00 (0.88 to 1.13)	1.41 (1.28 to 1.56)	1.90 (1.51 to 2.40)	2.43 (1.22 to 4.86)
Global test 1 ^d	0.2					0.009
Trend						
All years ^e	2.60 (1.50 to 3.70)					0.86 (0.78 to 0.96)
Interactions						
Interaction 1 ^f		−0.12 (−0.13 to 0.10)	1.08 (1.06 to 1.10)	0.94 (0.92 to 0.95)	0.89 (0.86 to 0.92)	
Interaction 2 ^g		−0.24 (−0.28 to 0.20)	1.14 (1.09 to 1.19)	0.81 (0.78 to 0.83)	0.72 (0.68 to 0.78)	
Interaction 3 ^h		−0.28 (−0.30 to 0.26)	0.92 (0.89 to 0.95)	0.87 (0.85 to 0.89)	0.75 (0.71 to 0.79)	
Global test 2 ⁱ	0.60	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.05
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 81 Impact of moving the start of the intervention period to 6 months before the real Health in Pregnancy grant period: 24-month intervention period

TABLE 107 Impact of moving the start of the intervention period to 6 months before the real HiP grant period: 24-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	0.09 (−4.20 to 4.40)	−0.24 (−0.32 to 0.16)	1.16 (1.06 to 1.27)	0.88 (0.82 to 0.94)	0.87 (0.74 to 1.02)	1.64 (1.08 to 2.49)
Period 3 ^c	−3.10 (−9.50 to 3.30)	−0.60 (−0.70 to 0.40)	0.96 (0.87 to 1.07)	1.22 (1.12 to 1.32)	1.49 (1.24 to 1.80)	1.73 (0.94 to 3.20)
Global test 1 ^d	0.30					0.07
Trend						
All years ^e	3.04 (2.00 to 4.00)					0.90 (0.82 to 0.99)
Interactions						
Interaction 1 ^f		−0.13 (−0.15 to 0.12)	1.08 (1.07 to 1.10)	0.96 (0.94 to 0.97)	0.92 (0.90 to 0.95)	
Interaction 2 ^g		−0.31 (−0.35 to 0.26)	1.10 (1.04 to 1.17)	0.70 (0.67 to 0.73)	0.56 (0.51 to 0.62)	
Interaction 3 ^h		−0.28 (−0.31 to 0.26)	0.92 (0.89 to 0.95)	0.87 (0.85 to 0.89)	0.74 (0.70 to 0.78)	
Global test 2 ⁱ	0.60	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.02
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 82 Impact of moving the start of the intervention period to 6 months before the real Health in Pregnancy grant period: 18-month intervention period

TABLE 108 Impact of moving the start of the intervention period to 6 months before the real HiP grant period: 18-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	0.50 (−3.80 to 4.80)	−0.10 (−0.20 to 0.01)	1.15 (1.03 to 1.29)	0.64 (0.59 to 0.70)	0.47 (0.38 to 0.58)	1.60 (1.07 to 2.40)
Period 3 ^c	−3.70 (−9.40 to 2.10)	−1.10 (−1.20 to 1.00)	0.95 (0.86 to 1.06)	1.20 (1.11 to 1.31)	1.47 (1.22 to 1.77)	1.60 (0.91 to 2.80)
Global test 1 ^d	0.10					0.08
Trend						
All years ^e	3.10 (2.20 to 4.10)					0.91 (0.83 to 1.00)
Interactions						
Interaction 1 ^f		−0.13 (−0.15 to 0.12)	1.08 (1.07 to 1.10)	0.95 (0.94 to 0.97)	0.92 (0.89 to 0.95)	
Interaction 2 ^g		−0.22 (−0.29 to 0.15)	1.10 (1.01 to 1.19)	0.55 (0.52 to 0.59)	0.37 (0.32 to 0.42)	
Interaction 3 ^h		−0.38 (−0.40 to 0.36)	0.94 (0.92 to 0.97)	0.92 (0.90 to 0.94)	0.82 (0.79 to 0.86)	
Global test 2 ⁱ	0.90	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.05
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 83 Impact of moving the start of the intervention period to 6 months before the real Health in Pregnancy grant period: 30-month intervention period

TABLE 109 Impact of moving the start of the intervention period to 6 months before the real HiP grant period: 30-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	0.03 (−4.40 to 4.50)	−0.37 (−0.44 to 0.30)	1.15 (1.06 to 1.24)	1.00 (0.94 to 1.06)	1.06 (0.92 to 1.23)	1.50 (0.98 to 2.28)
Period 3 ^c	−1.90 (−8.60 to 4.80)	−1.10 (−1.20 to 1.05)	0.98 (0.88 to 1.08)	1.25 (1.15 to 1.36)	1.58 (1.31 to 1.90)	1.27 (0.67 to 2.43)
Global test 1 ^d	0.60					
Trend						
All years ^e	2.90 (1.80 to 3.90)					0.94 (0.85 to 1.03)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.12)	1.08 (1.07 to 1.10)	0.96 (0.94 to 0.97)	0.92 (0.90 to 0.95)	
Interaction 2 ^g		−0.44 (−0.48 to 0.41)	1.09 (1.04 to 1.14)	0.76 (0.74 to 0.78)	0.64 (0.60 to 0.69)	
Interaction 3 ^h		−0.21 (−0.24 to 0.18)	0.88 (0.84 to 0.91)	0.86 (0.84 to 0.89)	0.71 (0.66 to 0.76)	
Global test 2 ⁱ	0.30	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.04
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 84 Impact of moving the start of the intervention period to 6 months after the real Health in Pregnancy grant period: 24-month intervention period

TABLE 110 Impact of moving the start of the intervention period to 6 months after the real HiP grant period: 24-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	−4.70 (−8.80 to 0.50)	−0.39 (−0.45 to 0.33)	1.09 (1.020 to 1.17)	1.14 (1.09 to 1.20)	1.34 (1.20 to 1.48)	1.43 (0.97 to 2.11)
Period 3 ^c	−8.20 (−13.90 to 2.60)	−1.20 (−1.30 to 1.10)	0.90 (0.82 to 0.98)	1.25 (1.18 to 1.33)	1.49 (1.30 to 1.72)	0.91 (0.53 to 1.58)
Global test 1 ^d	0.02					0.007
Trend						
All years ^e	3.70 (2.80 to 4.50)					0.97 (0.90 to 1.05)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.12)	1.10 (1.08 to 1.11)	0.97 (0.96 to 0.98)	0.95 (0.93 to 0.97)	
Interaction 2 ^g		−0.65 (−0.70 to 0.60)	1.08 (1.02 to 1.15)	0.73 (0.70 to 0.76)	0.63 (0.58 to 0.70)	
Interaction 3 ^h		−0.10 (−0.20 to 0.09)	0.86 (0.82 to 0.91)	0.75 (0.72 to 0.78)	0.56 (0.51 to 0.61)	
Global test 2 ⁱ	0.80	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.10
^a Pre-intervention period. ^b Intervention HiP grant. ^c Post-intervention period. ^d Global test for the periods in which the interactions were not significant. ^e Trend over the study period 2004–13. ^f Trend pre intervention. ^g Trend during the HiP grant period. ^h Trend post intervention. ⁱ Global test for the interactions.						

Appendix 85 Impact of moving the start of the intervention period to 6 months after the real Health in Pregnancy grant period: 18-month intervention period

TABLE 111 Impact of moving the start of the intervention period to 6 months after the real HiP grant period: 18-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	−4.50 (−8.80 to 0.30)	−0.36 (−0.42 to 0.31)	1.08 (1.01 to 1.16)	1.04 (0.99 to 1.09)	1.09 (0.98 to 1.23)	1.51 (1.02 to 2.23)
Period 3 ^c	−5.80 (−11.10 to 0.60)	−1.14 (−1.21 to 1.07)	0.89 (0.82 to 0.96)	1.16 (1.09 to 1.23)	1.31 (1.15 to 1.51)	1.09 (0.66 to 1.81)
Global test 1 ^d	0.06					0.03
Trend						
All years ^e	3.40 (2.60 to 4.30)					0.96 (0.88 to 1.03)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.12)	1.10 (1.08 to 1.11)	0.97 (0.96 to 0.98)	0.95 (0.93 to 0.97)	
Interaction 2 ^g		−0.60 (−0.70 to 0.50)	1.06 (0.98 to 1.16)	0.56 (0.53 to 0.60)	0.40 (0.35 to 0.45)	
Interaction 3 ^h		−0.21 (−0.24 to 0.18)	0.88 (0.84 to 0.91)	0.86 (0.84 to 0.89)	0.71 (0.66 to 0.76)	
Global test 2 ⁱ	0.40	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.04
<div><div>a</div> Pre-intervention period.</div> <div><div>b</div> Intervention HiP grant.</div> <div><div>c</div> Post-intervention period.</div> <div><div>d</div> Global test for the periods in which the interactions were not significant.</div> <div><div>e</div> Trend over the study period 2004–13.</div> <div><div>f</div> Trend pre intervention.</div> <div><div>g</div> Trend during the HiP grant period.</div> <div><div>h</div> Trend post intervention.</div> <div><div>i</div> Global test for the interactions.</div>						

Appendix 86 Impact of moving the start of the intervention period to 6 months after the real Health in Pregnancy grant period: 30-month intervention period

TABLE 112 Impact of moving the start of the intervention period to 6 months after the real HiP grant period: 30-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	−4.90 (−9.10 to 0.70)	−0.40 (−0.50 to 0.30)	1.090 (1.02 to 1.17)	1.19 (1.13 to 1.25)	1.42 (1.28 to 1.57)	1.36 (0.92 to 2.01)
Period 3 ^c	−6.40 (−12.30 to 0.50)	−1.30 (−1.40 to 1.20)	0.93 (0.84 to 1.02)	1.34 (1.25 to 1.44)	1.66 (1.42 to 1.94)	0.72 (0.40 to 1.29)
Global test 1 ^d	0.06					0.001
Trend						
All years ^e	3.50 (2.60 to 4.30)					0.98 (0.91 to 1.06)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.12)	1.10 (1.08 to 1.11)	0.97 (0.96 to 0.98)	0.95 (0.93 to 0.97)	
Interaction 2 ^g		−0.59 (−0.62 to 0.55)	1.05 (1.01 to 1.10)	0.78 (0.75 to 0.80)	0.69 (0.64 to 0.74)	
Interaction 3 ^h		−0.02 (−0.08 to 0.04)	0.82 (0.76 to 0.89)	0.74 (0.70 to 0.79)	0.56 (0.50 to 0.64)	
Global test 2 ⁱ	0.60	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.50
^a Pre-intervention period. ^b Intervention HiP grant. ^c Post-intervention period. ^d Global test for the periods in which the interactions were not significant. ^e Trend over the study period 2004–13. ^f Trend pre intervention. ^g Trend during the HiP grant period. ^h Trend post intervention. ⁱ Global test for the interactions.						

Appendix 87 Impact of moving the start of the intervention period to 1 year after the real Health in Pregnancy grant period: 24-month intervention period

TABLE 113 Impact of moving the start of the intervention period to 1 year after the real HiP grant period: 24-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	−4.20 (−8.20 to 0.10)	−0.46 (−0.52 to 0.40)	1.06 (0.99 to 1.14)	1.30 (1.23 to 1.36)	1.69 (1.51 to 1.88)	1.04 (0.72 to 1.50)
Period 3 ^c	−4.60 (−1.00 to 0.80)	−1.26 (−1.33 to 1.18)	0.89 (0.81 to 0.97)	1.35 (1.27 to 1.44)	1.68 (1.46 to 1.94)	0.50 (0.29 to 0.85)
Global test 1 ^d	0.10					0.002
Trend						
All years ^e	3.30 (2.50 to 4.00)					1.02 (0.95 to 1.10)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.13)	1.10 (1.09 to 1.12)	0.966 (0.958 to 0.974)	0.95 (0.93 to 0.96)	
Interaction 2 ^g		−0.51 (−0.56 to 0.47)	1.05 (0.99 to 1.12)	0.75 (0.72 to 0.78)	0.62 (0.57 to 0.69)	
Interaction 3 ^h		−0.01 (−0.07 to 0.05)	0.82 (0.76 to 0.89)	0.74 (0.69 to 0.78)	0.55 (0.48 to 0.63)	
Global test 2 ⁱ	0.60	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.60
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 88 Impact of moving the start of the intervention period to 1 year after the real Health in Pregnancy grant period: 18-month intervention period

TABLE 114 Impact of moving the start of the intervention period to 1 year after the real HiP grant period: 18-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	
Period 2 ^b	−3.70 (−7.90 to 0.50)	−0.40 (−0.46 to 0.33)	1.04 (0.97 to 1.13)	1.22 (1.16 to 1.29)	1.52 (1.35 to 1.70)	1.11 (0.76 to 1.62)
Period 3 ^c	−6.50 (−11.40 to 1.50)	−1.16 (−1.22 to 1.09)	0.86 (0.80 to 0.93)	1.23 (1.16 to 1.30)	1.42 (1.26 to 1.61)	0.69 (0.43 to 1.12)
Global test 1 ^d	0.04					0.04
Trend						
All years ^e	3.40 (2.70 to 4.20)					1.01 (0.94 to 1.08)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.13)	1.10 (1.09 to 1.12)	0.966 (0.958 to 0.975)	0.95 (0.93 to 0.96)	
Interaction 2 ^g		−0.63 (−0.70 to 0.56)	1.10 (1.01 to 1.21)	0.72 (0.68 to 0.77)	0.61 (0.53 to 0.70)	
Interaction 3 ^h		−0.13 (−0.17 to 0.08)	0.86 (0.82 to 0.91)	0.77 (0.74 to 0.80)	0.60 (0.54 to 0.65)	
Global test 2 ⁱ	0.30	< 0.0001	< 0.0001	< 0.0001	< 0.0001	0.08
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 89 Impact of moving the start of the intervention period to 1 year after the real Health in Pregnancy grant period: 30-month intervention period

TABLE 115 Impact of moving the start of the intervention period to 1 year after the real HiP grant period: 30-month intervention period

Imputed	Birthweight (g), coefficient (95% CI)	Booking status		Measures of stage, OR (95% CI)		Birth outcome, OR (95% CI)
		Gestational age at booking (weeks), coefficient (95% CI)	Booking before 25 weeks, OR (95% CI)	Preterm	Very preterm	Neonatal death
Periods						
Period 1 ^a	0.00	0.00	1.00	1.00	1.00	1.00
Period 2 ^b	−4.40 (−8.40 to 0.30)	−0.45 (−0.50 to 0.39)	1.07 (0.99 to 1.14)	1.23 (1.17 to 1.29)	1.57 (1.41 to 1.75)	1.01 (0.69 to 1.47)
Period 3 ^c	−5.60 (−11.40 to 0.20)	−1.10 (−1.20 to 1.03)	0.83 (0.73 to 0.95)	1.81 (1.66 to 1.98)	2.57 (2.14 to 3.09)	0.60 (0.34 to 1.07)
Global test 1 ^d	0.09					0.06
Trend						
All years ^e	3.30 (2.60 to 4.10)					1.01 (0.94 to 1.08)
Interactions						
Interaction 1 ^f		−0.14 (−0.15 to 0.13)	1.10 (1.09 to 1.12)	0.966 (0.958 to 0.974)	0.95 (0.93 to 0.96)	
Interaction 2 ^g		−0.55 (−0.58 to 0.51)	1.04 (0.99 to 1.08)	0.85 (0.83 to 0.88)	0.75 (0.70 to 0.81)	
Interaction 3 ^h		−0.13 (−0.23 to 0.035)	0.88 (0.77 to 0.99)	0.55 (0.50 to 0.59)	0.36 (0.30 to 0.43)	
Global test 2 ⁱ	0.90	< 0.0001	0.0001	< 0.0001	< 0.0001	0.10
<div><div>a</div>Pre-intervention period.</div> <div><div>b</div>Intervention HiP grant.</div> <div><div>c</div>Post-intervention period.</div> <div><div>d</div>Global test for the periods in which the interactions were not significant.</div> <div><div>e</div>Trend over the study period 2004–13.</div> <div><div>f</div>Trend pre intervention.</div> <div><div>g</div>Trend during the HiP grant period.</div> <div><div>h</div>Trend post intervention.</div> <div><div>i</div>Global test for the interactions.</div>						

Appendix 90 STrengthening the Reporting of OBservational studies in Epidemiology statement for reporting of observational studies

TABLE 116 STrengthening the Reporting of OBservational studies in Epidemiology statement for reporting of observational studies

Section	Item number	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (<i>Abstract</i>) (b) Provide in the abstract an informative and balanced summary of what was done and what was found (<i>Abstract</i>)
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported (<i>Background, The intervention, Rationale for the study</i>)
Objectives	3	State specific objectives, including any prespecified hypotheses (<i>Research objectives</i>)
Methods		
Study design	4	Present key elements of study design early in the paper (<i>Research design</i>)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up and data collection (<i>Study population including definitions of subgroups</i>)
Participants	6	(a) <i>Cohort study</i> : give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (N/A); <i>case-control study</i> : give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls (N/A); <i>cross-sectional study</i> : give the eligibility criteria, and the sources and methods of selection of participants (<i>Research design, Study population including definitions of subgroups</i>) (b) <i>Cohort study</i> : for matched studies, give matching criteria and number of exposed and unexposed (N/A); <i>case-control study</i> : for matched studies, give matching criteria and the number of controls per case (N/A)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable (<i>Table 4</i>)
Data sources/measurement	8 ^a	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group (<i>Study population including definitions of subgroups</i>)
Bias	9	Describe any efforts to address potential sources of bias (<i>Imputation Methods; Strengthening the inference</i>)
Study size	10	Explain how the study size was arrived at (<i>Power calculation</i>)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why (<i>Table 4</i>)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (<i>Statistical analysis, Economic analysis, Strengthening the inference, Models fitted and interpretation; Table 4</i>) (b) Describe any methods used to examine subgroups and interactions (<i>Study population including definitions of subgroups</i>)

continued

TABLE 116 Strengthening the Reporting of OBservational studies in Epidemiology statement for reporting of observational studies (*continued*)

Section	Item number	Recommendation
		(c) Explain how missing data were addressed (<i>Imputation methods</i>)
		(d) <i>Cohort study</i> : if applicable, explain how loss to follow-up was addressed (N/A); <i>case-control study</i> : if applicable, explain how matching of cases and controls was addressed (N/A); <i>cross-sectional study</i> : if applicable, describe analytical methods taking account of sampling strategy (<i>Statistical analysis</i>)
		(e) Describe any sensitivity analyses (<i>Strengthening the inference</i>)
Results		
Participants	13 ^a	(a) Report numbers of individuals at each stage of study (e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up and analysed) (<i>Numbers of observations used in analyses; Figure 1, Tables 2 and 3</i>)
		(b) Give reasons for non-participation at each stage (<i>Figure 1</i>)
		(c) Consider use of a flow diagram (<i>Figure 1</i>)
Descriptive data	14 ^a	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders (<i>Table 14</i>)
		(b) Indicate number of participants with missing data for each variable of interest (<i>Tables 12–14</i>)
		(c) <i>Cohort study</i> : summarise follow-up time (e.g. average and total amount) (N/A)
Outcome data	15 ^a	<i>Cohort study</i> : report numbers of outcome events or summary measures over time (<i>Tables 10–13</i>)
		<i>Case-control study</i> : report numbers in each exposure category, or summary measures of exposure (N/A)
		<i>Cross-sectional study</i> : report numbers of outcome events or summary measures (N/A)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% CI). Make clear which confounders were adjusted for and why they were included (<i>Results for the main analysis; Tables 15–23</i>)
		(b) Report category boundaries when continuous variables were categorised (<i>Tables 10–14</i>)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period (N/A)
Other analyses	17	Report other analyses done [e.g. analyses of subgroups and interactions (<i>Results of the subgroup analysis, Tables 24–25, Appendices 15–66</i>) and sensitivity analyses (<i>Results of sensitivity analysis; Appendices 67–89; Figures 3–8</i>)]
Discussion		
Key results	18	Summarise key results with reference to study objectives (<i>Principal findings</i>)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias (<i>Strengths and weaknesses</i>)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence (<i>Interpretation</i>)
Generalisability	21	Discuss the generalisability (external validity) of the study results (<i>Robustness and generalisability</i>)

TABLE 116 STrengthening the Reporting of OBservational studies in Epidemiology statement for reporting of observational studies (*continued*)

Section	Item number	Recommendation
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based (<i>Abstract</i>)
<p>a Give information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.</p> <p>Note An explanation and elaboration article discusses each checklist item and gives the methodological background and published examples of transparent reporting. The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist is best used in conjunction with this article (freely available on the websites of <i>PLOS Medicine</i> at www.plosmedicine.org/ and <i>Annals of Internal Medicine</i> at www.annals.org/, and <i>Epidemiology</i> at www.epidem.com/). Information on the STROBE initiative is available at www.strobe-statement.org.</p>		

A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and flow.

EME
HS&DR
HTA
PGfAR
PHR

Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk

This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health

Published by the NIHR Journals Library